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Abstract 
 
Due to the high prevalence of HIV-1 subtype C infection coupled with increasing antiretroviral 
(ARV) drug treatment failure, the elucidation of complex resistance mutational patterns arsing 
through protein coevolution is required. Despite the inclusion of LPV and DRV in second- and 
third-line, many patients still fail treatment. In this study, protease (PR) inhibitor resistance 
mutations were identified by comparing treatment versus naïve sequences datasets in Gag and 
PR. Thereafter, to investigate Gag-PR coevolution and pathways to LPV resistance, phylogenetic 
analyses and Bayesian networks were constructed. Following this, structural analyses combining 
homology modelling, molecular docking and molecular dynamic simulations were carried out on 
specific patterns of protease resistance mutations (PRMs). To complement these analyses, the 
structural impact of a mutated Gag cleavage site on PR resistance dynamics was also evaluated. 
Accordingly, this study identified 12 major PRMs and several resistance combinations. Of these, 
the M46I+I54V+V82A pattern frequently occurred. The second most frequently recurring pattern 
included L76V as a fourth mutation to the above triplet. Coevolution analyses revealed 
correlations between positions 10, 46, 54 and 82 in PR. Of these, minor PRM L10F occurred in 
6.4% of the dataset and was involved in pathways to LPV resistance. Additionally, Gag cleavage 
site (CS) mutation A431V was also correlated with L10F and the major PRMs. Distinct changes 
in PR’s active site, flap and elbow regions due to the PRMs (L10F, M46I, I54V, L76V, V82A) 
were found to alter LPV and DRV drug binding. When the PRMs were combined with the mutant 
Gag CS binding was greatly exacerbated. While the A431V Gag CS mutation coordinated several 
amino acid residues in PR, the L76V mutation was found to have a significant role in substrate 
recognition rather than directly inhibiting the drugs. These data show that the co-selection of 
mutations in Gag-PR greatly contributes to resistance outcomes and that our understanding on 
drug resistance is largely lacking, particularly where structure is concerned.          
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1.1 History of the human immunodeficiency virus 
In June 1981, a group of clinical experts based at the Centre for Disease Control and Prevention 
(CDC) documented that five relatively healthy patients between the ages of 29 and 36 all 
contracted a rare respiratory infection called Pneumocystis carinii pneumonia1 (PCP) in their 
Morbidity and Mortality Weekly Report. Additionally, whilst all five men confessed to having 
sexual relations with other men and used inhalant drugs, three patients had defective lymphocyte 
proliferation coupled with considerably low T cell counts (CDC, 1981). Following the CDC’s 
initial report, several cases all leading into the year of 1982 described larger groups of homosexual 
men showing the same symptoms, with mortality steadily increasing. By September 1982, the 
CDC had concluded that given the clinical manifestations and nature of the emerging infectious 
disease, this new illness would be known as acquired immune deficiency syndrome (AIDS). Later 
AIDS would be identified in various groups, including patients receiving blood transfusions, 
injection drug users, Haitian individuals residing in the United States (US) and in children of 
parents with AIDS (Goedert and Gallo, 1985). This implied that this unidentified etiological agent 
was transmitted via blood-borne, vertical and sexual means and was not limited to homosexuals. 
 
In 1983, Françoise Barré-Sinoussi and Luc Montagnier isolated a retrovirus from the lymph node 
of a 33-year-old French homosexual patient. Since the virus was only able to infect T cells, they 
concluded that the patient was infected with a T cell-tropic retrovirus and was subsequently named 
lymphadenopathy-associated virus (LAV) (Barré-Sinoussi et al., 1983). Although the link 
between AIDS and LAV remained uncertain at this time, Luc Montagnier and Barré-Sinoussi 
would go on to win the Nobel Prize for initially isolating and characterizing HIV in 2008. 
Elsewhere, Robert Gallo and colleagues had isolated a virus from 48 patients in 1984. These 
patients included those with AIDS, a healthy homosexual male, mothers with AIDS and patients 
with symptoms of pre-AIDS2. After multiple tests, Gallo’s team coined the virus human T-
lymphotropic virus type III (HTLV-III) and suggested its role as the causative agent of AIDS 
(Gallo et al., 1984).  
 
It was eventually revealed that LAV and HTLV-III were in fact the same virus and was 
subsequently renamed the human immunodeficiency virus (HIV) in 1986 (Coffin et al., 1986).  
 
                                                          
1 PCP is a rare, serious infection of the lungs that are usually seen in severely immunocompromised 
individuals.      
2 Pre-AIDS is referred to as symptoms that precede the CDC’s official definition of AIDS, e.g. 
lymphadenopathy.  
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1.2 Classification and origin of HIV             
HIV belongs to the Lentivirus genus within the Retroviridae family (Williams and Burdo, 2009) 
and is classified into two main types, namely, HIV type I (HIV-1) and HIV type II (HIV-2). 
Although both types share structural similarities, HIV-1 is responsible for the global pandemic 
seen today (Xiao et al., 2017). However, while HIV-2 was initially localized to West Africa, it 
has since traversed to the United States, Europe, India and other parts of Africa (Campbell-Yesufu 
and Gandhi, 2011).  
 
HIV-1 is divided into groups M (main), N (non-M; non-O), O (outlier) and P. Group M is further 
subdivided into nine subtypes (A–D, F–H, J and K) (Lau and Wong, 2013) and about 98 
circulating recombinant forms3 (CRFs). Of these, group M subtype C is currently the most 
prevalent form of HIV-1, globally (Castley et al., 2017). HIV-2 is divided into eight groups, 
namely A–H, where groups A and B are the most frequent and likely the only pathogenic ones 
(Eberle and Gürtler, 2012). Both HIV-1 and HIV-2 originated from independent zoonotic events 
when a simian immunodeficiency virus (SIV) jumped species from non-human primates to 
humans (Peeters et al., 2010). Two distinct SIVs were involved in cross-species transmission for 
the main groups of HIV-1 to arise. As such, the natural viruses found in chimpanzees (SIVcpz) 
led to the genetic development of HIV-1 groups M and N whilst those found in gorillas (SIVgor) 
led to the HIV-1 group O variants. Similarly, the natural sooty mangabey4 virus (SIVsmm) is the 
closest genetic relative of HIV-2 (Pandrea et al., 2008). 
 
Interestingly, Kalish et al. (2004) showed that people hunting primates for bushmeat in Central 
Africa were often exposed to SIV infection. Nevertheless, the weak nature of SIV allows for the 
human immune system to fully suppress the virus within weeks of acquisition. Therefore, several 
successive infections from person-to-person and the presence of high-risk transmission networks 
were required for SIV to mutate into HIV. Consequently, the turn of the 20th century which led to 
the collapse of colonialism, increased trade with global proprietors, sociopolitical reform and an 
increase in prostitutes provided the perfect channel for HIV to develop and spread. A study 
conducted by Faria et al. (2014) on the transmission network of HIV-1 concluded that group M 
utilized the behavioural and socioeconomic changes to establish and maintain future 
transmissions (Parrish et al., 2008) in what would become one of the “most devastating infectious 
diseases” to emerge in human history (Sharp and Hahn, 2011).                       
                                                          
3 CRFs are combinations of different HIV-1 subtypes, e.g. CRF08_BC is a combination of subtypes 
B and C. 
4 The sooty mangabey (Cercocebus atys) are old world monkeys indigenous to West Africa.  
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1.3 Geographical distribution of the HIV-1 subtypes 
According to a report published in 2018 by the Joint United Nations Programme on HIV/AIDS, 
there were 36.9 million people living with HIV, globally. In addition, there were 1.8 million new 
infections and 940,000 AIDS-related deaths (UNAIDS, 2018). An estimated 20% of the 
population of Lesotho, South Africa, Zimbabwe and Botswana are HIV-positive (Chin, 2017). In 
South Africa alone, there is an estimated 7.52 million individuals currently living with HIV 
(STATS SA, 2018). One of the most challenging issues faced currently is preventing the 
transmission of HIV-1 (Kurth et al., 2011). Finding ways to control the epidemiological spread 
of HIV-1 can not only prevent further increases in the number of new HIV infections but can also 
reduce the economic burden faced by many developing countries.  
 
Thus far, universal efforts in generalizing the pandemic is hindered by the worldwide 
geographical heterogeneity of the HIV-1 subtypes (Buonaguro et al., 2007) as seen in Figure 1.1. 
Due to the diversity of HIV-1 in Southern Africa, several HIV-1 subtypes and CRFs are found in 
Cameroon and in the Democratic Republic of Congo. Accordingly, subtype C is endemic to 
Eastern and sub-Saharan Africa, the south of Brazil and the Indian Pacific whereas subtype B is 
mostly prevalent in the US, Japan, Europe and Northern Africa (Chin, 2017). CRF01_AE 
(recombinant between HIV-1 subtypes A and E) and CRF02_AG (recombinant between subtypes 
A and G) accounts for 5% and 8% of global HIV infections and are prevalent in Southeast Asia 
and West Africa (Daw et al., 2017). Interestingly, the idea that a single virus preferentially 
introduced into a dense population which rapidly transmitted, or otherwise known as the founder-
effect was suggested to play a role in the geographical distribution of the HIV-1 subtypes seen 
today (Buonaguro et al., 2007; Chin, 2017).         
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Figure 1.1   Worldwide geographical distribution of the HIV-1 subtypes and CRFs. Illustration 
taken from Butler et al. (2007).  
 
1.4 Clinical manifestations of HIV infection 
Over the years several mathematical models have been used to breakdown the clinical progression 
from HIV infection to AIDS. Though differences exist between patients, a general trend was 
outlined as seen in Figure 1.2. Accordingly, this trend encompassed three distinct stages known 
as the acute infection, chronic infection and AIDS phase (Alizon and Magnus, 2012). During 
acute infection, flu-like symptoms including headache, cough and fever occurs within 2–4 weeks 
(Robb et al., 2016). Additionally, weight loss, oral and genital ulcers, skin rash as well as fatigue 
have also been associated with the early stage of HIV infection. Importantly, individuals in acute 
stage have high viral turnover rates and can easily transmit to non-infected people quickly. 
Consequently, 38–50% of all new infections occur at the acute HIV infection stage (Henn et al., 
2017). 
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With the onset of flu-like symptoms during acute HIV infection, the body’s immune response 
kicks in. The cellular immunity or cell-mediated immune response5 which is mediated by 
lymphocytes known as T-cells is activated after 1–2 weeks of infection. This is followed by the 
humoral response5 (or antibody-mediated humoral response which sequesters specific B-cells to 
form plasma cells to secrete antibodies into the lymph and blood) 4–8 weeks post-infection 
(Alizon and Magnus, 2012). Through the activation of immune responses, viral copy numbers 
decrease with lower levels of replication keeping the viral load constant. This is referred to as the 
viral load set point and is the chronic infection stage (Dykes and Demeter, 2007). Since host CD4 
T-cells are actively targeted by the virus (Douek et al., 2002), its numbers are greatly reduced, 
which leads to the AIDS stage (Dykes and Demeter, 2007). This stage is the most severe and is 
characterized by extremely low CD4 T-cell count (usually <200 per μL), high viral copies and 
damaged immune systems. Furthermore, the frailty of the immune system results in the 
acquisition of several opportunistic infections (Friedman-Kien et al., 1981).              
 
 
 
Figure 1.2   The typical three clinical stages observed in untreated HIV-1 infected individuals 
with axes showing the viral load and CD4 T-cell count. Illustration taken from Landi et al. (2008).  
 
                                                          
5 Information on immune responses adapted from Nauta J. 2011. Humoral and cellular immunity. In 
Nauta J. (eds), Statistics in Clinical Vaccine Trials. Springer-Verlag Berlin Heidelberg, pp. 13–17.  
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1.5 Genetic and physical characteristics of HIV 
In general, all retroviruses possess similar physical and genetic characteristics. One of the main 
features that make retroviruses unique is that the virus comprises two positive-sense RNA strands 
(Kieken et al., 2002). Each strand comprises nine genes over three reading frames as shown in 
Figure 1.3 below. Of these, the gag, pol and env genes encodes the virus’s main structural and 
enzymatic components. The last six include regulatory genes tat and rev as well as the vif (viral 
infectivity factor), vpu (viral protein U), vpr (viral protein R) and nef (negative regulation factor) 
accessory proteins. The gag gene encodes the virus’s main structural components, matrix, capsid 
and nucleocapsid while pol encodes for the viral protease, reverse transcriptase and integrase 
enzymes. The surface envelope glycoprotein is encoded with the env gene (Watts et al., 2009). 
Importantly, these genes are flanked by identical 5' and 3' long terminal repeats (LTRs). 
Transcription regions within the LTRs can activate and repress factors that influence the rates of 
gene expression (Burnett et al., 2009; Shah et al., 2014).   
 
 
Figure 1.3   Genetic map of HIV-1 showing the three reading frames, the virus’s nine genes and 
the 5' to 3' long terminal repeat (LTR) regions. Image taken from Foley et al. (2017).  
 
 
Physically, the HIV-1 virion6 is approximately 100 nm in size and spherical in shape. The viral 
envelope contains 72 spikes which are composed of trimers of envelope’s (Env) gp120 and gp41 
surface and transmembrane glycoproteins, respectively (Gelderblom et al., 1987). The HIV-1 
matrix (MA; p17) protein which is a thin layer lining the inner surface of the virion lipid bilayer 
helps hold the Env proteins together after maturation has occurred (Gelderblom et al., 1987). 
Furthermore, in a mature virion, the HIV capsid (CA, p24) protein oligomerizes to form a shell 
around the virus’s RNA and core-associated proteins (Freed, 1998). 
 
                                                          
6 A structurally and genetically complete infectious virus particle as it exists outside a host.  
 
8 
 
1.6 The HIV-1 lifecycle 
The replication cycle of HIV-1 comprises two distinct phases: (a) the early phase where virions 
bind to the host cells followed by cDNA integration and (b) the late phase in which viral gene 
expression occurs to allow for maturation and release of the now infectious viral particles (Nisole 
and Saïb, 2004). Several steps occur (Figure 1.4) to produce mature, infectious virus: (i) binding 
of HIV to its receptor (CD4) and preferred co-receptor7 (ii) fusion with the host cell membrane, 
(iii) un-coating of the viral capsid and subsequent nucleic acid release, (iv) reverse transcription 
of viral RNA, (v) integration into host cell’s DNA, (vi) transcription and translation, (vii) 
assembly of the immature virions and budding from cells and (viii) final maturation of immature 
viral particles to fully infectious virions (reviewed in Barré-Sinoussi et al., 2013).  
 
 
 
                                                          
7 Co-receptors are a group of chemokine proteins. In the HIV-1 lifecycle, R5 and X4 viruses interact 
with CCR5 or CXCR4 co-receptors, respectively.   
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Figure 1.4   Diagram of the HIV-1 lifecycle. Replication begins when HIV-1 binds the CD4 
receptor and its co-receptors following which fusion of the virion to the host membrane occurs. 
After HIV’s capsid is uncoated the viral proteins and RNA are released into the cytoplasm. 
Thereafter, the virus’s RNA is reverse-transcribed into DNA and the pre-integration complex 
(PIC) is formed and translocated into the nucleus. At this stage, the viral DNA is integrated with 
the host’s genetic material and encoded into new viral proteins and RNA. These components are 
then transported to the cell surface where they are assembled into immature virus particles. These 
progeny viruses are subsequently released. Finally, the protease cleaves the virus’s structural 
polyprotein, Gag to form fully, infectious HIV virions. Note: restriction factors (tetherin, 
APOBEC3G, tripartite motif-containing 5α (TRIM5α) and SAMHD1; purple) and the virus’s 
regulatory proteins (Vpu, Vif and Vpx; red) are also shown. Abbreviations: CCR5 = CC-
chemokine receptor 5 (Illustration adapted from Barré-Sinoussi et al., 2013). 
 
 
1.7 HIV-1 antiretroviral therapy 
The elucidation of the HIV-1 lifecycle provided invaluable information for the development of 
several drugs designed to actively target specific steps in the virus’s replicative process (Gu et al., 
2014). Zidovudine, a reverse-transcriptase inhibitor was the first antiretroviral (ARV) drug 
approved for HIV treatment by the Food and Drug Administration (FDA) (Warnke et al., 2007). 
Since then, it has become apparent that a combination of ARV drugs is more effective against the 
virus that a single inhibitor. This approach is often referred to as highly active antiretroviral 
therapy or HAART (Cohen, 2006; Arts and Hazuda, 2012). Since its inception, HAART is 
generally able to reduce the viral load to undetectable numbers (Fang et al., 2007) whilst 
extending patient life expectancy by several years (Smith et al., 2013; Meintjes et al., 2017). 
 
There are over 26 FDA approved ARV drugs that belong to eight drug classes (NIH, 2018). These 
are the nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase 
inhibitors (NNRTIs), CCR5 antagonist, fusion inhibitor (FI), post-attachment inhibitor (PAI), 
integrase strand transfer inhibitors (INSTIs), pharmacokinetic enhancers (PKs) and the protease 
inhibitors (PIs) as seen in Table 1.1 below. Briefly, the NRTIs are considered chain terminators 
as they block reverse transcriptase from producing DNA via its incorporation into the process. 
Contrastingly, NNRTIs binds to reverse transcriptase thereby changing the flexibility of the 
enzyme (Tang and Shafer, 2012). The CCR5 antagonist blocks the CCR5 co-receptor thus 
preventing virus entry into the cell (Lopalco, 2010) whilst the FIs prevent HIV-1 from entering 
the CD4 cells (Falkenhagen and Joshi, 2018). Contrastingly, the PAIs are monoclonal antibodies 
that bind the receptive CD4 cells to block HIV-1 entry (Henrich and Kuritzkes, 2013). The INSTIs 
are a class of drugs that inhibits the HIV-1 integrase enzyme thus preventing it from making more 
copies of itself. The PKs are used in HIV-1 therapy to pharmacokinetically enhance or boost the 
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effectiveness of ARVs (Arts and Hazuda, 2012). Lastly, the PIs are a class of competitive 
inhibitors that target the HIV-1 protease enzyme during maturation (Yang et al., 2012) and will 
be further discussed in section 1.9.3 as they are the focus of the current study. 
 
Table 1.1   List of commonly used ARV drugs approved by the FDA. 
 
DRUG CLASS GENERIC NAME TRADE NAME 
Nucleoside reverse 
transcriptase inhibitors 
Abacavir ZIAGEN 
Tenofovir alafenamide VEMLIDY 
Emtricitabine EMTRIVA 
Tenofovir disoproxil fumarate VIREAD 
Lamivudine EPIVIR 
Zidovudine RETROVIR 
Non-Nucleoside Reverse 
Transcriptase Inhibitors 
Doravirine PIFELTRO 
Efavirenz SUSTIVA 
Etravirine INTELENCE 
Nevirapine VIRAMUNE VIRAMUNE XR 
Rilpivirine EDURANT 
Pharmacokinetic 
Enhancers 
Cobicistat TYBOST 
Ritonavir* NORVIR 
Post-Attachment Inhibitor  Ibalizumab-uiyk TROGARZO 
Fusion Inhibitor Enfuvirtide FUZEON 
Protease Inhibitors 
Atazanavir REYATAZ 
Lopinavir/Ritonavir KALETRA 
Nelfinavir VIRACEPT 
Darunavir PREZISTA 
Saquinavir INVIRASE 
Tipranavir APTIVUS 
Fosamprenavir LEXIVA 
Amprenavir AGENERASE 
 Indinavir CRIXIVAN 
Integrase Strand Transfer  
Inhibitors 
Bictegravir BIKTARVY# 
Dolutegravir TIVICAY 
Elvitegravir STRIBILD# 
Raltegravir ISENTRESS 
CCR5 Antagonists Maraviroc SELZENTRY 
 
* Ritonavir is a protease inhibitor, however, it serves as a pharmacokinetic enhancer or booster. 
# Available as part of a fixed dose combination pill only.  
 
 
In South Africa, the classes of drugs currently available include the NRTIs, NNRTIs, PIs and 
INSTIs (NDOH, 2019). Drugs from these classes are administered in three varying regimens 
depending on the patient’s age, weight, secondary infections and even gender. In the first-line 
treatment regimen, one NNRTI and two NRTIs are administered as a fixed dose combination 
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tablet. However, recent guidelines have also stipulated the use of an INSTI drug, namely 
Dolutegravir, in first-line treatment regimens (NDOH, 2019). Currently, Dolutegravir is 
administered as a fixed dose combination with Tenofovir and Lamivudine and is prescribed to 
clients > 10 years of age and > 35 kg, and as a standard dose in adolescents, adults and children 
> 20 kg. In second-line, the regimen consists of two NRTIs and a PI whilst third line regimens 
consists of a PI, NNRTI and an INSTI (NDOH, 2019). An overview of the available ARVs used 
in the three treatment regimens are described in Table 1.2. 
 
Table 1.2   Overview of the ARV drugs employed in the three drug regimens in South Africa 
(adapted from the NDOH, 2019 guidelines). 
 
First-line regimen: 
Two NRTIs + one NNRTI 
Emitricitabine (FTC) 
NRTI 
Tenofovir (TDF) 
Lamivudine (3TC) 
Abacavir (ABC) 
Efavirenz (EFV) 
NNRTI 
Nevirapine (NVP) 
Second-line regimen: 
Two NRTIs + one PI 
Tenofovir (TDF) 
NRTI 
Lamivudine (3TC) 
Zidovudine (AZT) 
Emitricitabine (FTC) 
Abacavir (ABC) 
Lopinavir (LPV)* 
PI 
Atazanvir (ATV) 
Third-line regimen: 
One NNRTI + one PI + one 
INSTI 
Etravirine (ETR) NNRTI 
Darunavir (DRV)* PI 
Raltegravir (RAL) INSTI 
 
* LPV and DRV are boosted with ritonavir (r): LPV/r and DRV/r 
 
       
1.8 ARV drug resistance 
Due to the low proof-reading capability of the HIV-1 reverse transcriptase enzyme, the virus can 
accumulate numerous mutations in the genome (Hu and Hughes, 2012). Although most of these 
mutations adversely affect enzymatic function, the trade-off between reduced fitness and the 
virus’s ability to evade ARVs allow some of these mutations to gain an evolutionary advantage 
(Richman et al., 2004). Hence, these mutant strains continue to replicate and will eventually 
predominate thereby rendering treatment ineffective as seen in Figure 1.5 below. Although the 
success of ARV therapy cannot be disputed, the development of ARV drug resistance remains a 
serious concern (Dudley et al., 2014; Silver et al., 2018). Even though these drug resistance 
mutations exhibit different trends for different drugs, certain mutations are often enough to resist 
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multiple inhibitors belonging to the same family or class. This is known as cross-resistance and 
has been observed in several studies (Condra et al., 1995; Hertogs et al., 2000; Race, 2001; Rhee 
et al., 2010; Diphoko et al., 2018; Penrose et al., 2018).  
 
 
Figure 1.5   Diagram showing the development of drug resistant viruses over time (Image taken 
from AIDSMAP, 2014). 
 
 
Usually, to ensure the drug regimens are effective, patients are carefully monitored (Iacob et al., 
2017). Patient monitoring includes a sequence of steps from initial diagnosis to treatment and are 
assessed by stages. These stages are diagnosis, linkage to medical care, initiating ART, adherence 
to treatment regimens and viral suppression to undetectable levels in the blood (HIV. gov, 2019) 
through the monitoring of CD4 cell counts and viral load data (WHO, 2006). Although 
genotyping the viral sequences can provide invaluable information on which resistance mutations 
are present, the relationship between resistance mutations are complicated (Zhang et al., 2010). 
Currently, clinical decisions on the selection of drug regimens are based on predictive algorithms 
such as the HIVdb algorithm on the Stanford HIV Drug Resistance Database (Sing and Däumer, 
2006; Shen et al., 2016). Since the focus area of this study is to evaluate the mechanism by which 
mutations in protease (PR) and its natural substrate Gag work to evade the PIs, the enzyme, 
substrate and its associated resistance will be discussed in detail in the following sections. 
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1.9 Protease structure, function, inhibitory drugs and resistance 
 
1.9.1 Structure 
The HIV-1 PR belongs to a family of aspartic proteases that is symmetrically structured to form 
a homodimer consisting of two identical subunits each comprising 99 amino acids (AAs) (Katoh 
et al., 1987; Yang et al., 2012). Each PR subunit is composed of a single α-helix and nine β-sheets. 
Of these, four β-sheets that run anti-parallel relative to each other form the conserved dimer 
interface (Todd et al., 1998; Velazquez-Campoy et al., 2003) as shown in Figure 1.6. Structural 
studies indicate that residues 1–4 and 96–99 in each subunit of the four anti-parallel β-sheets 
forms the dimer interface of PR (Choudhury et al., 2003). The dimer interface results in the 
formation of the hydrophobic active site cavity consisting of PR’s catalytic triad D25-T26-G27 
from both monomers (Wlodawer et al., 1989; Zhang et al., 2008). More so, the anti-parallel β-
sheets restrict access to the substrate cavity by forming two flexible flaps to cover the active site 
region. In a ligand-free state, PR assumes a semi-open conformation whereas a PR-ligand 
complex induces a closed conformation. Two models have been proposed for flap opening and 
closing states (Yang et al., 2012). The first theorizes that a collision complex between the ligand 
and PR occurs when the flaps are fully opened which then induces a closed conformation as the 
substrate approaches the active site (Scott and Schiffer, 2000). The second model proposes that 
the ligand first approaches a semi-open state which then prompts the flaps to fully open as it enters 
the substrate cavity. The flaps then extend over the substrate to adopt a closed conformation for 
proteolysis (Collins et al., 1995; Toth and Borics, 2006). While the flaps are indispensable for 
catalysis of the viral PR, their exact conformational states during cleavage is debatable (Soares et 
al., 2016). 
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Figure 1.6   Structural representation of the HIV PR showing its active site, flap and identical 
subunits. Image take from Venkatakrishnan et al. (2012). 
 
 
1.9.2 Function      
In nature, the role of the HIV-1 PR is to cleave the nascent polyproteins and is thus essential for 
viral replication (Adachi et al., 2009). Consistent with studies evaluating other non-viral PR’s, it 
is recognized that the acid-base mechanism involving two important active site aspartic residues 
are essential for catalysis to occur (Brik and Wong, 2003). The widely accepted mechanism of 
catalysis was initially described by Suguna et al. (1987). The authors suggest that of the two 
aspartic acids, only one is unprotonated. Therefore, the negatively charged aspartic group 
activates the nucleophilic water located between the aspartic acids which then proceeds to attack 
the substrate’s carbonyl group to generate an oxyanion tetrahedral intermediate. Finally, the 
substrate’s amide nitrogen atom is protonated and rearranged to breakdown the intermediate 
leading to the formation of the hydrolysis products (Figure 1.7). 
 
 
15 
 
 
 
Figure 1.7   Chemical mechanism showing the proteolytic cleavage of the hydrolysis products. 
Image taken from Brik and Wong (2003).   
 
 
In Gag, five cleavage sites (CSs) are recognized by PR during hydrolysis as depicted in Table 1.3 
below. Although these regions share limited sequence similarity they are similarly structured. As 
such, it was proposed that the mechanism by which PR cleaves Gag also depends on the structure 
of the substrate. Moreover, while PR exhibits symmetry within its subunits, the Gag substrates 
are asymmetrical in size and charge of the AA residues (Prabu-Jeyabalan et al., 2002). 
 
Table 1.3   WT sequences for the HIV-1 subtype C Gag CSs (adapted from De Oliveira et al., 
2003). 
 
CLEAVAGE SITES SEQUENCE 
Matrix-Capsid VSQNY -- PIVQN 
Capsid-p2 KARVL -- AEAMS 
p2-Nucleocapsid NTNIM -- MQKSN 
Nucleocapsid-p1 ERQAN -- FLGKI 
p1-p6 RPGNF -- LQSRP 
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1.9.3 Inhibitory drugs   
As previously mentioned, the analogous structure of the PIs to the Gag CSs make them ideal 
inhibitors of HIV-1 maturation (Mudgal et al., 2018). As shown in Table 1.1 above, there are 10 
FDA approved PIs currently available on market, nine of which are shown in Figure 1.8 below. 
In general, the mechanism of inhibition begins when the hydroxyl group of the PI interacts with 
the carboxyl group of the aspartic active site residues via hydrogen bonding. Consequently, 
binding to the active site AAs prevents the HIV-1 PR from successfully cleaving Gag. While 
several attempts have been made to modify the current PIs, none have been as successful as 
second-generation PIs Lopinavir (LPV) and Darunavir (DRV) which were modified from 
Ritonavir (RTV) and Amprenavir (APV), respectively (Lv et al., 2015). 
 
In LPV, the 5-thiazolyl and the 2-isopropylthiazolyl of RTV’s P2 and P2' groups are replaced 
with a phenoxyacetyl and six-membered cyclic urea, respectively. These substitutions have been 
shown to improve the potency against drug resistant variants (Sham et al., 1998). On the other 
hand, having been FDA-approved in 2006, DRV is the newest PI on market (Lv et al., 2015). The 
only difference between DRV and APV is the substitution of tetrahydrofuran with bis-
tetrahydrofuran in the P2 group. Consequently, replacing APV’s chemical moiety allows DRV to 
form more hydrogen bonds with PR. Due to these modifications LPV boosted ritonavir (LPV/r) 
and DRV boosted ritonavir (DRV/r) have high genetic barriers against the resistant PR variants 
in comparison to the other PIs (Doherty et al., 2011; Aoki et al., 2018).  
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Figure 1.8   Chemical structures of the PIs. Image adapted from Lv et al. (2015). 
 
 
1.9.4 Drug resistance 
Despite their success, mutations arising in the viral PR have been associated with LPV and DRV 
drug resistance (Weber et al., 2015). In LPV, the most common resistance mutations include 
V32I, M46I/L, G48V/M, I54V/T/A/L/M, L76V, V82A/T/F/S, I84V and L90M (Lv et al., 2015) 
whilst V32I, L33F, I47V/A, I50V, I54L/M, L76V and I84V have been clinically associated with 
DRV resistance (Tremblay, 2008). Generally, resistance to the PIs occur when the viral PR 
accumulates several primary or major mutations in various regions of the enzyme (Wensing et 
al., 2010). Major mutations directly affect resistance by altering the structure of the catalytic site. 
This results in reduced contact between PR and the inhibitors. In addition, several secondary or 
minor resistance mutations emerge at a later stage to compensate for the changes induced by the 
major protease resistance mutations (PRMs) (Budambula et al., 2015). Therefore, this suggests 
that the way in which PR resists the PIs is dependent on complex evolutionary and resistance 
dynamics.  
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1.10 Gag structure, function and its role in PI resistance 
 
1.10.1 Structure and function 
The autocatalytic cleavage of the aspartyl protease enzyme from Gag-Pol (PR160) prompts the 
cleavage of both Gag-Pol and Gag (PR55) at predefined sites in the polyproteins (Weber and 
Agniswamy, 2009). Gag or group specific antigen is essential for viral infectivity and maintaining 
the structural integrity of HIV (Ning et al. 2016). The protein comprises four main domains, i.e. 
matrix, capsid, nucleocapsid and p6 (Bharat et al., 2014). In addition to these domains, two small 
spacer peptides (p2 and p1) that assist in the regulation of structural changes accompanying 
maturation are also found within Gag (Sundquist and Kräusslich, 2012). For successful 
maturation of the virions, the proteolytic cleavage of Gag occurs in a very precise and ordered 
manner as seen in Figure 1.9 below. 
 
 
Figure 1.9   Diagram showing the proteolytic cleavage of Gag by PR. The first site of cleavage 
in between p2 and nucleocapsid. This is followed by cleavage at the matrix-capsid and p1|p6 sites. 
Finally, the small spacer peptides are cleaved from capsid and nucleocapsid. Abbreviations: MA 
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= matrix, CA = capsid and NC = nucleocapsid. PDB codes: 2H3I (Matrix), 1L6N (N-terminal 
Capsid), 1A43 (C-terminal Capsid), 1U57 (p2), 1A1T (Nucleocapsid) and 2C55 (p6). 
 
 
1.10.1.1 Matrix 
The HIV-1 matrix (MA; p17) protein is a thin layer lining the inner surface of the virion lipid 
bilayer after maturation (Doherty et al., 2005). Structurally, the 132 amino acid protein (Hill et 
al., 1996) consists of an amino-terminal (N-terminal) globular head and a flexible carboxyl-
terminal (C-terminal) tail. Globular structures are typically spherical or “globe-shaped” water 
soluble proteins. In matrix, the head is composed of a 310 helix (Freed, 2015) and four alpha 
helices that is capped by a 3-stranded beta sheet. A 5th α-helix connects the capsid and MA 
domains (Freed, 2015), projecting away from the β-sheet to expose the C-terminal residues and 
forms the tail (Fiorentini et al., 2006). Based on the ionic strength and concentration of the protein 
buffer, MA may exist as either monomers, dimers, timers or oligomers of monomers, dimers and 
trimers (Forster et al., 2000).  
 
Functionally, MA facilitates the targeting of Gag-Pol and Gag to the plasma membrane via 
myristoylation and PIP2 signals8. Additionally, MA is also involved in the nuclear import of the 
pre-integration complex (PIC) (Freed, 1998). The PIC is a large nucleoprotein composed of 
several viral and cellular proteins that allows integration during replication (Thierry et al., 2015). 
Interestingly, MA also has cytokine-like functions that act on pre-activated human T cells 
encouraging proliferation, viral replication after p17R host cellular receptor binding and pro-
inflammatory cytokine release. Therefore, MA may have an important role in the virus- and host-
derived factors that contribute to favourable HIV-1 infection and replication (Fiorentini et al., 
2006). 
 
1.10.1.2    Capsid   
In a mature virion, the HIV capsid (CA, p24) protein oligomerizes to form a shell around the 
virus’s RNA and core-associated proteins (Freed, 1998). All morphological variances of the CA 
domain are derived from a collection of hexameric (rings) CA monomers (Maillard et al., 2011) 
that has the same tertiary structure (Ganser-Pornillos et al., 2007). CA comprises two separate 
domains: the N-terminal domain (NTD 1–145) and the C-terminal domain (CTD 146–231) (Gitti 
et al., 1996), connected by a flexible linker (Lingappa et al., 2014). Structural studies revealed 
                                                          
8 Plasma membrane-specific phosphatidylinositol-4,5-bisphosphate (PIP2) and myristoylation 
facilitates Gag membrane targeting to the plasma membrane. 
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that CA is predominantly composed of α-helices, with seven and four α-helices in the NTD and 
CTD, respectively (Bharat et al., 2012). Moreover, the NTD of CA contains an amino-terminal 
β-hairpin and resembles an arrowhead whereas the globular CTD comprises one 310 helix 
(Berthet-Colominas et al., 1999). Extensive intermolecular NTD-NTD interactions and to a lesser 
extent NTD-CTD interactions stabilize the hexameric rings. This stabilization occurs 
predominantly between helices 8–11 on the C-terminal side and 4–7 on the N-terminal side. 
Flexible CTD-CTD interactions link the adjacent hexameric rings, allowing for the formation of 
the curved lattice (Fassati, 2012) while inter-hexamer angle variation between the longitudinal or 
lateral positions or at the broad and narrow ends of CA has been suggested. Furthermore, the 
asymmetrical structure infers that no two CAs are identical (Zhao et al., 2013). Therefore, the 
flexibility and complex molecular interactions supports a variety of conformations that contribute 
to structural variation in CA (Gres et al., 2015). 
 
Additionally, each CA domain has a different function in HIV-1 morphogenesis. Although the 
NTD of CA is not necessary for immature virion assembly, it is indispensable for mature core 
formation (Borsetti et al., 1998). Contastingly, the CTD of CA is important for both the formation 
of the core and in virion assembly (McDermott et al., 1996). Additionally, all retroviruses 
comprise a conserved region of 20 AAs known as the major homology region (MHR) which is 
located in the CTD of CA (Wills and Craven, 1991). While this region is not clearly understood 
(Bell and Lever, 2013), its presence has been suggested to have a role at post-assembly and during 
assembly stages (Cairns and Craven, 2001). The entire MHR region forms a compacted strand 
turned helix stabilized by hydrogen bonds (Gamble et al., 1997). The MHR has been suggested 
to have a role CTD dimerization contributing to the stability of the viral shell (Ivanov et al., 2005). 
As such, mutations in this region may affect viral assembly. 
 
1.10.1.3 Nucleocapsid 
The 55 amino acid nucleocapsid (NC; p7) protein (Bell and Lever, 2013) packages two copies of 
the viral RNA genome into the assembling virions (Berkowitz et al., 1996). A prominent feature 
of NC is the presence of two highly conserved Cys-X2-Cys-X4-His-X4-Cys (CCHC) signatures 
that resemble zinc-finger motifs. The zinc-fingers, each containing an aromatic residue (F16 in 
the N-terminal zinc finger and W37 in the C-terminal zinc finger) (Darlix et al., 2011) coordinate 
a zinc ion (Lingappa et al., 2014) and are divided by a RAPRKKG basic domain linker (Godet et 
al., 2012). These separately folded zinc-fingers resemble beads attached to a string (Summers et 
al., 1992). 
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Functionally, in addition to genome packaging, NC can renature nucleic acids with catalytic rates 
of about four orders of magnitude. In reverse transcription, NC can also stimulate tRNALys binding 
to the primer binding site found at the N-terminal region of the genome, initiate reverse 
transcription from the bound tRNALys and partake in strand transfer (Rodriguez-Rodriguez et al., 
1995; Guo et al., 1997; Freed, 1998). Furthermore, annealing by NC enhances the formation of 
the converted loop-loop interaction into a stable duplex and the formation of RNA dimers (Lu et 
al., 2011). 
 
1.10.1.4 p6 
The C-terminal region of Gag comprises a proline-rich (Freed, 1998), 52 amino acid p6 domain 
(Votteler et al., 2011) where two amino acid sequences are translated, the -1 frameshift Gag-Pol 
p6 and the in-frame Gag p6 domain (Bell and Lever, 2013). Although the structure of the p6 
domain of Gag remains unclear (Freed, 2015), it is known that the domain displays little, if any 
secondary structure (Stys et al., 1993), instead serving as a flexible docking site for cellular host 
factors (Gottlinger et al., 1991). The p6 domain is also necessary for the incorporation of viral 
accessory protein, Vpr into the virions (Solbak et al., 2013). Vpr is associated with trans-
activation of the LTR, import of the pre-integration complex (PIC) in non-dividing cells, the 
induction of apoptosis9 and cell halt at the G2/M transition pathway10. 
 
1.10.1.5 p2 and p1 spacer peptides 
The 14 amino acid p2 peptide is found wedged between the N-terminal MA and C-terminal NC 
proteins (Bell and Lever, 2013). The C- and N-termini of the CA and p2 domains respectively, 
were shown to form two parts of an α-helix. Electron cryotomography analyses show that p2 
forms a six α-helical bundle that stabilizes Gag hexamers in immature virus particles (Wright et 
al., 2007). As a result, cleavage of p2 from NC is necessary for the formation of ribonucleoprotein 
within RNA and condensation of the CA domain. The late cleavage of CA|p2 allows 
morphogenesis through the cadence of CA-CA interactions. The importance of the integrity of 
the CA|p2 segment in formation of immature CA was shown in an electron microscopic study 
(Gross et al., 2000). 
 
The 16 amino acid p1 peptide lies between the CTD of NC and the NTD of p6. This peptide 
contains two highly conserved proline residues, namely P445 and P439. Hill et al. (2007) 
                                                          
9 Programmed cell death 
10 The G2/M transition is a point in the cell’s lifecycle where after the second growth phase (G2) and 
DNA replication (S phase), mitosis occurs (M phase) to separate the cell into identical daughter cells. 
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implicated the importance of p1 for Pol and Gag incorporation into the virus particles. The 
“slippery site” involved in the Gag-Pol ribosomal frameshift overlaps with the end of p1 leading 
to potentially complex effects of mutations at this site (Bell and Lever, 2013). The substitution of 
either proline (P445 and P439) by leucine results in lower stability of the NC-RNA complex and 
rescinds infectivity (Hill et al., 2002). Moreover, mutations at the cleavage sites at either end of 
p1 have discrepant effects. For example, mutations in NC|p1 have no effect on proviral 
integration, whereas mutations at the C-terminal that produces p15 (NC|p1|p6) or p8 (p1|p6) 
peptides decreases the amount of integrated provirus on subsequent infection. This differential 
effect may suggest the role of NC|p1 in proviral integration as opposed to p15 and p8 (Coren et 
al., 2007). 
 
1.10.2 Resistance 
The collection of resolved structures on individual Gag domains contributes to the intrinsic and 
functional behaviour of Gag at the molecular level (Novikova et al., 2018). As a result, it is now 
evident that Gag and its individual domains have significant roles in the lifecycle and 
perseverance of HIV (Freed, 1998; Mailler et al., 2016; Tomasini et al., 2018). Even so, an 
extensive review by Fun et al. (2012) highlights several Gag mutations within and outside the 
CSs that are associated with drug resistance or exposure. Mutations in Gag, particularly at NC|p1 
and p1|p6 CSs have been extensively reported (Borman et al., 1996; Nijhuis et al., 1999; Maquire 
et al., 2002; Prado et al., 2002; Dam et al., 2009). Additionally, while mutations in Gag can restore 
substrate processing (Myint et al., 2004; Tamiya et al., 2004; Ho et al., 2008; Parry et al., 2009), 
it has also been shown that Gag can confer resistance in the absence of mutations in the viral PR 
(Nijhuis et al., 2007; Gupta et al., 2010).  
 
1.11 Molecular mechanisms of drug resistance 
The molecular mechanisms of drug resistance are commonly elucidated through structural 
comparisons of the wild type and mutant proteins. In the HIV-1 PR, several structural changes 
associated with single amino acid substitutions have been identified: i) direct active site mutations 
that alter the interactions of PR with the substrate or inhibitor, ii) mutations occurring at the dimer 
interface affecting PR stability and iii) distal mutations showing an assortment of structural 
affects, such as mutations occurring at the flaps and those without direct contacts with inhibitors 
(Weber and Agniswamy, 2009). Whilst several mutations at the Gag CSs can be co-selected along 
with resistance mutations in the viral PR, the molecular mechanism by which these mutations 
contribute to resistance is unclear. However, it has been shown that Gag CS mutations can 
enhance the van der Waals interactions between the mutant PR and substrate (Özen et al., 2014). 
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As Gag is a large protein in nature, the mechanisms behind the structural synergistic effects of 
Gag and PR mutations requires further investigation (Su et al., 2019).     
 
1.12 Variability in HIV-1 subtype C 
Genomic variability differs across the subtypes. These discrepancies are based not only on the 
subtype but also the genomic region. Therefore, specific, functionally important regions in HIV 
are conserved across the subtypes, such as the CD4 binding sites (Alexandre et al., 2011). HIV-1 
subtype C exhibits high sequence variability (Lynch et al., 2009) which has been attributed to 
several distinct genetic features including three NF-κB binding sites at the long terminal repeats 
(Rodenburg et al., 2001), as well as a truncated Rev (Ndung'u et al., 2001, Gordon et al., 2003) 
and a five AA insertion in the Vpu protein. While the truncated Rev protein and the additional 
NF-κB binding sites may alter gene expression by influencing viral replication (Iordanskiy et al., 
2010), the enlarged Vpu protein may impact subtype C virulence via the regulation of Vpu 
functions including enhancing virion release and/or CD4 degradation (McCormick-Davis et al., 
2000). Interestingly, some mutations associated with drug resistance in other subtypes have been 
identified as natural polymorphisms in subtype C (Lynch et al., 2009). Examples of these 
signature mutations include PR’s M36I in non-B subtypes and I93L in subtype C (Santos and 
Soares, 2010). Contrastingly, some studies have reported the contribution of polymorphic 
residues in drug resistance (Bessong, 2008; Wainberg and Brenner, 2012). Furthermore, a higher 
level of diversity exists in subtype C Gag CSs in comparison to other group M subtypes (Li et al., 
2013). This diversity may arise through ARV drug selection pressure, mutations or as natural 
polymorphisms (Verheyen et al., 2009). 
 
1.13 Proteins 
Proteins are the macromolecular machines of life as they perform complex molecular processes 
with rapid efficiency and accuracy. These processes are usually dependent on the protein’s ability 
to bind other small molecules (Chica, 2018). Specifically, proteins form the abundance of cellular 
dry mass and is imperative for regulating biological function and molecular structure. Some of 
these functions include cellular messaging, maintenance of cell shape, catalytic reactions and the 
transport of small molecules. Although, these macromolecules exhibit great diversity in shape 
and size, all proteins are comprised from 20 common AAs (Janke et al., 2019). Together with 
these AAs, proteins display primary, secondary, tertiary structures that will be discussed in the 
subsequent sections of this chapter. 
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1.13.1 Primary structure 
Simply, the primary structure of a protein is a linear chain of AAs (Farhadi, 2018). Large 
polypeptide chains are formed when the carboxyl and amino groups of two different AAs form a 
peptide bond thus linking them together (Janke et al., 2019). Importantly, while the amino and 
carboxyl groups are conserved across all the AAs, the individual side chains are different. These 
side chains are what distinguishes AAs from each other (Farhadi, 2018).  
 
In nature, the amino acids that form specific proteins is dependent on an RNA template which is 
transcribed from a DNA sequence. The template codes for the AAs as triplet of bases, also referred 
to as a codon, from adenine, cytosine, guanine or uracil. As such, AAs can be identified based on 
either a three letter or single code (Wright, 2011). Since proteins form complex structures in 
nature, which is known as folding, the sequence of AAs plays a role in the conformation of the 
final structure. Furthermore, the AA side chains can also adopt numerous conformations referred 
to as rotamers. Specific conformational rotamers adopt the lowest energy. This energy is 
determined by the conformation of the backbone, the side chain the rotamer is interacting with 
and the environment (Wright, 2011).  
 
1.13.2 Secondary structure 
Secondary structures are formed due to repeated regular conformations of a polypeptide chain 
(Anfinsen et al., 1961; Zhang et al., 2018). The arrangement of peptide bonds results in the 
formation of specific structural elements in various regions of the proteins. The most common 
being α-helices and β-sheets (Eisenberg, 2003; DeBenedictis and Keten, 2019). Briefly, α-helices 
are formed when the phi and psi angles exhibit constant displacement between the nitrogen and 
α-carbon of N-Cα, Cα and carbonyl carbon of Cα-C and C-N. Furthermore, there are 3.7 AA 
residues per turn (Haimov and Srebnik, 2016). Contrastingly, β-sheets are formed from 
consecutive strands separated by turns. Varied hydrogen bond networks can form depending on 
the orientation of the strands. In essence, β-sheets can assume parallel, anti-parallel and mixed 
orientations (Craveur et al., 2013).  
 
1.13.3 Tertiary structure 
Tertiary structures are formed when specific regions known as loops and the secondary structural 
elements adopt a satisfactory three-dimensional (3D) state during protein folding. Since loops 
rarely have hydrogen bonds between residues, they exhibit high flexibility and are therefore less 
ordered (Subramani and Floudas, 2012). Moreover, folding is dependent on the hydrophobic 
packing of residues, dispersion of hydrophobic and hydrophilic residues in water and the non-
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covalent interactions between AA side chains. Additionally, regions of a protein that can 
independently fold into a stable 3D structure are referred to as domains (Wright, 2011), for 
example the individual Gag domains discussed in section 1.10.   
 
1.13.4 Quaternary structure 
Simply put, the quaternary structure of proteins refers to the 3D structure of several protein 
subunits such as dimers, trimers and tetramers (Godbey, 2014). These structures are bound by 
non-covalent bonds, salt linkages and disulfide bonds. Since these bonds are considered weak, 
dissociation of the individual protein subunits can occur (Pelley, 2007). As such, quaternary 
structures allow proteins to provide substrate binding sites, perform specialized functions and 
create concise spatial arrangements for the catalysis of chemical reactions (Veenhoff et al., 2002).  
 
1.13.5 Relationship between protein sequence and structure 
In 1973, Christian Anfinsen postulated that the 3D conformation, corresponding to the native 
structure of a protein depends on the AA sequence and has since become known as Anfinsen’s 
dogma. In essence, this meant that given optimal conditions, the specificity of an AA sequence 
results in a stable native structure. Contrastingly, Levinthal (1968) hypothesized that the tertiary 
structure of proteins relies on complex pathways based on their environment and chemical 
properties. This hypothesis has since been coined Levinthal’s paradox (Wright, 2011).  
 
Furthermore, proteins display great structural dynamics as they are not static even during 
equilibrium (Argudo et al., 2017; Chen and Makhatadze, 2017). Still this inherent flexibility is 
essential for proteins to accurately and efficiently perform their regular functions (Teilum et al., 
2009). Coupled with this, it is simpler to generate sequence data experimentally than to predict 
its native structure. This is especially highlighted by Levinthal’s paradox. Therefore, many 
software accommodate this complexity in their predictions of 3D protein structures (Wright, 
2011). An overview of the method used to predict and assess protein dynamics is discussed in the 
subsequent sections.         
 
1.14 Computational methods to predict protein interactions 
 
1.14.1 Homology modelling 
While the collection of protein structures is slowly gaining momentum, the structure of numerous 
proteins remains unsolved. Though it is impossible to solve all protein structures in existence, 
innovation into the computational prediction of protein tertiary structures is slowly filling this 
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gap. One such method includes homology modelling. Homology or comparative modelling is a 
method used to predict the tertiary structure of proteins from its AA sequence. The notion is that 
the structures exhibits greater stability and evolves more slowly over time. As such, homology 
modelling assumes that while similar sequences will adopt an almost identical structure, distant 
sequences will also retain a high level of similarity. Consequently, the method relies on a template 
of a known structure to compare against and predict the unknown structure (Muhammed and Aki-
Yalcin, 2018). Several steps are involved in homology modelling, namely, template selection, 
alignment of the template and target sequences, model building, model optimization and 
validation. Currently, several homology modelling software are available, however, the two most 
commonly used software include MODELLER and Swiss-Model. Unfortunately, a drawback of 
homology modelling is that these theoretical tertiary structures cannot be predicted if the 
corresponding template’s structure of a protein in the same family has not been solved (e.g. NMR 
or X-ray crystallography) (Chenug and Yu, 2018). Despite this, homology modelling is 
considered highly accurate, fast and low cost with clearly defined steps (Muhammed and Aki-
Yalcin, 2018).        
 
1.14.2 Molecular docking 
Proteins do not act in an independent manner in complex biological processes. In fact, proteins 
often interact with small molecules or ligands to complete important functional tasks (Salmaso, 
2018). This phenomenon has since attracted a great many scientists in the drug industry. The 
ability to accurately predict binding modes and interpret these data can provide invaluable 
information for the development of novel drug binding ligands (Salmaso and Moro, 2018). These 
methods have since been referred to as molecular docking. Since molecular docking estimates the 
best binding pose of a ligand and its associated protein, it requires an experimental or theoretical 
predicted tertiary structure (Salmaso, 2018). 
 
Molecular docking occurs in two stages, i.e. the search for conformation or binding poses and the 
scoring function that correlates a score to each binding pose generated (Kitchen et al., 2004; 
Huang and Zou, 2010). During conformational searches, the algorithm should accurately evaluate 
the specified conformation space outlined by the free energy landscape whereas the binding scores 
should be associated with the global minimum energy of the hypersurface11 (Salmaso and Moro, 
2018). In general, two approaches can be considered during docking, i.e. rigid and flexible 
docking. In the first approach, the independent protein and ligand are bound based on shape and 
                                                          
11 A physical space that considers the Nth dimension instead of only 2D and 3D models.  
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volume. The second approach assumes flexible docking in which binding is accomplished based 
on reciprocal effects of both the ligand and protein (Prieto-Martínez et al., 2018). Based on these 
approaches, there are currently several molecular docking software currently available for 
commercial and research purposes (Ciemny et al., 2018). Importantly, while molecular docking 
is fervently employed in the drug industries, this approach has been used to evaluate the 
interactions of existing protein-ligand systems, such as in HIV (Tong et al., 2017; Tarasova et al., 
2018; Vora et al., 2019).  
 
1.14.3 Molecular dynamics 
Since protein-ligand interactions play vital roles in key biological processes, studying these 
interactions is an important approach in understanding the basis of protein functionality (Fu et al., 
2018). A popular approach to evaluate these interactions is molecular dynamics (MD). Simply 
put, a MD simulation is a method used to compute the behavior of atoms and molecules over time 
(Lipkowitz, 1990). Briefly, the atomic particles are modelled with a specified charge and mass. 
The electrostatic force field, calculated from the atomic charge is used to estimate the force on 
each atom in the system. The force is then used to update the positions of the atoms and evolve 
the system over time. Consequently, MD simulations provide useful information on protein 
conformation and dynamics (Frenkel and Smit, 2002). This method has gained enormous 
popularity over the years due to software upgrades that has vastly improved the speed of 
calculations (Perricone et al., 2018).  
 
MD software include Chemistry of HARvard Macromolecular Mechanics (CHARMM), 
GROningen Machine for Chemical Simulations (GROMACS) and Assisted Model Building with 
Energy Refinement (AMBER). Apart from classical MD simulations, these packages also provide 
useful tools for protein assessment, including predicting the binding-free energy scores of protein-
ligand systems as discussed below. 
 
1.14.4 Predicting protein-ligand binding-free energies 
As previously discussed, the recognition of ligands by proteins drive many biological processes. 
The strength of this recognition is characterized by binding affinities (Jiao et al., 2008). The two 
most popular methods used to determine binding-free energies are the Molecular Mechanics-
Poisson Boltzmann and Generalized Born Surface Area calculations (MM-PBSA and MM-
GBSA). The MM-P(G)BSA approach to estimate binding-free energies are based on 
thermodynamics as shown in equation (1) (Case, 2014). The equation shows that the binding-free 
energy is the difference between the solvated complex, ligand and protein. 
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∆𝐺𝑏𝑖𝑛𝑑,𝑠𝑜𝑙𝑣 =  ∆𝐺𝑐𝑜𝑚,𝑠𝑜𝑙𝑣 − (∆𝐺𝑟𝑒𝑐,𝑠𝑜𝑙𝑣 + ∆𝐺𝑙𝑖𝑔,𝑠𝑜𝑙𝑣) (1) 
 
Each of these components are calculated based on the trajectory of the complex as well as the 
atomic interactions. Thus, equation (1) can also be written as equation (2): 
 
𝐺 =  𝐸𝑏𝑛𝑑 + 𝐸𝑒𝑙 + 𝐸𝑣𝑑𝑊 + 𝐺𝑝𝑜𝑙 + 𝐺𝑛𝑝 − 𝑇𝑆  (2) 
 
In equation (2) the first three terms (Ebnd, Eel, EvdW) are standard MM terms corresponding to bond, 
electrostatic and van der Waals (vdW) interactions. The polar and non-polar contributions are 
represented by Gpol and Gnp. In the MM-P(G)BSA calculations, the polar contributions are 
estimated either using the GB model or PB equation. Contrastingly, the non-polar contribution is 
estimated by the solvent accessible surface area (SASA). The TS term refers to the absolute 
temperature (T) multiplied by the entropy (S). Entropy calculations are estimated using the normal 
mode analysis (Genheden and Ryde, 2015). Normal mode analyses have a large margin of error 
therefore introducing significant uncertainty. Additionally, these calculations are computationally 
expensive (Graham et al., 2013). As a result, entropy calculations can be omitted if comparisons 
are being made between ligands binding to the same protein.   
 
1.15 Sequence-based methods in predicting protein interactions 
In addition to the structural approach, sequence-based methods have also been employed to 
evaluate protein interactions (Rao et al., 2014). These methods are usually applicable to larger 
protein datasets since sequence information is available for most proteins as opposed to their 
structure (Sael et al., 2012) as discussed in 1.13.1. Additionally, a vast majority of protein 
functional information is maintained in the sequence databases (Sael et al., 2012). Examples of 
sequence-based methods include gene cluster methods, phylogenetic reconstruction, coevolution 
analyses and network-related methods (Liu et al., 2012).  
 
In this study, we employed the use of phylogenic reconstruction, coevolution analyses and 
Bayesian networks to evaluate various co-evolutionary resistance pathways in Gag-PR (chapter 
three). 
 
1.16 Study significance, hypothesis and research aims 
South Africa has one of the largest ARV programs, globally that is unfortunately coupled with 
limited access to third-line treatment regimens (NDOH, 2019). An important challenge of this 
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consequence is the development of ARV drug resistance. Consequently, the emergence of 
acquired drug resistance in South Africa is on the rise (Chimukangara et al., 2019). With two PIs, 
i.e. LPV and DRV on the forefront of second- and third-line treatment regimens, respectively, the 
emergence of PI resistance mutations is concerning as is the evidence supporting the accumulation 
of resistance mutations in Gag (Fun et al., 2012). More so, information regarding the way in which 
Gag-PR mutational patterns are evolutionarily selected and interact on a structural level is limited 
(Zhang et al., 2010). Additionally, in spite of the large amount of structural information available 
on subtype B proteins, limited studies have focused on subtype C itself (Costa et al., 2014).  
 
Thus, the focus of this study was to elucidate the mechanisms by which Gag-PR coevolution can 
affect LPV and DRV resistance in HIV-1 subtype C. In doing so, we did not only evaluate the 
pathways to resistance but also the structural implications of complex resistance patterns in 
evading drug selection pressure.   
 
1.16.1 Hypothesis 
It is hypothesized that Gag-PR coevolution drives the accumulation of complex drug resistance 
mutational patterns. It is further hypothesized that interactions of these patterns of mutations can 
alter the molecular structure of Gag-PR to evade drug binding and maintain enzymatic function.  
 
1.16.2 Research aims 
Based on the hypothesis, two main aims were evaluated in this study: 
 
i. To determine Gag-PR coevolution under drug selection pressure. 
ii. To evaluate the structural mechanisms by which complex, coevolving resistance 
mutational patterns affect PI drug binding and Gag cleavage. 
 
1.17 Thesis outline 
This thesis is presented in six chapters as follows: 
 Chapter one provides a literature review of the HIV discovery, diversity and ARV 
treatment with focus on PR and its natural substrate, Gag. This section also highlights 
several concepts surrounding protein structure and function. 
 Chapter two highlights the drug resistance mutations in Gag and PR using sequences 
from a South Africa cohort and public databases. This chapter also pinpoints patterns of 
PRMs. 
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 Chapter three investigated Gag-PR coevolution and describes the probable pathways to 
LPV/r resistance using combination of phylogenetic methods and Bayesian network 
learning. 
 Chapter four describes the structural implications of a pattern of PRMs on LPV and 
DRV binding in two South Africa viral PR sequences. 
 Chapter five investigated the coevolutionary impact between the mutant A431V NC|p1 
Gag CS and PRMs described in chapter four. The focus of this chapter was to elucidate 
the mechanism by which the CSs are favoured over the drugs. 
 Chapter six provides a general discussion and conclusion highlighting the main findings 
observed in chapters two to five. It also provides a list of study limitations and future 
recommendations.     
 
 
 
 
 
 
 
     
 
 
 
 
 
 
 
 
 
 
31 
 
 
 
 
 
 
 
 
Chapter two 
 
Detecting drug resistance mutations in 
Gag and protease 
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2.1 Introduction 
The PIs are amongst some of the most potent ARVs currently used to treat HIV-1 infected patients 
(Midde et al., 2016). Although the success of PIs cannot be disputed, the development of drug 
resistance mutations can increase the risk of therapy failure (Kožíšek et al., 2012; Baxter et al., 
2016; Tsai et al., 2017). Therefore, the selection of protease resistance mutations (PRMs) can 
limit the options available for treatment while possibly allowing for resistance to develop in the 
other drug classes within the treatment regimen (Barber et al., 2012). Hence, the identification 
and effective characterization of PRMs can aid in pre-treatment screening processes that can 
possibly lead to the reduced risk of treatment failure.   
 
Whilst mutations in the viral PR are widely known to inhibit the effects of PIs (Shafer, 2017), 
mutations in Gag have been documented to do the same (Tamiya et al., 2004; Dam et al., 2009; 
Clavel and Mammano, 2010; Li et al., 2014). Though mutations in Gag are noted, their presence 
has not been considered in the selection of drug regimens for the current PIs. The ability of Gag 
and PR to behave as “partners in resistance” (Fun et al., 2012) emphasizes our disregard on the 
selection of Gag mutations in resistance outcomes. Moreover, as with PR, certain known PI-
resistance or exposure associated mutations in Gag have been linked to certain PIs (Cote et al., 
2001; Prado et al., 2002; Mo et al., 2007; Larrouy et al., 2010). This suggest that Gag follows a 
similar trend to PR when selecting mutations under drug selection pressure.  
 
Although information for patient sequences, drug regimens with their predictive efficaciousness 
and genotyped data indicating PI-resistance is publicly available, this information is primarily 
based on subtype B (Li et al., 2013). As previously mentioned in section 1.2 of the literature 
review, subtype C is currently the most predominate subtype (Günthard and Scherrer, 2016). 
Although subtype associated differences in the development of drug resistance is still debatable 
(Lessells et al., 2012), subtype genetic diversity (Wainberg and Brenner, 2012; Santoro and Perno, 
2013) and discrepancies in the selection of mutations between subtypes (Grossman et al., 2004; 
Sui et al., 2014) is still important to consider.  
 
Here we assessed the prevalence of drug resistance mutations in Gag and PR in HIV-1 subtype C 
PI-treatment associated datasets from publicly available repositories combined with sequences 
from a KZN cohort. It should be noted that some of these data was previously analyzed by Singh 
(2015) and is being reassessed here to confirm former observations made in our lab as well as to 
contextualize later chapters. 
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2.2 Methods 
 
2.2.1 Sequence dataset 
The dataset consisted of HIV-1 viral sequences genotyped from South African patients failing a 
PI-inclusive treatment regimen. To increase the sample size of the dataset, Gag and PR sequences 
were also retrieved from two HIV public databases, as described below.  
 
2.2.1.1 PR Cleavage Site (PCS) cohort 
The PCS cohort consisted of patients recruited between 2009–2013 at McCords and King Edward 
VIII hospitals in Durban, South Africa. All PCS study participants were on a LPV/r-inclusive 
treatment regimen for at least six months at the time of enrolment. These participants had a viral 
load of >1,000 copies/mL. The median CD4 cell count was 135 cells/μL prior to treatment. CD4 
data following drug therapy was not available for these patients. The number of PR and Gag 
sequences included in the dataset was dependent on whether the samples were successfully 
sequenced by previous students (Pillay, 2015; Singh, 2015). Consequently, 86 Gag and 130 
treatment exposed PR sequences were included in the final dataset.  
 
This retrospective study was approved by the Biomedical Research Ethics Committee (BE446/15) 
and can be viewed in Appendix E. 
 
2.2.1.2 Sequences obtained from public databases 
A total of 44 Gag and 2,316 treatment exposed PR sequences from HIV-1 subtype C infected 
patients were obtained from the HIV Stanford Drug Resistance (https://hivdb.stanford.edu/) and 
Los Alamos Sequence (http://www.hiv.lanl.gov) databases. To ensure confidence in the study 
observations, the patients had to be on at least one PI to be included in the dataset.  
 
The control groups, obtained from the Los Alamos database comprised 2,610 and 7,303 HIV-1 
subtype C Gag and PR sequences, respectively. The dataset obtained for the control groups 
followed a stringent search criterion where all sequences had to be ARV naïve.  
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2.2.2 Sequence analysis 
Each Gag and PR treatment associated dataset was grouped separately for sequence alignment 
and downstream analyses. For quality control purposes, duplicates and sequences with 
hypermutations were detected using the Los Alamos ElimDupes and Hypermut tools 
(http://www.hiv.lanl.gov) and subsequently removed (Li et al., 2013) as shown in Figure 2.1 
below. The Gag and PR sequences were then aligned against a drug naïve patient-derived subtype 
C reference sequence (accession number: AY772699) and the subtype B HXB2 reference strain 
(accession number: K03455) in MAFFT v.7.402 (Katoh and Standley, 2013) and manually edited 
in BioEdit v.7.2.5 (Hall, 1999).  
 
Figure 2.1   Overview of the study dataset and control groups utilized in this study for PR and 
Gag. 
 
 
The RegaDB sequence analysis tool (www.rega.Kuleuven.be/cev/regadb) was used to perform a 
codon-by-codon analysis on the sequence datasets. The sequence analysis tool compared each 
sequence to the reference sequences and calculated the presence or absence of a mutation at each 
amino acid (AA) position. The frequency of mutations at each AA position was then calculated 
per the following formula: 
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𝐹 (%) =  
𝑆
𝑁
 𝑥 100 
 
F : Frequency of each mutation 
S : Sum of mutation 
N : Total number of sequences at each position 
 
 
Thereafter, the Stanford Resistance HIVdb algorithm (http://hivdb.stanford.edu/) was used to 
identify and interpret the PR drug resistance mutations. Mutations in Gag found associated with 
PI drug resistance or exposure was identified based on Fun et al. (2012). 
 
2.2.3 Statistical analysis 
The Fisher’s exact test was performed to assess proportional differences of mutations between 
the treatment exposed and naïve Gag and PR sequence datasets. A p-value of <0.01 was 
considered statistically significant. The statistical tests were performed in SPSS v.25 (SPSS Inc., 
Illinois). 
 
 
2.3 Results 
 
2.3.1 Drug resistance mutations in PR 
From the data analysis, 12 major PRMs and 20 amino acid variants were identified as seen in 
Figure 2.2. Overall, the highest percentage of mutations were identified at position 82 (25%). This 
was followed by positions 54 (23%) and 46 (19%). Interestingly, variation at these positions 
indicate that certain AAs are selected at a greater frequency than others. For example, mutation 
V82A (n=221; 23%) occurred at a higher frequency than V82C/M/S/T (n=23; 2%). This could 
also be seen for I54V (n=211; 22%) and M46I (n=157; 16%). Contrastingly, all other variants 
occurred at much lower frequencies (<3%), excluding L76V (n=70; 7%) and L90M (n=138; 
14%). Of note, D30N, V32I, G48V, L76V, I84V, N88S and L90M were the only variants 
observed at these positions.  
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Figure 2.2   Proportion of position and specific major resistance mutations identified in the PR 
sequence dataset (only 964 out of the 1,972 PR sequences had major PRMs). Outer ring: 
Percentage (%) of overall mutations at a specific position. Inner ring: Proportion of specific 
amino acid variants. Abbreviations: P = position and n = total number of mutations at specific 
amino acid positions. Note 1: All amino acid variants were found significantly (p<0.01) higher 
in the treated vs naïve groups. Only I47V (p=0.026) and V82M (p=0.011) were non-significant 
(p>0.01). Note 2: Data from the naïve sequence dataset not shown. 
 
 
Interestingly, several combinations of mutations ranging between one and six were observed 
amongst the major PRMs (Table 2.1). Apart from the mutations that occurred alone, one of the 
most commonly occurring combinations was M46I+I54V+V82A (red). In addition, this recurring 
pattern was also observed in many of the other combinations (i.e. combinations of 4–5) as 
highlighted in red in Table 2.1, including the most frequent combination of four 
M46I+I54V+L76V+V82A (purple). All other combinations varied and depicted no observable 
mutational pattern.  
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Table 2.1   Combinations of major resistance mutations identified in the 964 protease sequences. Note: Combinations ranged from one to six.  
 
COMBINATIONS n COMBINATIONS n COMBINATIONS n 
ONE 
L90M 43 I50L 5 I47V 1 
V82A 35 M46L 4 V82T 1 
D30N 23 I47A 2 I84V 1 
M46I 8 L76V 2 V82T 1 
I54V 6 N88S 2   
TWO 
I54V+V82A 35 N88S+L90M 2 M46I+I84V 1 
M46I+L90M 10 M46I+L76V 2 M46L+I47A 1 
V82A+L90M 4 M46I+N88S 2 I47A+N88S 1 
D30N+L90M 4 L76V+V82A 2 M46L+V82A 1 
I54V+L90M 3 V32I+V82A 1 I54L+L90M 1 
I54V+I84V 3 M46I+I50L 1 V32I+I47A 1 
I84V+L90M 3 M46I+I50V 1 I54V+V82M 1 
M46I+V82A 2 M46I+I54V 1 V82M+L90M 1 
G48V+V82A 2 V32I+I47V 1 L76V+V82C 1 
THREE 
M46I+I54V+V82A 43 I54V+V82S+L90M 2 M46I+V82A+L90M 1 
I54V+V82A+L90M 13 M46I+I54V+L90M 2 M46I+L76V+L90M 1 
M46L+I54V+V82A 7 I54V+V82A+I84V 2 G48V+I54V+V82T 1 
I54V+L76V+V82A 5 M46I+I47A+I84V 1 I54L+I84V+L90M 1 
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M46L+V82A+L90M 4 V32I+I47A+V82A 1 V82A+I84V+L90M 1 
M46I+I84V+L90M 3 M46I+L76V+V82A 1 D30N+I54V+V82A 1 
I54V+I84V+L90M 3 M46I+N88S+L90M 1 I54V+V82C+L90M 1 
M46I+I54L+L90M 2 M46L+I47A+N88S 1   
FOUR 
M46I+I54V+L76V+V82A 35 M46I+I54V+L76V+I84V 2 M46I+I54V+L76V+V82M 1 
M46I+I54V+V82A+L90M 8 M46L+G48V+I54V+V82S 1 M46I+I50V+I54V+L90M 1 
M46I+I50V+I54V+V82A 6 V32I+M46I+I54V+V82A 1 M46L+I54V+V82C+L90M 1 
M46I+I54V+I84V+L90M 2 G48V+I54V+V82T+L90M 1 I54V+V82T+I84V+L90M 1 
M46I+I54L+L76V+I84V 2 M46I+I54V+V82C+I84V 1 V32I+I54L+L76V+V82A 1 
G48V+I54V+V82S+L90M 2 M46I+I54V+V82T+L90M 1   
M46L+I54V+L76V+V82A 2 I54V+V82A+I84V+L90M 1   
FIVE 
M46I+I54V+L76V+V82A+L90M 8 M46I+I50V+I54V+L76V+V82A 1 V32I+M46I+I54V+L76V+I84V 1 
M46I+I50V+I54V+V82A+L90M 2 M46I+I47V+I54V+L76V+V82A 1 M46L+G48V+I54V+V82S+L90M 1 
M46I+I54V+L76V+V82C+I84V         2 M46I+I47V+I54V+V82C+L90M 1   
M46I+I54V+V82A+I84V+L90M 1 M46I+I47V+I54V+L76V+V82C 1   
SIX 
M46I+I54V+L76V+V82C+I84V+L90M 2     
 
Note: n – frequency of occurrences observed within the study group.  
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Additionally, several resistance-associated mutations occurred at varying frequencies as seen in 
Figure 2.3. Of these, 12 were classified as non-polymorphic, minor resistance mutations and four 
as other, polymorphic PI accessory mutations by the HIVdb algorithm. Excluding positions 10 
(16%), 20 (5.9%), 71 (6.1%) and 74 (16.8%), variation at the remaining positions were infrequent, 
occurring at 2.1% or less. The most common variants at these positions included L10F (n=126; 
6.4%), L10I (n=107; 5.4%), A71V (n=111, 5.6%) and T74S (n=311; 15.8%). 
 
 
Figure 2.3   Frequency of accessory resistance mutations12 identified in the viral PR with known, 
non-polymorphic, minor mutations represented by the purple bars and other, polymorphic 
mutations identified during drug resistance represented by the pink bars. Note 1: For those with 
multiple amino acid variants, the cumulative percentage is displayed above the coloured bars. 
Note 2: All amino acid variants were found significantly (p<0.01) higher in the treated (n=1,972) 
vs naïve (n=6,565) groups except for L10V (p=0.000), V11I (p=0.270), K20M (p=0.000) and 
T74S (p=0.000) which occurred more frequently in the control groups. Note 3: Data from the 
naïve control dataset not shown.   
 
 
                                                          
12 The Stanford HIVdb algorithm classifies PR’s accessory resistance mutations in two ways: i) non-
polymorphic, accessory/minor resistance mutations that are associated with reduced susceptibility to 
PI drugs and as ii) other, polymorphic, accessory mutations that can increase viral replication with PI-
resistance mutations.  
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2.3.2 Gag mutations associated with PI resistance/exposure 
As the concept of PI drug resistance associated with mutations in Gag is still gaining momentum, 
there are currently no software-based tools that can identify resistance mutations in Gag based on 
the sequence dataset. Consequently, manual methods of identification are required based on 
previously published works. The review conducted by Fun et al. (2012) provides a comprehensive 
list of resistance associated mutations in Gag that were determined based on in vitro studies. The 
paper also goes on to classify these mutations as either resistance associated, i.e. they were found 
to directly impact PI resistance, or exposure associated (those that arose as a result of PI exposure 
but may not have had a significant impact of drug resistance). Therefore, based on Fun et al. 
(2012), a total of 30 Gag mutations were identified in the Gag treated sequence dataset. These 
mutations were further grouped into two categories, comprising 11 resistance and 19 exposure 
associated mutations.  
 
The resistance associated mutations included R76K, Y79F, T81A, V128I, Y132F, A431V, 
K436R, I437V, L449F/P/V, R452K and P453L/T as shown in Figure 2.4. Amongst these, CS 
mutations A431V (NC|p1), L449F (p1|p6) and R452K (p1|p6) revealed significantly (p<0.01) 
higher frequencies in the treated versus naïve groups whilst the remaining mutations occurred at 
comparable, non-significant (p>0.05) frequencies in both sequence datasets. 
 
This suggests that unlike the CS mutations which occurs to actively play a role in drug resistance 
(i.e. genetic selection), the other resistance-associated mutations possibly occur more randomly 
but aids in resistance when present under drug selection pressure.   
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Figure 2.4   Frequency of Gag resistance-associated mutations in the treated (n=107) versus naïve 
(n=2265) sequence datasets. Significant differences (p<0.01) are denoted by the red asterisks (*).  
 
 
Figure 2.5 provides an overview of the known PI exposure associated Gag mutations identified 
in the sequence dataset. Accordingly, mutations K62R, N373P, I401V, R409K and S451T were 
significantly (p<0.01) higher in the treated versus naïve group. Additionally, apart from N373P 
and S451T which are p2|NC and p1|p6 CS mutations, respectively, all other mutations were 
detected at non-CS positions.      
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Figure 2.5   Frequency of Gag exposure-associated mutations in the treated (n=107) versus naïve 
(n=2265) sequence datasets. Significant differences (p<0.01) are denoted by the red asterisks (*).  
 
 
2.3.3 Identification of presumptive Gag resistance associated mutations 
To identify presumptive Gag resistance-associated mutations, the frequencies of mutations in the 
treated versus naïve groups were compared. Accordingly, mutations that occurred significantly 
(p<0.01) greater than 10% in the treated versus naïve group were considered resistance associated 
mutations.  
 
Twelve presumptive Gag mutations were identified in the sequence dataset, as depicted in Figure 
2.6. Interestingly, these mutations were only found at non-CSs. Of the 12 mutations, six (T53N, 
S54A, Q69K, D122T, S125D and N126E) were identified in matrix (p17), four (D260E, I256V, 
D319E and R335K) in capsid (p24) and two (P485A and L498S) in p6. No mutations were 
identified in the NC domain.   
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Figure 2.6   Frequency of presumptive Gag resistance-associated mutations identified in the 
treated (n=107) versus treatment naïve (n=2265) sequence datasets.  
 
 
2.4 Discussion 
Using a large HIV-1 subtype C dataset comprised of publicly available sequences and those of 
patients recruited in KZN, this study identified various PI-resistance mutations previously linked 
to both PR and Gag. Additionally, several presumptive Gag mutations associated with PI-
resistance/exposure were also identified.  
 
These data revealed that out of the 1,972 PR sequences, only 964 (49%) harboured major PRMs. 
As such, more than half (51%) of the PR sequence dataset did not present with drug resistance 
mutations, suggesting that non-adherence is a prominent factor in the development of resistance 
mutations, as reported by other studies (Levison et al., 2011; Wallis et al., 2011; Court et al., 
2016; Kyaw et al., 2017).  
 
In this study positions 82, 54 and 46, having the highest percentage of variation, are in the active 
site (82) and flap regions (46, 54) of the viral PR and are therefore integral for substrate cleavage 
(Saleh et al., 2017). As such, mutations at these positions can aid the virus in outcompeting the 
inhibitor for more efficient cleavage and subsequently escape drug selection pressure (Liu et al., 
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2008; Weber and Agniswamy, 2009; Yu et al., 2015). Additionally, the selection of specific 
mutational variants (M46I, I47A, G50V, I54V, V82A) over others (M46L, I47V, G50L, I54L, 
V82CMST) at these positions suggests that AA selection also has an important role in maintaining 
protein functionality when resistance is induced. Dwyer (2001) showed that the electronic 
characteristics13 of an AA could be comparable to the effect of hydrophobicity on the 
conformational preferences during protein folding. In this study, the frequently occurring triplet 
of M46I+I54V+V82A are described as common PI-resistance mutations by the Stanford Drug 
Resistance Database in ATV/r14, FPV/r, IDV/r, LPV/r2 and NFV/r (Appendix D; Figures 1–2). 
Moreover, the selection of L76V in conjunction with the above mutations, as observed in this 
study, has been shown to not only enhance LPV/r resistance (Young et al., 2010) but also allows 
for low-level DRV/r resistance to occur (HIVdb algorithm; Appendix D; Figure 3).  
 
Whilst several accessory PI mutations were observed in this study, the most prevalent included 
L10F/I, A71V and T74S. The L10F/I mutations have been linked to reduced susceptibility and/or 
increased replication capacity to numerous PIs when found associated with other resistance 
mutations (Prado et al., 2002; Rhee et al., 2010; De Luca et al., 2016; Aoki et al., 2018). The 
polymorphic A71V mutation has been found in association with other PI-resistance mutations in 
numerous studies (Shafer et al., 2007; Lopes et al., 2015; Huang et al., 2017; Pessôa and Sanabani, 
2017). Although the role of A71V is largely unknown (Gonzalez et al., 2008), a study conducted 
by Chang and Torbett (2011) revealed that in combination with I84V, A71V restored the 
structural stability of the PR to within 1°C of the WT15. The high prevalence of T74S observed in 
this study was consistent with other studies investigating the selection of drug resistance 
mutations in patients receiving a PI-inclusive treatment regimen (Taylor et al., 2011; Etta et al., 
2017; Lu et al., 2017). Although T74S is polymorphic in most non-B subtypes (Deforche et al., 
2006), its presence in treatment-associated outcomes suggests that it provides a selective 
advantage and can either improve or maintain viral replication capacity in the presence or absence 
of PR resistance mutations, respectively.  
 
                                                          
13 Electronic characteristics refers to the physico-chemical nature of the amino acid side chains such 
as the hydrophobicity, pKa, steric effects (bulk of the side chain), etc. Thus, these characteristics were 
used to provide a scale: O (strong electron donor), U (weak donor), Z (ambivalent), B (weak electron 
acceptor) and X (strong acceptor) (Dwyer, 2001).  
14 High-level drug resistance. 
15 In other words, there was only a 1°C difference in the melting temperature between the WT 
and mutant when measured using Differential Scanning Calorimetry. Therefore, the mutant is 
comparatively stable.   
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Of the 11 resistance-associated Gag mutations, only the A431V (NC|p1), L449F (p1|p6) and 
R452K (p1|p6) mutations were found significantly higher in the treatment exposed versus naïve 
sequence dataset (Figure 2.4). The A431V mutation has been linked to several PIs, including 
LPV/r (Mammano et al., 1998; Cote et al., 2001; Mo et al., 2007; Nijhuis et al., 2009). In this 
study, the A431V mutation was found in 26% (n=107) of the viral Gag sequences. It has been 
shown to confer resistance in the absence of major PRMs (Dam et al., 2009; Nijhuis et al., 2009) 
and act in a compensatory manner when PRMs are present by improving viral fitness (Mammano 
et al., 2000; Cote et al., 2001). This mutation often occurs with major PRMs, V82A (Bally et al., 
2000; Malet et al., 2007) and M46I/L (Myint et al., 2004). A study conducted by Nijhuis et al. 
(2009) on subtype B infected patients receiving a LPV/r-inclusive treatment regimen revealed 
that A431V was also selected in viruses comprising an M46I+L76V PR double mutant, increasing 
LPV/r resistance by 10.6-fold and improving viral replication capacity by 10%. Contrastingly, 
Myint et al. (2004) revealed that A431V had deleterious effects on the replication capacity of 
D30N, N88D and L90M PR mutants suggesting that A431V is synergistically co-selected with 
specific PRMs.   
 
Unlike A431V, the L449F mutation increased viral replication capacity in the PR mutants 
observed in the Myint et al. (2004) study. This mutation has been shown to reduce the 
susceptibility of various PIs when combined with major PRMs D30N/N88D and with V82A or 
L90M in subtype B (Fun et al., 2012). However, unlike A431V, L449F cannot confer resistance 
alone (Fun et al., 2012), and instead acts in a solely compensatory role (Yates et al., 2006; Girnary 
et al., 2007; Kolli et al., 2009). Recently, in a structural study investigating the effects of p1|p6 
CS mutations on an I50V+A71V subtype B PR mutant, Özen et al. (2014) demonstrated that 
L449F increased the van der Waals forces in the enzyme-substrate complex, thereby restoring 
PR’s active site dynamics. Similar to L449F, the R452K Gag mutation, frequently occurring with 
D30N/N88D, I84V and I50V, has a compensatory role during PI-selection pressure (Kolli et al., 
2009).  
 
Additionally, several Gag mutations associated with PI exposure were identified in this study, 
five (G62R, S373P, I401V, R409K and S451T) of which occurred at significantly higher 
frequencies in the treated dataset (Figure 2.5). Although the G62R mutation occurred in 22% of 
the Gag sequence dataset in this study, its role in resistance is not yet understood (Koh et al., 
2009). In a study investigating a novel PI (GRL-02031) against a multi-drug resistant PR, Koh et 
al. (2009) observed that G62R along with three other Gag mutations developed upon a 37th 
passage after exposure to GRL-02031 on MT-4 cell lines. Interestingly, one of the other mutations 
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found in the Koh study included NC mutation, R409K. Despite evidence linking R409K to APV/r 
(Gatanaga et al., 2002; Aoki et al., 2009), these studies did not report changes to APV 
susceptibility in vitro. As such, its role in PI-resistance is unclear. However, Stray et al. (2013) 
reported that R409K together with five other Gag mutations was able to reduce the efficacy of a 
novel PI (GS-8374) by 14-fold after >300 days of passage on MT-2 cell lines. This study suggests 
that since only one polymorphism was selected in PR, the Gag mutations were selected to confer 
resistance, playing a role as primary resistance mutations. In a similar manner to R409K, NC 
mutation I401V has been linked to treatment failure (Myint et al., 2004), however the mechanism 
by which it acts is not understood.  
 
This study identified two Gag CS PI-exposure associated mutations (S373P and S451T). Codon 
373 of the p2|NC CS is highly variable and comprises three mutational variants (S373P/Q/T) that 
are associated with PI-exposure (Fun et al., 2012). The S373P mutation has been linked to LPV 
studies in subtype B (Mckinnon et al., 2011; Sutherland et al., 2014) and in CRF02_AG (Teto et 
al., 2017). The S451T mutation in the p1|p6 region has been associated with LPV in subtype B 
(Masse et al., 2007) and DRV in the POWER16 trials (Dierynck et al., 2007). 
 
Finally, 12 presumptive resistance associated mutations spanning the MA, CA and p6 regions of 
Gag were also observed (Figure 2.6). Previous data from our lab identified only two of the 12 
presumptive Gag mutations, namely, Q69K and I256V (Singh, 2015). However, the dataset was 
considerably smaller (954 subtype C naïve and 54 acutely infected individuals vs. 80 PI-treated 
individuals) than what was used in the current study. While mutations outside the Gag CSs have 
been linked to drug resistance (Gatanaga et al., 2002; Callebaut et al., 2011; Parry et al., 2011), 
the numerous functional roles of MA, CA and p6 as discussed in section 1.10 of the literature 
review, suggests that mutations in these domains arise to maintain proper function at various 
stages in the virus’s lifecycle rather than affecting resistance in a more direct manner, like the CS 
mutations (van Maarseveeen et al., 2012). 
 
 
2.5 Conclusions  
The aim of this chapter was to identify the selection of drug resistance mutations in Gag and PR 
in treatment vs naïve groups. In this study, several major PRMs, mostly associated with LPV/r 
were identified. Using a large dataset, these data supported previous findings observed in our lab 
                                                          
16 The POWER trials were clinical trials used to evaluate the efficacy and safety of Darunavir with 
low dose Ritonavir in comparison to other PIs.  
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(Singh, 2015) on the selection of M46I+I54V+V82A as well as several studies reported elsewhere 
(Van Zyl et al., 2013; Grossman et al., 2014). Moreover, the inclusion of L76V to this triple 
combination was not only a prominent feature of the findings observed in this study but also of 
those reported by Singh (2015). Additionally, these data indicated that certain Gag mutations, 
specifically A431V, appears to play a role in treatment associated outcomes. Therefore, chapter 
three investigated Gag-PR coevolution to evaluate how mutations in PR and Gag interact in 
pathways leading to LPV/r resistance. 
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Chapter three 
 
Evaluating the coevolving nature of the 
HIV-1 Gag-protease proteins under ARV 
drug selection pressure 
 
 
--This chapter was adapted from our research publication entitled “Gag-protease 
coevolution shapes the outcome of Lopinavir-inclusive treatment regimens in 
chronically infected HIV-1 subtype C patients”. 
 
V. Marie and M. Gordon, Bioinformatics, Published Ahead of Print, doi: 
10.1093/bioinformatics/btz076   
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3.1  Introduction 
As mentioned previously (see section 1.9.4 of chapter one), LPV/r and DRV/r are two HIV-1 PIs 
that have the highest genetic barriers, requiring at least three mutations in LPV/r and more in 
DRV/r for high-level drug resistance to occur (Doherty et al., 2011). Consequently, the multi-step 
mechanism and high genetic barrier of these PIs results in a complex combination of mutational 
pathways leading to drug resistance (Rabi et al., 2013). Although many combinations of PI 
mutations occur, some are more frequent than others suggesting that these patterns of mutations 
are not occurring at random (Zhang et al., 2010).  
 
However, recognizing Gag-PR coevolution and its role in facilitating alternative pathways to PI 
resistance is crucial. Despite our knowledge on the impact of PRMs on therapy failure, the 
introduction of Gag mutations with PR remains largely unclear (Li et al., 2014). Since protein 
coevolution can result in mutations at functionally important sites (Chakrabarti and Panchenko, 
2010), the intimate interactions of Gag and PR during viral maturation can allow these proteins 
to coevolve and subsequently escape drug selection pressure (Giandhari et al., 2016). Therefore, 
it is important to understand these resistance dynamics to fully elucidate the pathways leading to 
drug resistance and ultimately therapy failure.  
 
Here we used Bayesian network learning (BNL), which is a statistical model that describes the 
conditional independencies between a set of variables (Pearl, 1998), to elucidate pathways leading 
to LPV/r failure. To identify the sites at which coevolving Gag and PR residues occur, we utilized 
a coevolution sequence analysis tool and conducted a positive selection analysis. Finally, using 
these data we evaluated the multivariable effect of Gag and PR mutations. To the best of our 
knowledge, this is the first study used to explore the combined effects of Gag and PR mutations 
in pathways to LPV/r resistance. 
 
 
3.2 Methods 
 
3.2.1 Sequence dataset 
Fifty-Eight complete Gag and PR sequences were retrieved from the PCS cohort as described in 
section 2.2.1.1 of chapter two. Noteworthy, unlike the other 57, one patient was on another PI 
(i.e. Ritonavir) during first-line before switching to LPV/r and failing second-line treatment, like 
the other 57 patients. Prior to concatenation, the Gag, PR and reference sequences were aligned 
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and manually edited as described in chapter two, section 2.2.2. The final concatenated sequence 
alignment length was 1,797 nucleotides. 
 
3.2.2 Phylogenetic reconstruction 
Phylogenetic trees were constructed in MrBayes v.3.2 (Ronquist et al., 2012) for Bayesian 
inference (BI) and RaxML v.8.1.17 (Stamatakis, 2014) for maximum-likelihood (ML) estimation. 
Prior to tree generation, the best-fitting nucleotide substitution model was determined according 
to the Akaike Information Criterion (AIC) using jModelTest. The GTR+I+G model selected by 
AIC, together with the likelihood calculations, was used to modify the following parameters in 
the MrBayes block: revmatpr = dirichlet (1.9444, 6.2812, 1.0534, 1.0472, 8.3907, 1.0000), 
statefreqpr = dirichlet (0.3750, 0.1868, 0.2374, 0.2008), shapepr = fixed (0.6600) and pinvarpr = 
fixed (0.3860). Tracer v.1.5 (http://beast.bio.ed.ac.uk/software/tracer) was used to assess the prior 
and posterior distributions, following which 25% of the samples were discarded as burn-in and a 
consensus tree was generated. The RaxML trees were generated via 1000 steps of rapid 
bootstrapping and a ML search with model parameters estimated up to 0.001. FigTree v.1.4.3 
(http://tree.bio.ed.ac.uk/software/figtree/) was used to observe the topology of the phylogenetic 
trees and the Java-based application Compare2Trees 
(http://www.mas.ncl.ac.uk/~ntmwn/compare2trees/index.html) was used to compare tree 
topology between the two methods. 
 
3.2.3 Identifying positive selection 
To examine the selection pressure in Gag-PR, the rate ratio of non-synonymous to synonymous 
(ω) substitutions were estimated using the CodeML program in the PAML 4.0 package (Yang, 
2007). Accordingly, ω=<1, ω=1, ω=>1 assumes purifying, neutral and positive selection, 
respectively. The ω value and likelihood estimates were calculated for three pairs of site models: 
M0 (one ω) vs M3 (discrete), M1a (nearly neutral) vs M2a (positive selection) and M7 (beta) vs 
M8 (beta&ω=>1). Using the likelihood ratio test (LRT), the statistical significance between pairs 
of site models were used to assess the model fit to the data and indicate positive selection. Briefly, 
the LRT is twice the log-likelihood difference between each pair of models [2Δℓ = 2(ℓ1 – ℓ0)]. 
Since the LRT follows an asymptotically chi (χ2) distribution with the number of degrees of 
freedom calculated in the difference of free parameters, it can be used to test if the null model is 
accepted against the alternative model (p-value). Thereafter, the Bayes Empirical Bayes method 
was used to identify specific sites under positive selection. 
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3.2.4 Evaluating the coevolving nature of Gag-PR 
The Coevolution Analysis for Protein Sequences (CAPS) program (Fares and Travers, 2006) 
was used to evaluate Gag-PR coevolution. Briefly, the time-dependent evolutionary variation 
identifies the coevolving AA sites e and k by comparing the transition of AAs at sequences i and 
j (θek)ij. The evolutionary variation is estimated using a blocks substitution matrix (BLOSUM) 
and the transitions of AAs are corrected by calculating the divergence time of sequences i and j. 
The comparison of 5000 randomly sampled estimates were used to identify the coevolving 
codons. Furthermore, CAPS corrects for multiple tests of non-independence data by a step-
down permutation procedure. 
 
3.2.5 Mapping resistance pathways with BNL 
BNL was performed using the B-Course software (Myllymäki et al., 2002). The BNL dataset 
consisted of an equal amount of HIV-1 subtype C PI-naïve sequences of Gag-PR (obtained from 
the Los Alamos Database). Only mutations greater than a 10% prevalence in the treatment 
exposed and naïve sequence datasets were included in the network. Two networks were generated, 
one independently constructed for PR whilst the second incorporated variables from Gag-PR to 
observe a compounded effect. The robustness of the networks was assessed with a non-parametric 
bootstrap analysis of 5,000 replicates calculated in R. Additionally, for every resampled dataset, 
BNL was performed again in B-course to ensure the dependencies observed in the networks 
remained unchanged after multiple comparisons. In the networks, nodes are the colour 
coordinated variables while arcs are the arrows connecting them. Variables belonging to the same 
position are grouped together. While BNL implies bi-directionality wherein the presence of a 
mutation affects the prevalence of another mutation, arc direction does not indicate causality. 
Instead, arc direction allows a multivariable effect to be observed based on individual mutation 
conditional dependencies (Deforche et al., 2006). 
 
 
3.3 Results 
 
3.3.1 Tree reconstruction and the detection of positively selected Gag-PR sites 
To evaluate the selection pressure and coevolution of Gag and PR, phylogenetic trees were 
inferred using ML and BI methods. Tree topologies for both the ML and BI methods were similar 
with an overall topological score of 93.67% as observed in Figure 3.1. 
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Figure 3.1   Phylogenetic reconstruction of the Gag-PR sequences showing (a) maximum-likelihood (ML) and (b) Bayesian inference (BI) trees. Bootstrap 
support from 1000 replicates (ML) and posterior probabilities (BI) >70% are shown by the red asterisks (*). Similarities between the trees as computed 
by the Java-based application Compare2trees is indicated below the figure.   
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The PAML package identified 24 positively selected sites at the posterior probability level of 
greater than 99% as seen in Figure 3.2. Out of the 24 positively selected sites, three were from 
PR, namely codons L10, L63 and V82. While codons 10 and 82 are sites at which drug resistance 
mutations occur, codon 63 is regarded as one of the most variable sites in PR. In Gag, 21 positively 
selected sites were identified including eight in MA, seven in CA, three between the p2 and NC 
regions as well as three in the p6 domain. Interestingly, four codons linked to PI exposure 
associated mutations, namely A62, N374, S381 and P474 were identified (Figure 3.2) while only 
one PI resistance associated codon (Y79) was selected by the CodeML analysis.  
 
 
 
Figure 3.2   Frequency of the positively selected amino acid codons in Gag and PR. The numbers 
within the coloured bars indicate the number of codons selected at a specific region. Note: Bold 
font – sites associated with drug resistance/exposure mutations. 
 
 
3.3.2 Gag and PR coevolution 
Similarly, to previously reported studies (Travers et al., 2007; Codoñer et al., 2017), we used 
CAPS to identify several coevolving Gag-PR residues under drug selection pressure. Our analyses 
revealed significant correlations in PR between codons at which minor (10, 24 and 58) and major 
(46, 54 and 82) PRMs occur. Furthermore, an overlapping coevolving codon group of 10, 46, 54 
and 82 was also observed. Interestingly, out of these codons, 10 and 82 was also positively 
selected by PAML (Figure 3.2). Finally, Table 3.1 describes the PRMs identified by the CAPS 
analysis and their structural location in PR.  
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Table 3.1   Protease amino acid codons identified in the coevolution analysis. 
 
Residue in 
Protease 
Structural Position Classificationa Common Mutationsb 
10 10’s loop Minor L10F/I/R/V/Y 
16 10’s loop Other ? 
20 Core domain Minor K20I/M/R/T/V 
24 Active site region Minor L24F/I 
33 Core domain Minor L33F/I/V 
46 Flap region Major M46I/L/V 
54 Flap region Major I54A/L/M/S/T/V 
58 Core domain Minor Q58E 
63 60’s loop Other L63P 
71 Core domain Other A71I/L/T/V 
77 Core domain Other V77I 
82 Active site region Major V82A/C/F/I/L/M/S/T 
90 Core domain Major L90M 
a 
Mutations were classified accordingly: major or primary resistance mutations are known to 
directly cause drug resistance, minor or accessory resistance mutations arise at a later stage to 
compensate for the changes associated with major mutations, and other refers to mutations or 
polymorphisms classified as neither a major or minor resistance mutation.    
b 
Mutations obtained from the Stanford HIV drug resistance list. 
  
 
Several codons in Gag found associated with PI resistance and/or located at the Gag CSs including 
E365, S373, A374, A431, R452 and Q474 were identified. Of interest was codon 431 which is 
commonly associated with Gag CS resistance mutation A431V (see chapter two, Figure 2.3). 
Although A431 only correlated with polymorphic codon 77 in PR, it had a significant role in a 
pathway leading to LPV/r failure which is discussed in the Gag-PR network below. 
 
3.3.3 Most probable network in PR 
Using BNL we determined the most probable network for PR under drug selection pressure 
(Figure 3.3A). Twenty variables including the LPV/r treatment node were present in the final 
dataset. Of these, six were LPV-associated resistance mutations and 14 were WT/polymorphic 
AA residues. The BNL revealed two probable pathways to LPV/r resistance. The first pathway 
involved a direct association between treatment and 54V as parent. Through 54V, the pathway 
revealed direct associations between 10F and 82A+46I, with the combination 46I+54V+82A 
commonly seen in LPV failure. A direct inverse connection between resistance mutation 76V and 
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WT L24 as well as an indirect inverse connection between 82A and WT Q58 connects 76V to 
triple combination 46I+54V+82A. The second pathway connected 82A with LPV/r via the 
subtype C signature mutation L93 as child. 
 
3.3.4 Most probable network for Gag-PR 
The most probable Gag-PR network comprised 35 variables including the LPV/r treatment node 
(Figure 3.3B). Together with the six PRMs described in Figure 1A, 10 variables from Gag was 
included in the final dataset. Interestingly, instead of altering the interactions observed in PR 
(Figure 3.3A), the Gag mutations added to the existing network and mostly correlated with other 
Gag mutations. In terms of resistance pathways, a direct association was observed between LPV 
and 54V via P63 (through an inverse association with 63L). While 54V maintained its association 
with 46I+82A, Gag mutation 431V correlated with this combination. Moreover, a strong direct 
association linked 10F with 431V. Unlike its dependency on Q58 and L24 in the PR network, 
L76V was also found associated with 46I, occurring after the 46I+54V+82A combination. 
Noteworthy was Gag polymorphic variable 69K which formed a parent arc with the LPV 
treatment node. 
 
 
 
 
 
 
 
 
 
56 
 
Figure 3.3   Most probable network showing associations between drug resistance mutations, polymorphisms, wild-type residues and Lopinavir (LPV/r) 
treatment in (A) protease and (B) Gag-protease. Arc thickness represents bootstrap support. Note: Arc direction does not represent the order of 
accumulation of mutations or causality but may indicate a multivariable effect in the network.  
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3.4 Discussion 
Using a combination of phylogenetic and Bayesian statistical inferences, we identified several 
positively selected and coevolving Gag-PR sites under drug selection pressure and used this 
information to construct Bayesian networks to identify pathways to LPV/r resistance.  
 
In the context of evolution, reconstructing ancestral phylogeny is crucial since phylogenetic trees 
can provide information on the evolutionary history of genes (Soltis and Soltis, 2003). Maximum-
likelihood and Bayesian methods use probabilistic approaches to estimate tree topologies. 
Usually, statistical nodal support is calculated by random alignment resampling with replacement 
in a technique known as bootstrapping. Although acceptable, interpreting bootstrap values is 
challenging (Hassan et al., 2017). Instead of inferring the single most probable tree observed in 
ML, Bayesian methods produce a set of credible trees (0.95 CI17) that reflects the posterior 
probability topology given the data (Paraskevis et al., 2004; Hassan et al., 2017). In comparison 
to bootstrapping, Bayesian posterior probability has been suggested to be less biased in 
phylogenetic accuracy (Hassan et al., 2017). Therefore, in this study, both ML and BI methods 
were used to construct the phylogenetic trees. To obtain an effective sample size (ESS) >200 in 
BI, the Markov chain Monte Carlo (MCMC) length was set to 10,000,000. With only a 6.33% 
difference between the ML and BI topologies, the trees were considered acceptable for the 
positive selection and CAPS analyses as discussed below. 
 
Positive selection is the acquisition of advantageous mutations. These signature mutational 
patterns contribute towards functional protein shifts (Qian et al., 2017) and has been widely 
studied using codon substitution models (Romero et al., 2016). In this study, a comparison of 
different site models revealed that models allowing for positive selection (M2a and M8) fit the 
data better than their counterparts (M1a and M7). Although most sites were under a strong 
purifying selection, several of the positively selected sites were mostly located in Gag. Similarly, 
CAPS revealed that most coevolving sites were found in Gag than PR. Taken together, this 
suggests that Gag can tolerate mutational changes better than PR. Interestingly, this theory was 
corroborated in a study conducted by Darapaneni et al. (2015) where 61% of the viral PR was 
conserved, particularly within the dimer interface, active site and flap regions. This suggests that 
AA changes are restricted to specified regions in PR to maintain the structural integrity of the 
enzyme during cleavage. Contrastingly, Gag displays high natural variability (Li et al., 2013), 
particularly at the CSs (Torrecilla et al., 2014). Prabu-Jeyabalan et al. (2002) demonstrated that 
                                                          
17 Confidence Interval 
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substrate recognition by PR is determined by the asymmetric structure of the CSs and not 
necessarily the AA sequence. This theory, coined the “substrate envelope” hypothesis was based 
on studies involving inactive PR variants complexed with peptide substrates (Prabu-Jeyabalan et 
al., 2002; Tie et al., 2005). Although few, codons located at the CSs including E365 (CA|p2), 
S373 (p2|NC) A431 (NC|p1) and R452 (p1|p6) were identified in this study. Additionally, Özen 
et al. (2014) showed that the “conserved dynamic behaviour” of PR’s active site, together with 
complimentary enzyme-substrate mutations increases substrate recognition. Considering the 
location of the PRMs identified in these sequences (Table 3.1), this suggests that PR and CS 
mutations work together to alter the substrate envelope of PR, increasing Gag proteolysis and 
providing a competitive advantage over the PIs. 
 
To understand the resistance dynamics of specific mutations at various coevolving sites, we 
explored pathways to resistance in PR and observed the multivariable effect of what happens 
when Gag mutations are then introduced. In this study, the combination of M46I+I54V+V82A 
selected by PR is unsurprising since this is the three most common substitutions seen in LPV/r 
failure (Barber et al., 2012; Van Zyl et al., 2013; Grossman et al., 2014). As previously mentioned, 
in tandem with this combination, the introduction of L76V can also lead to DRV/r cross-resistance 
(Tang and Shafer, 2012). Although several studies have demonstrated the impact of genetic 
diversity on pathways to drug resistance (Sylla et al., 2008; Martinez-Cajas et al., 2009; Barber 
et al., 2012), the stepwise accumulation and multivariable interaction of mutations in pathways to 
resistance is largely unknown. In this study, two probable pathways in PR leading to LPV/r failure 
were described, one beginning with I54V and the other with V82A. Interestingly, Zhang et al. 
(2010) described a conditional structural independence between 46+54+82, where 46 and 54 are 
mutually independent given 82. Therefore, the authors posited that the sequential order of 
mutations would be either 46-82-54, 82-46-54 or 82-54-46. However, a separate study conducted 
by Zhang et al. (1997) described an order of 54-46-82 and 46-54-82. Although both studies 
reiterate these dependencies, our study suggests that the deciding factor as to whether I54V or 
V82A is selected first is dependent on L10F, where if I54V is selected first then L10F is also 
selected. However, if V82A is selected first followed by I54V then either the L10F mutation or 
the WT L10 could be favoured. Although more work would be required to confirm this theory, 
L10F could be functionally important. Previously, Martinez-Picado et al. (1999) showed that 
viruses harbouring the L10R mutation together with M48I+L63P+V82T+I84V replicated at the 
same rate as the WT, thereby suggesting its role in restoring viral fitness. However, the role of 
L10F when the M46I+I54V+V82A combination is selected together with L76V as seen in this 
study, is still unclear. Interestingly, Wong-Sam et al. (2018) showed that L76V reduces 
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hydrophobic contacts with I45/47 in PR’s flaps and D30/T74 in PR’s core, corresponding with 
protein instability. However, the authors postulated that reduced contacts caused by Val76 can 
allow for greater flap mobility. Furthermore, Louis et al. (2011) showed that the co-selection of 
M46I counteracts this instability by enhancing proteolytic cleavage in subtype B. This suggests 
that L76V occurs to modify flap dynamics to maintain cleavage with the altered Gag CSs whilst 
maintaining resistance to LPV/r.  
 
Interestingly, the pathways to resistance changes significantly when other PIs are investigated. 
For example, Deforche et al. (2006) showed that though L10F, M46I and I54V were present in 
the network, only major PRMs D30N, N88S and L90M connected with the NFV node as parent. 
However, using a temporal nodes Bayesian network, Hernandez-Leal et al. (2000) showed that 
when IDV was present, a direct pathway existed between M46I, I54V and V82A through L90M 
as parent. Thus, the selection of specific mutations and intricate changes in the pathways to 
resistance are attributed to the drug itself. However, these networks may still change if Gag 
mutations are also introduced.     
 
In the Gag-PR network a combination of L10F+M46I+I54V+V82A and A431V was observed. 
The A431V Gag mutation can cause resistance to all PIs except DRV (Fun et al., 2012) even in 
the absence of PRMs (Nijhuis et al., 2007). Moreover, its level of resistance is comparable to that 
of a single major PRM such as V82A (Nijhuis et al., 2009) and it can improve Gag cleavage 
regardless of the protease variant (Kolli et al., 2009). Although A431V has been associated with 
V82A (Prabu-Jeyabalan et al., 2004), a direct relationship was observed with I54V in this study. 
This could suggest that A431V and its link to V82A is dependent on the presence of I54V and 
M46I. This is consistent with the findings observed by Singh (2015) wherein A431V was mostly 
found in viruses with PRMs (M46I+I54V+V82A) than those without. This suggests that the if 
PRMs are selected, A431V serves to act in a structural compensatory role at a later stage.  
 
Of note was non-CS mutation Q69K (chapter two; Figure 2.5). In this study, Q69K indirectly 
associated with A431V via G62K and V77 in PR. Singh (2015) reported that Q69K increased 
viral replication by 13% in the presence of A431V and M46I+I54V+V82A suggesting that it 
occurs to further compensate for changes associated with these mutations. Additionally, although 
CAPS identified the coevolving pair of 77 and 431, an indirect inverse association between these 
two codons was noted in the network. Interestingly, Gupta et al. (2015) demonstrated that a PR 
double mutant (V77I+L33F) resulted in a more stable structure with altered flap dynamics in the 
presence of Nelfinavir (NFV) in comparison to the WT. This could suggest that while A431V 
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works to restore cleavage, V77I works to stabilize the mutant PR by changing the open/closed 
conformation of the flaps to compensate for the modified CS. However, more work is required to 
elucidate the relationship between A431V+V77I in the presence of LPV/r. 
 
 
3.5 Conclusions 
Since mutations share unequal importance in drug resistance outcomes, the complexity of 
mutational patterns is challenging to interpret for treatment purposes. This study showed that 
strong dependencies exist between the evolutionary selection of PRMs and those identified in 
Gag. In particular, the combination of L10F+M46I+I54V+L76V+V82A together with A431V in 
Gag was shown to follow a specific pathway in patients receiving a LPV/r-inclusive treatment 
regimen. However, to fully understand the resistance dynamics between Gag and PR, a true 
understanding regarding the effects of PR’s mutational patterns in the presence of PI drugs 
without Gag is first required. Therefore, the next chapter investigated the structural implications 
of two multi-drug resistant protease sequences in the presence of LPV as well as DRV (since 
DRV is administered in 3rd-line ARV therapy).    
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Chapter four 
 
Examining DRV and LPV binding in the 
presence of multi-drug resistance 
mutational patterns in HIV-1  
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4.1 Introduction 
As described in chapter one of the literature review (section 1.9.4), the HIV-1 PIs were developed 
to mimic the substrate transition state to inhibit Gag cleavage during maturation (Lv et al., 2015). 
However, PR’s ability to acquire multiple resistance mutations at various positions can cause PI 
cross-resistance (Rhee et al., 2010). This phenomenon has led to suboptimal binding in several 
on-market drugs. Amino acid variation at positions 10, 46, 54, 82, 84 and 90 comprise some of 
the most commonly associated drug resistance mutations in the viral PR (Wensing et al., 2017).  
 
In our study, BNL (section 3.3.3 of chapter three) found associations between mutations L10F, 
M46I, I54V, L76V and V82A. These mutations (L10F, M46I, I54V, V82A) have serious 
implications on LPV (Boender et al., 2016; Paredes et al., 2017) and DRV drug binding, 
particularly if L76V is simultaneously co-selected, as it can enhance the level of drug resistance 
(Young et al., 2010; Louis et al., 2011; Boender et al., 2016). Although phenotypic and genotypic 
tests can be employed to evaluate resistance mutations, these assays only provide information on 
the experimental or functional aspects of the virus (Hu et al., 2011). Consequently, information 
evaluating the structural impact of such a complex combination of mutations are not clearly 
understood. 
 
Furthermore, since it has been shown that various mutations have distinct effects in subtype C 
versus subtype B (Kiguoya et al., 2017), and that certain AAs are selected more frequently than 
others, as shown in Chapter two of this study, the question arises as to why and how are mutations 
selected? 
 
Therefore, the purpose of this chapter was to investigate the structural implications of a complex 
combination of PRMs on LPV and DRV binding in HIV-1 subtype C using MD simulations and 
binding-free energy scores.          
 
 
4.2 Methods 
 
4.2.1 Multi-drug resistant PR sequences 
Two PR sequences comprising multi-drug resistant (MDR) phenotypes were retrieved from the 
PCS cohort. These sequences have specific resistance profiles and was selected based on the 
information obtained from the Bayesian networks in Chapter three as described in Table 4.1 
below. 
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Table 4.1   Sequence identities with their specific resistance profiles. 
 
Sequence Identity Comment Protease resistance profile 
Wild-type AY772699 None 
PCS124 MDR; four PI mutations L10F, M46I, I54V, V82A 
PCS069 MDR; five PI mutations L10F, M46I, I54V, L76V, V82A 
 
Note: PCS124 (accession number: MK446206) and PCS069 (accession number: MK446189). 
 
Additionally, both PCS069 and PCS124 was also selected because they possess the A431V Gag 
CS mutation which was shown to be important in the LPV resistance pathways in chapter three. 
However, for the purpose of this chapter, only the PR sequences together with the drugs (i.e. LPV 
and DRV) will be structurally explored. A graphical representation of the methods used to analyze 
the structural implications of the PI resistance mutations on drug binding is indicated in Figure 
4.1 below.   
 
 
 
Figure 4.1   Illustration showing the sequential steps used to investigate the structural implications 
of resistance mutations on drug binding.  
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4.2.2 Homology modelling 
Homology modelling of the viral PR was conducted in MODELLER v.9.16 (Webb and Sali, 
2014). To construct the tertiary structures a suitable template was first selected. Accordingly, the 
atomic coordinates for an HIV-1 subtype C PR bound to NFV (PDB ID: 2R5Q) was retrieved 
from the PDB (Coman et al., 2008). The 2R5Q PR was resolved by X-ray diffraction to 2.3 Å and 
did not contain any PI drug resistance mutations. Prior to modelling, the ligand (NFV) was 
removed and the template and target sequences (viral PR) were aligned in MAFFT (Katoh and 
Stadley, 2013). 
 
4.2.3 MD optimization of the PR models   
The PR sequences were optimized using the MD package Amber 14 (Case, 2014). Topology and 
coordinate files were generated using the LeaP program. The ff03.r1 Amber force field for 
proteins was applied to the system. The system was explicitly solvated by the TIP3P water 
molecules with a margin of 12.0 Å. The SHAKE algorithm was used to restrain the covalent 
hydrogen bonds (Ryckaert et al. 1977) and the particle mesh ewald (PME) method with a 10.0 Å 
cutoff was used to calculate the Coulomb (electrostatic) interactions in the system (Darden et al. 
1993). Prior to equilibration, a two-step minimization was performed as follows: (i) minimization 
of the waters with 3,000 steps of steepest-descent and 2,000 steps of conjugated gradient and (ii) 
minimization of the entire system with 7,000 steps of steepest-descent and 3,000 steps of 
conjugated gradient minimizations. Following minimization, the entire system was gradually 
heated to from 0 to 300 K over 50 picoseconds (ps) using the constant volume and normal 
temperature (NVT) mechanics. Thereafter, the system switched to the isothermal isobaric 
(constant pressure and normal temperature; NPT) mechanics for a further 50 ps. Finally, five 
nanoseconds (ns) of MD simulations were carried out. Additionally, the temperature of the system 
was monitored using the Langevin dynamics thermostat. Additionally, when force constraints 
were applied, the atomic residues were restrained at 2.0 kcal/mol.        
 
4.2.4 Molecular docking 
The optimized PR structures and ligands (DRV and LPV) were docked to generate the receptor-
ligand complex and obtain the various binding poses. Molecular docking was carried out using 
AutoDock Vina (Trott and Olson, 2010). The binding poses with the lowest binding scores were 
selected for the final MD production simulations. 
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4.2.5 MD production simulations 
Final MD production simulations were performed on the PR-drug complexes as described in 
section 4.2.3 with some modifications. Briefly, the ligands were parametrized using the AM1-
BCC charges in Amber’s Antechamber program. The General Amber force field (GAFF) was 
applied to the receptor-ligand system. Lastly, final simulations were carried out over 100 ns 
(10,000,000 cycles). Snapshots were taken every 5,000th generation to ensure that an ensemble of 
uncorrelated frames were obtained.    
 
4.2.6 MM-GBSA calculations 
 The binding-free energies of the receptor-ligand complexes were calculated using the MM-
GBSA method (Kollman et al., 2000) in Amber. Free-energies were calculated over 2,000 
snapshots from the last 80–100 ns production trajectories. The energy calculations were used to 
compare the level of drug binding between the MDR and WT PRs. Therefore, entropy 
calculations were not included in our analyses as comparisons were made between the same 
proteins (i.e. the viral PR).      
 
 
4.3 Results 
 
4.3.1 Prediction of theoretical tertiary structures 
The 2R5Q subtype C PR was shown to have a high sequence similarity to the consensus C 
(calculated using all the subtype C treatment exposed PR sequences with the Los Alamos 
Consensus Maker Tool) and the AY772699 reference sequence used in this study as shown in 
Figure 4.2 below. With a 92% sequence similarity between the AY772699 reference sequence 
and 2R5Q, the template was considered acceptable for molecular modelling of the MDR PR 
sequences. Additionally, the template had no gaps and therefore did not require any gap penalties 
or manual adjustments to be made.   
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Figure 4.2   Codon alignment showing sequence similarity between the AY772699 reference 
sequence, consensus C and the 2R5Q template used for the prediction of the HIV-1 viral PR.  
 
 
4.3.2 Assessing model refinement and the optimal binding poses 
To assess the MD properties and level of equilibration, system energies and structural stability of 
the PR models were evaluated, as depicted in Figure 4.3 below. Accordingly, Figure 4.3a–c 
demonstrated that the kinetic, potential and total energies gradually increased, corresponding to 
the 50 ps heating phase from 0 to 300 K. Of note, the kinetic energy remained constant thus 
indicating that the thermostat, which monitors kinetic energy to assess temperature through the 
system was functional. Additionally, the potential and total energy initially increased during 
constant volume mechanics (NVT) and then decreased when the system switched to constant 
pressure (NPT) before stabilizing indicating equilibrium had been reached.  
 
To evaluate the stability of the structures, a root mean square deviation (RMSD) calculation was 
performed for each PR model as shown in Figure 4.3d–f. Of the three models, the WT (Figure 
4.3d) appeared the most stable with a relatively lower RMSD than the PCS124 (Figure 4.3e) and 
PCS069 (Figure 4.3f) models. Interestingly, the PCS124 PR model depicted greater stability over 
the five ns simulation in comparison to PCS069.  
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Figure 4.3   System and structural assessment of the HIV-1 WT and mutant PR models. Figure 4.3 (a)–(c) and (d)–(f) represents the energy terms and the 
RMSD for the wild-type (AY772699) and mutant protease (PCS124 and PCS069), respectively.    
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To generate the PR-drug complexes for the MD production simulations, we performed molecular 
docking analyses with AutoDock Vina. The search space evaluated eight different binding poses 
for each PR-drug complex with varying binding scores. Therefore, the models with the lowest 
binding scores were selected for downstream analyses. The binding scores for all models ranged 
from -7.4 to -9.8 kcal/mol. Furthermore, the ligands were flexibly docked and allowed for torsions 
and/or rotatable bonds to be considered. Consequently, the drugs were “neatly” docked into PR’s 
substrate cavity and varied through the WT and mutants as seen in Figure 4.4 below. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4   Binding poses generated for the HIV-1 LPV- and DRV-PR bound complexes over 
the 100 ns MD simulation.  
 
 
4.3.3 Evaluating PR’s stability 
To assess the structural stability of the PR-drug systems, RMSD plots were generated over the 
100 ns simulation as depicted in Figure 4.5. Accordingly, the LPV complexes (Figure 4.5a) were 
most stable in comparison to the DRV-bound PR mutants (Figure 4.5b). However, when 
comparing the WT and mutants in both the LPV and DRV models, the WT complexes (black) 
displayed greater structural stability over the 100 ns (Figure 4.5a–b). Interestingly, between the 
LPV-bound mutants, the PCS124-LPV complex (red) displayed the closet structural stability to 
the WT whilst the PCS069-LPV mutant (green) only stabilized around 65 ns. Contrastingly, the 
DRV-bound PCS124 mutant only reached a relatively stable equilibrium around 80–100 ns. In 
the DRV-bound PCS069 mutant a plateau was observed between 35 and 55 ns as well as in the 
last 90–100 ns of the simulation. 
WT-LPV PCS124-LPV PCS069-LPV 
WT-DRV PCS124-DRV PCS069-DRV 
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Figure 4.5   Time series RMSD plots of the (a) LPV- and (b) DRV-bound complexes. Note: the 
HIV-1 WT, PCS124 and PCS069 mutants are represented by the black, red and green lines, 
respectively.  
 
 
Interestingly, the DRV- to LPV-bound fluctuations in the PR mutants was further reiterated by 
the flexibility of PR’s AA residues, as observed by the root mean square fluctuation (RMSF) plot 
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in Figure 4.6 below. In particular, the mutant-DRV complexes displayed greater particle 
flexibility in comparison to the WT. Contrastingly, in the LPV-bound WT model, greater 
fluctuations were observed around the flap (Figure 4.6a; dotted circles) and elbow regions. 
Additionally, particle variation between the PR’s subunits were also seen (Figure 4.6a and b; 
purple circles). 
 
 
 
Figure 4.6   RMSF analysis of the (a) LPV- and (b) DRV-bound complexes. Note: the HIV-1 
WT, PCS124 and PCS069 mutants are represented by the black, red and green lines, respectively. 
 
In addition to residue fluctuations, the distance between the PRMs and active site residue D25 
was altered as shown in Table 4.2. The LPV-bound PCS124 model displayed a greater distance 
with AA residues 46 (21.159 Å) and 82 (10.084 Å). Contrastingly, in the DRV-bound PCS124 
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model, residues 10 (8.745 Å), 46 (19.929 Å) and 82 (7.955 Å) were found at smaller distance 
when compared to the PCS069-DRV model (9.714 Å; 19.804 Å and 8.886 Å, respectively). 
Interestingly, when compared with the WT, the distance between the AAs in the WT and D25 
was greater for most residues in both DRV-bound PR models. Contrastingly, only residues 54 
and 82 in the LPV-bound PCS124 and PCS069 models, respectively displayed a smaller distance 
to the WT. Finally, the angles of the PRMs and thereby the rotation of the AA side chains between 
the models were also altered.  
 
Table 4.2   Distance between active site residue D25 and the PRMs in the HIV-1 WT and mutant 
drug models (all measurements in Å).  
 
Codons 
Wild-type* PCS124# PCS069#, ǂ 
LPV DRV LPV DRV LPV DRV 
10 8.047 11.154 9.164 8.745a 10.801 9.714a 
46 18.222 18.633 21.159 19.929 19.228 19.804 
54 17.789 15.477 16.930b 15.322a 18.578 16.217 
76 11.903 12.996 - - 11.925 11.759a 
82 9.361 9.676 10.084 7.955a 8.884b 8.886a 
 
* Wild-type amino acids = L10, M46, I54, L76 and V82. 
#  Drug resistance amino acids = L10F, M46I, I54V, L76V and V82A. 
ǂ L76V in PCS069 only. 
a  Wild-type distance is greater than the DRV mutants. 
b Wild-type distance is greater than the LPV mutants. 
 
 
4.3.4 Predicted binding-free energies for the PR-drug models 
To evaluate the level of drug binding when bound to the mutant PR, the overall binding-free 
energies for each complex was calculated as depicted in Table 4.3 below. In general, the LPV-
bound PR complexes displayed lower binding energies and thus a stronger structural stability in 
comparison to the DRV-bound models. Interestingly, the greatest binding stability was observed 
for the PCS069-LPV model (-23.4128 kcal/mol) where a -0.9826 kcal/mol difference was seen 
between the mutant and WT. However, when compared with the PCS124 model, a -3.4417 
kcal/mol energy difference was observed. 
 
Contrastingly, the WT-DRV model (-19.3166 kcal/mol) depicted the strongest binding mode in 
comparison to the DRV-bound PR mutants. Similarly, to the LPV-PR models, the PCS069-DRV 
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model (-17.9286 kcal/mol) generated a further energetically-favourable binding mode than the 
PCS124-DRV bound model (-15.8152 kcal/mol). 
 
Table 4.3   Binding-free energies of the HIV-1 PR-drug complexes calculated over 2,000 
snapshots in kcal/mol. 
 
Complex ΔEVDW ΔEEEL ΔGGB ΔGSURF ΔGgas ΔGsolv ΔGbind 
Lopinavir 
WT-LPV -29.5581 -10.4458 21.4441 -3.8704 -40.0039 17.5737 -22.4302 
PCS124-LPV -29.1449 -2.6835 15.6074 -3.7501 -31.8283 11.8573 -19.9711 
PCS069-LPV -28.7231 -18.2620 26.7036 -3.1313 -46.9851 23.5723 -23.4128 
Darunavir 
WT-DRV -26.3212 -12.6814 23.2752 -3.5891 -39.0026 19.6861 -19.3166 
PCS124-DRV -24.9921 -3.1009 15.2767 -2.9989 -28.0930 12.2778 -15.8152 
PCS069-DRV -27.9972 -9.4031 22.6892 -3.2175 -37.4003 19.4717 -17.9286 
 
Note: ∆EVDW = van der Waals contributions; ∆EEEL = electrostatic contributions; ∆GGB = polar 
contributions; ∆GSURF = non-polar contributions; ∆Ggas = free energy in gas phase; ∆Gsolv = 
solvation free energy; ∆Gbind = binding free energy.  
 
 
4.3.5 PR-drug interactions 
To explore the interactions between the inhibitor and PR, we constructed two-dimensional (2D) 
interaction maps for each drug complex as shown in Figures 4.7–4.12 below. Expectedly, the 
WT-LPV model revealed a hydrogen bond between catalytic residue D25 and LPV (Figure 4.7). 
Moreover, three additional hydrogen bonds were seen with residues A28, G48 and G49. Of note, 
van der Waals (vdW) interactions with V82/V82' (V181)18 was observed. Additionally, three 
alkyl (V32, I47 and I84) and one ℼ-alkyl (I50) interaction involving sites at which LPV-associated 
PRMs were noted. 
 
                                                          
18 In nature, one chain in PR contains 1–99 AAs. Therefore, chain two starts from 100–198. In practice, 
we can also refer to the second chain AA numbers as prime, for example V82A in chain A and V82A' 
in chain B. 
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Figure 4.7   Amino acid interaction map of the HIV-1 WT complexed with LPV. 
 
 
Figures 4.8 to 4.9 represent the PCS124-LPV and PCS069-LPV models, respectively. 
Interestingly, in the PCS124-LPV model (Figure 4.8), residues I50, G49 and catalytic triad AA 
G27 hydrogen bonded with LPV’s oxygen atoms. Moreover, while V82A formed an alkyl bond 
with LPV, V82A' formed a ℼ-alkyl bond with LPV’s methylbenzene ring. In the PCS069-LPV 
model (Figure 4.9), conventional hydrogen bonds were seen with D25 and G48 whilst codon R8' 
(R107) formed a double hydrogen bond with two oxygen atoms in LPV. Notably, in addition to 
V82A/V82A', minor PRM L10F' (L109F) formed a ℼ-alkyl interaction with the drug’s 
methylbenzene. Interestingly, L10F in chain A was not involved in ligand binding.   
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Figure 4.8   Amino acid interaction map of the HIV-1 isolate PCS124 complexed with LPV.  
 
 
 
 
 
 
 
 
 
Figure 4.9   Amino acid interaction map of the HIV-1 isolate PCS069 complexed with LPV. 
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Unlike in the WT-LPV model, the D25 in the WT-DRV model (Figure 4.10) was attractively 
charged to a nitrogen atom in DRV. In addition, A28 and D29/30 formed hydrogen bonds with 
the 4-aminobenzenesulfonamide of DRV whilst G27' (G126) hydrogen bonded with the oxygen 
atom in the acetate group of the (3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-yl (bis-furyl) 
molecule. Similarly, to the WT-LPV model, resistance associated sites V32, I47, I50 V82 and I84 
also interacted with DRV.  
 
Figure 4.10   Amino acid interaction map of the HIV-1 WT complexed with DRV. 
 
 
Interactions between DRV and the mutant PR models are depicted in Figures 4.11–4.12. 
Accordingly, in the PCS124-DRV model (Figure 4.11), R8 and G48' (G147) formed conventional 
hydrogen bonds with the 4-aminobenzenesulfonamide molecule and the nitrogen atom of the bis-
furyl acetate. Furthermore, R8 also formed a ℼ-cation interaction with the benzene ring of 4-
aminobenzenesulfonamide. Residue I50 formed a ℼ-donor hydrogen bond with DRV’s aromatic 
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benzene. In comparison to the WT-DRV model, catalytic residue D25 lost its hydrogen bond and 
formed a vdW interaction with DRV instead. Moreover, only L10F and V82A formed vdW and 
ℼ-alkyl interactions with DRV, respectively.  
 
 
Figure 4.11   Amino acid interaction map of the HIV-1 isolate PCS124 complexed with DRV. 
 
 
The PCS069-DRV model (Figure 4.12) revealed carbon hydrogen bonds with residues D30' 
(D129) and G48' (G147) as well as the heterocyclic furan of DRV’s bis-furyl acetate. In a similar 
manner to the PCS124-DRV model (Figure 4.11), D25 only retained vdW interactions with DRV. 
Interestingly, the PCS069-DRV model was the only complex to have lost its interactions with 
codon 82 in PR. Contrastingly, it was also the only model to gain a vdW interaction with I54V.     
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Figure 4.12   Amino acid interaction map of the HIV-1 isolate PCS069 complexed with DRV. 
 
 
4.4 Discussion 
Biological function is largely dependent on molecular dynamics of protein systems. Therefore, 
drug resistance mutations can alter the mechanism by which the HIV-1 PR cleaves in nature (Cai 
et al., 2014). Here, we predicted three molecular models corresponding to two PR mutants 
(PCS124 and PCS069) comprising major PRMs and a structure resembling the subtype C WT PR 
(AY772699). Homology modelling is an important tool that has been used to investigate 
molecular structural dynamics when experimental data is not available (Yuan and Xu, 2018) and 
several studies have used this approach to explore the dynamical behaviour of the HIV-1 PR 
(Lockhat et al., 2016; Amamuddy et al., 2018; Delino et al., 2018; Nayak et al., 2019). 
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Prior to docking experiments, the PR structures were refined to produce a favourable energy state. 
Therefore, we used explicit MD simulations to mimic the physiological state observed in nature. 
In this study the level of protein stability between the models appeared to be WT > PCS124 > 
PCS069. This is unsurprising since in the absence of drug therapy, the WT is functionally fit 
(Quiñones-Mateus and Arts, 2003; Hu and Kuritzkes, 2014). This suggests that the WT PR 
represents a “simpler”, thermodynamically stable form of PR in comparison the mutants when 
PIs are not present. Thereafter, AutoDock Vina generated favourable docking poses that were 
within the confines of PR’s substrate envelope. Additionally, subtle differences in the orientation 
of the ligands may be due to the flexible docking carried out by AutoDock. Flexible docking 
algorithms are more accurate in predicting binding modes since it allows movement of the 
rotatable bonds in the ligand (Pagadala et al., 2017). Therefore, as multiple AA side chains are 
affected by the movement of the backbone atoms of the protein (Pagadala et al., 2017), it is 
conceivable that the ligand should also be flexible enough to accommodate this movement 
allowing for greater binding affinity and more precise binding. 
 
To evaluate the structural changes induced by the PRMs on drug binding, we performed 100 ns 
MD production simulations on the LPV- and DRV-bound PR models. Accordingly, the RMSD 
plots revealed that the WT models were significantly more stable than either of the drug-bound 
mutants. Proteins are dynamically flexible macromolecules that can exhibit large structural 
changes over of time (Haspel et al., 2010). Consequently, the PCS124/069 mutants may have 
folded into multiple alternative structures to continually find the optimal energy minima to evade 
drug binding while remaining active for Gag cleavage. In contrast, this suggests that the WT 
easily folded and maintained a stable native state since it did not comprise any mutational changes 
in the active site or flap regions and was thereby susceptible to drug binding in comparison to the 
mutants. Of interest was the discrepancy between the stability of the LPV- versus DRV-bound 
mutants. Here, the RMSD plots revealed greater stability with LPV rather than DRV. A study 
conducted by Dierynck et al. (2007) showed that MDR PRs comprising 10–14 PI resistance 
mutations resulted in reduced binding affinity coupled with limited antiviral activity for LPV. 
Contrastingly, for DRV, the study showed that weaker antiviral activity was not observed even 
with a 1,000-fold decrease in binding affinity. Consequently, this suggests that the LPV-
associated PI mutations highlighted in this study displays greater structural evasiveness to LPV 
than DRV. Furthermore, the Dierynck study observed that the number of DRV-associated 
mutations also correlated with the level of drug binding. Therefore, this theory may also translate 
to the number of mutations selected by the mutants as observed with RMSD fluctuations between 
the quatro-PCS124 and penta-PCS069 PR models. 
 
79 
 
Furthermore, a link between the RMSD and RMSF plots regarding the DRV-bound mutants were 
also observed. In nature, active proteins can rapidly manipulate their local fluctuations, adopt a 
specific conformation and transition between conformations (Kmiecik et al., 2018). In this 
instance, the DRV-bound mutants showed larger fluctuations in PR’s AA residues as compared 
to LPV. In the WT models, fluctuations at the flaps and elbow suggests that particle motion at 
these regions occurred to allow for the open/closed conformation of PR and to accommodate 
movement of the ligand and thereby binding through the 100 ns simulation. Generally, flap 
flexibility is restricted when PR is bound to an inhibitor (Trylska et al., 2007). However, Piana et 
al. (2002) showed that residues 24–30 and 45–55 in the viral PR correlated with substrate motion. 
Moreover, it has become acceptable that interaction of PR’s flaps with a substrate influences the 
interval and frequency of flap opening (Trylska et al., 2007; Goldfarb et al., 2015; Yu et al., 2017). 
Interestingly, the RMSF plots also revealed a level of asymmetry between the two PR chains. 
This phenomenon has been previously observed in several studies evaluating the structural 
conformation of the HIV-1 PR (Lexa and Carlson, 2011; Huang et al., 2017; Paulsen et al., 2017). 
Cai et al. (2014) postulated that the asymmetrical ligand prompts asymmetry in the otherwise 
symmetrical PR. Thus, the two chains could behave differently in the mutant PRs to the evade PI 
drugs. Moreover, differences in the interatomic distances between catalytic residue D25 and the 
mutant/WT models reiterate a mechanism for drug resistance. Specifically, reduced interatomic 
distance between D25 and the PCS069 model was consistent where the inclusion of L76V 
promoted reduced hydrophobic contacts and greater flexibility as an alternative mechanism for 
drug resistance (Wong-Sam et al., 2018). Contrastingly, the WT AA residues were distally located 
to D25. This discrepancy could be linked to the sequential accumulation of mutations in the 
PCS124/069 mutants and the positioning of AA side chains. For instance, as described in chapter 
three, if L76V is selected then there is a high probability of the co-selection of M46I to counteract 
the changes induced by the substitution of leucine to valine (Louis et al., 2011). Additionally, 
since torsion angles phi and psi are important factors in controlling protein folding (Saravanan 
and Selvaraj, 2017), suggesting that differences in the interatomic distance with the altered torsion 
angles occurred to maintain conformational flexibility of PR when the PRMs are present. 
 
Thereafter, we performed binding-free energy calculations to assess the level of drug binding. 
Considering the above observations, it was expected that DRV would bind to PR at a lesser extent 
that LPV. More specifically, with only a -2.4447 kcal/mol average energy difference between the 
two mutants relative to the WT, the PRMs did not have a significant effect on drug binding. 
Previous studies have shown that viral PRs with either 19 (Agniswamy et al., 2012) and 21 (Louis 
et al., 2011; Louis et al., 2013) mutations were required for a major reduction in the loss of 
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hydrophobic contacts to occur. However, this study showed that the PCS069 model portrayed 
lower binding energies in comparison to the PCS124 models. This infers that resistance 
comprising the L76V pattern could be due to specific AA interaction with the drug or it is 
substrate related.  
 
Finally, to explore the detailed PR-drug interactions, several interaction maps were constructed 
to observe specific residues in PR involved in ligand binding. These analyses revealed that 
residues R8, D25, A28, G27, G48, G49 and I50 in the WT and mutants formed important 
hydrogen bonds with LPV. In the HIV-1 PR aspartic residue 25 deprotonates a water molecule to 
produce a tetrahedral intermediate while the second aspartic (D25') facilities Gag cleavage 
(Chaudhury and Gray, 2009). Consequently, due to its catalytic activity mutational changes from 
D25 to A, Y, H or N eliminates PR’s enzymatic activity (Huang and Chen, 2013). Thus, a strong 
hydrogen bond linking D25 to a ligand in the WT PR is expected. Outwardly, the unfavourable 
interaction observed between D25 and LPV in the PCS124 mutant (Figure 4.8) suggests that PR 
has “recognized its Trojan horse” and structurally conformed to directly inhibit enzymatic 
catalysis and drug binding. Apart from D25, it has been shown that residues R8 and G27 at the 
base of the active site and G49 at the flap tips stabilize the PR dimer (Weber, 1990; Wlodawer 
and Gustchina, 2000) while A28 and I50 are important AA residues for substrate recognition 
(Scott et al., 2000). Of note, Ceccherini-Silberstein et al. (2004) showed that apart from G16, G48 
and G73, the remaining PR glycine residues are highly conserved. This suggests that binding to 
the glycine residues causes subtle rearrangements in the PR structure that are also complimentary 
to the changes induced by the PRMs.  
 
Interestingly, codons V82/V82' were found to have vdW interactions in the WT-LPV complex, 
whereas alkyl/ℼ-alkyl interactions with LPV were observed in the PCS124 and PCS069 mutants. 
Other bond types including alkyl and ℼ-alkyl bonds can improve the hydrophobic bonding 
between a receptor and ligand (Arthur and Uzairu, 2019). Therefore, the switch to alkyl/ℼ-alkyl 
bonds from vdW interactions in the mutants suggests a stronger association with the mutant 
alanine at position 82 than valine. Weber and Agniswamy (2009) demonstrated that in the 
presence of SQV, IDV and DRV, the alanine substitution shifted residues 81 and 82 to 
compensate for the loss of interactions induced by the smaller side chain. In addition, a study 
conducted by Liu et al. (2008) revealed that in a PR comprising a single I54V mutation, significant 
conformational changes observed in the flap region were coupled with structural changes in the 
80’s loop. In a similar manner, Nakashima et al. (2016) revealed that double PR mutant 
I47V/I50V induced structural flexibility to the enzyme. Since M46I is found in the PR’s flaps, it 
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is sufficient to assume that this mutation can also influence PR flexibility. Therefore, in this study, 
the stronger bond coupled with the shift in main chain residues suggests that partial enzymatic 
rigidity was induced to inhibit the drug whilst retaining its ability to cleave Gag. Furthermore, 
this bonding effect could also be correlated with L10F which formed a ℼ-alkyl bond with LPV in 
the PCS069 mutant. Agniswamy et al. (2013) showed that loss of contact between PR and novel 
PIs were due the displacement of a water molecule by L10F.  Furthermore, since only one L10F 
residue was involved in ligand binding, this asymmetry could aid in maintaining PR’s flexibility 
by not restricting the enzyme with phenylalanine’s large bulky aromatic rings in both chains. 
 
Like the LPV models, specific AA residues including R8, G27, A28, D29/30, G48 and I50 were 
all involved in DRV-PR interactions. Interestingly, in a study evaluating the binding differences 
between DRV and its structural analog APV, Hou et al. (2009) found that stable interactions were 
observed between specific AAs (A29, D30, G48) and the bis-furyl and 4-
aminobenzenesulfonamide moieties of DRV. This agreed with the findings observed in the 
current study (Figures 10–12). Furthermore, the bis-furyl (or bis-THF) moiety was designed to 
produce a network of hydrogen bonds with the main chain atoms of the viral PR (Agniswamy et 
al., 2015). Our analyses revealed more vdW interaction instead, particularly in the L76V-PCS069 
mutant corresponding to the binding-free energies. Contrastingly, in addition to several hydrogen 
(A28, D29/D30, and G27) and alkyl/ℼ-alkyl bonds (Figure 4.10), the WT-DRV model also 
revealed a strong attractive charge between D25 and DRV. This indicates that the level of drug 
binding in the WT is much stronger in comparison to the mutants which is also supported by our 
GBSA calculations. Further reiterating this point was the loss of strong bonds between DRV and 
D25 in both the PCS124 and PCS069 mutants as only vdW interactions were noted. Therefore, a 
loss of contact between PR and these chemical moieties (bis-furyl and 4-
aminobenzenesulfonamide) is the main reason for DRV resistance (Raugi et al., 2016). 
 
Finally, our study revealed a vdW interaction between I54V and the PCS069-DRV mutant (Figure 
4.12). As vdW interactions are considered for short-ranges this suggests that the flaps were pulled 
down closer to the drug. This agreed with a study conducted by Agniswamy et al. (2019) where 
the flap tips curled downwards in a DRV-bound I54V PR mutant. Flap “curling” has been linked 
to the open/closed states of PR when DRV is present. Yu et al. (2015) demonstrated that flexible 
curling of the flap tips into PR induces an open state. This observation suggests that PR utilizes 
mutations in its flaps to induce a semi-open conformation coupled with a loss of contact to 
minimize atomic bonds and inhibit drug binding. 
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4.5 Conclusions 
The native structure of proteins is complex where it can transition between several states to adapt 
to changes within the genome, or its environment (Gidalevitz et al., 2011). In this study we 
evaluated the structural implications caused by LPV and DRV resistance associated mutations 
L10F, M46I, I54V, L76V and V82A when complexed with the drugs. Our analyses indicate that 
these mutations cause significant structural flexibility to the viral PR particularly within the flap 
regions. Moreover, it was also seen that the viral PR was relatively more susceptible to LPV in 
comparison to DRV. Furthermore, since L76V contradicted itself by showing stronger drug 
binding when it was included, the impact of this mutation in this context was still unclear. 
Therefore, chapter five investigated the structural mechanism by which the mutant PR’s cleave 
the NC|p1 Gag CS that comprised the A431V resistance mutation.     
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Chapter five 
 
Structural impact of the HIV-1 NC|p1 
A431V Gag cleavage site mutation on the 
PCS124 and PCS069  
protease mutants 
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5.1 Introduction 
As previously discussed in chapter two, under drug selection pressure pathogens can effectively 
and rapidly accumulate mutations in various drug targets (Hooper and Jacoby, 2015; Kennedy 
and Read, 2017; Nguyen et al., 2018). Whilst most drug resistance mutations are clustered close 
to the active site (King et al., 2004), the HIV-1 PR has been shown to acquire mutations in distal 
locations, such as the flexible flaps and substrate cleft to evade drug binding (Ragland et al., 2014; 
Flynn et al., 2017). Though these resistant PR’s are functionally weaker, they are still able to 
cleave the substrate and thereby outcompete the inhibitor for hydrolysis (Kantor et al., 2002; Rhee 
et al., 2003).  
 
Incidentally, mutations arising in other proteins, such as Gag are being frequently reported (Fehér 
et al., 2002; Dam et al., 2009; Pillay et al., 2014; Teto et al., 2017; Su et al., 2018; Williams et al., 
2019). The NC|p1 A431V Gag mutation is of interest, since it is associated with patients failing 
PI therapy (Lambert-Niclot et al., 2008; Giandhari et al., 2015). Additionally, in agreement with 
other studies (Verheyen et al., 2006; Malet et al., 2007), our analyses revealed direct associations 
between major LPV PRMs and A431V (chapter three).  
 
While Gag-PR coevolution has been reported (Doyon et al., 1996; Zhang et al., 1997; Kolli et al., 
2006; Dam et al., 2009), the mechanism by which hydrolysis is restored and the molecular basis 
in which these Gag CS mutations are selected is unclear. 
 
Therefore, continuing from chapter four, this chapter investigated the mechanism by which the 
A431V Gag CS mutation structurally interacts with the mutant PR to properly maintain enzymatic 
cleavage under drug selection pressure.              
 
 
5.2 Methods 
 
5.2.1 Modelling of the NC|p1 Gag CS viral sequences 
To maintain consistency and gain insightful knowledge on the co-selection of mutations in Gag-
PR, the PCS069 and PCS124 viral sequences utilized in Chapter four was carried forward. As 
previously discussed, these viral sequences co-selected the NC|p1 CS mutation, A431V. The 
template selected for homology modelling (PDB ID: 2FNS) was an HIV-1 WT NC|p1 substrate 
complexed with an inactive HIV-1 subtype B PR (Prabu-Jeyabalan et al., 2006). The sequence 
region spanned from residues R429 to G435 as shown in Figure 5.1 below.  
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While templates spanning the entire target region is advantageous, there are currently only two 
entries for the NC|p1 CS in the PDB19.  Additionally, as this region is relatively smaller (10 AAs) 
and does not comprise any tricky loops in comparison to other proteins, the 2FNS template is 
considered acceptable for use. 
 
 
 
 
 
 
Figure 5.1   Sequence alignment of the HIV-1 subtype B, AY772699 reference, the 2FNS 
template and the target sequences. Note: the PCS124 and PCS069 NC|p1 Gag cleavage sites only 
have the A431V resistance mutation.  
 
 
Thereafter, sequence alignment and homology modelling were carried out as described in section 
4.2.2 of chapter four. 
 
5.2.2 Geometric optimization of the ligand 
In comparison to the drugs (LPV and DRV), the Gag CSs are molecularly larger and somewhat 
bulkier due to the AA side chains. Furthermore, because these ligands were theoretically 
modelled, optimizing their tertiary structure is imperative. Therefore, to ensure that the Gag CSs 
are geometrically and stereo-chemically accurate, a geometric optimization was carried out. 
Briefly, the Gag CSs were optimized using a semi-empirical quantum mechanics (qm) simulation 
with the sqm program in AmberTools v.14 (Case, 2014). Simulations were optimized at the 
Hamiltonian level using the AM1 qm-theory. The number of self consistent field (SCF) iteration 
cycles required for the geometry to converge and stereo-chemical equilibration to be reached was 
100. Thereafter, the Antechamber program was used to prepare the files for Leap.  
 
5.2.3 Docking, MD simulations and binding-free energies  
Once ligand optimization had been achieved, the docking, PR-Gag production simulations and 
calculation of binding-free energies were performed according to sections 4.2.4 to 4.2.6 of chapter 
four, respectively. 
 
                                                          
19 http://www.rcsb.org/ : search criterion NC-p1 
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5.3 Results 
 
5.3.1 Gag-PR conformational stability 
The time series RMSD for the PCS124-A431V and PCS069-A431V models are depicted in 
Figure 5.2. As observed, the PCS124-A431V model maintained a relatively stable complex from 
50–100 ns whilst the PCS069-A431V model showed greatest structural equilibrium at 
approximately 48–77 ns and then again from 88–100 ns. Although definitive equilibrium was 
reached at specific intervals, the overall A431V-bound PCS124 and PCS069 models depicted 
very similar RMSD values over the entirety of the production simulations.  
 
 
Figure 5.2   Time series RMSD plots of the HIV-1 isolate A431V-PR bound models.  
 
 
To evaluate specific residue fluctuations in PR, we constructed RMSF plots as seen in Figure 5.3 
below. Interestingly, similar trends in particle flexibility of the A431V-PR mutants was observed 
with the DRV-bound PR models (chapter four; Figure 4.6b) in comparison to the LPV-PR 
complexes (chapter four; Figure 4.6a). Moreover, the PCS069-A431V model displayed increased 
particle flexibility over more AA residues in chain B than A thus indicating a greater level of 
asymmetry in the L76V-inclusive mutant (Figure 5.3; dotted circle). 
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Figure 5.3   RMSF analysis of the A431V-PR bound mutants. Note: the HIV-1 PCS124-A431V 
and PCS069-A431V models are represented by the solid black and red lines, respectively.    
 
 
5.3.2 NC|p1 binding to the PR mutants 
Expectedly, the NC|p1 Gag CSs are stereo-chemically larger than their PI antagonists. As such, 
the CSs encompass a greater surface area within the PR’s substrate cavity, as seen in Figure 5.4 
below. Although, the NC|p1 CSs comprise several bulky side chains, such as phenylalanine’s 
aromatic benzene ring at position 433, the AA side chains are rotatable as seen by the alternative 
conformations in the PCS124 and PCS069 mutant models (Figure 5.4).  
 
The A431V NC|p1 mutants exhibited significantly stronger binding (Figure 5.4) as compared to 
the LPV- and DRV-bound PR mutants (chapter four; Table 4.3). Specifically, when comparing 
the most energetically-favourable binding mode, there was a 3-fold energy difference between 
the A431V mutant (-62.4605 kcal/mol) and the drug-bound mutant (PCS069-LPV: -23.4128 
kcal/mol). Interestingly, the L76V-inclusive PCS069 model exhibited a greater binding affinity 
(-62.4605 kcal/mol) for the NC|p1 mutant in which a -12 kcal/mol energy difference was observed 
in comparison to the PCS124 model (-50.3386 kcal/mol). 
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Figure 5.4   MM-GBSA binding-free energies of the A431V NC|p1 Gag CSs bound to the 
PCS124 and PCS069 HIV-1 PR mutants. Note 1: all predicted energies were calculated over 
2,000 snapshots and are represented in kcal/mol. Note 2: ∆EVDW = van der Waals contributions; 
∆EEEL = electrostatic contributions; ∆GGB = polar contributions; ∆GSURF = non-polar 
contributions; ∆Ggas = free energy in gas phase; ∆Gsolv = solvation free energy; ∆Gbind = binding 
free energy.   
 
 
5.3.3 Gag-PR interaction maps 
To evaluate the specific interactions between the NC|p1 Gag CS and the PR mutants, we 
constructed Gag-PR interaction maps as depicted in Figures 5.5–5.6 below. Accordingly, the 
PCS124-A431V model revealed hydrogen bonds between residues A28_PR and K436_Gag, 
G48_PR and the nitrogen atom connecting residues L434_Gag and G435_Gag as well as a double 
hydrogen bond between PR’s R8' (R107) and the oxygen atoms of Gag residues E428 and Q430. 
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Additionally, a hydrogen bond between D25_PR and the carbon atom of I437 in Gag was also 
observed. Moreover, residue D29 in PR was attractively charged to R429 in Gag. Of note, whilst 
L10F_PR formed an alkyl bond with A431V in Gag, G27 and I47 in PR also formed close vdW 
interactions with V431. In addition, major PRMs V82A' (V181A) and M46I formed vdW 
interactions with residues R429 and F433 in Gag, respectively. Furthermore, a ℼ-ℼ T-shaped 
stacking20 was formed with F53 in PR and F433 in Gag. Interestingly, in addition to substrate 
cleft residue V32 in PR, L76_PR formed vdW interactions with K436_Gag whilst both I50/I50' 
(I149) formed close vdW interactions with each other, G48_PR, L76_PR and the NC|p1 substrate.  
 
 
 
Figure 5.5   Amino acid interaction map showing the association between the HIV-1 isolate 
PCS124 protease and the mutated NC|p1 Gag cleavage site. Note: the A431V Gag mutation is 
indicated in red.  
 
 
Figure 5.6 represents the interaction map for the PCS069-A431V model. When compared to the 
PCS124 substrate-bound model, it was evident that the PCS069 PR mutant formed significantly 
                                                          
20 ℼ-stacking refers to non-covalent, attractive interactions between two aromatic rings. 
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more interactions with the substrate. In particular, 12 hydrogen bonds were formed between the 
PCS069 residues and the NC|p1 CS. Of these, PR residue R8' formed three hydrogen bonds with 
the oxygen atoms in residues E428, R429 and Q430 in Gag. Interestingly, while D29_PR formed 
two hydrogen bonds with both oxygen atoms in Q430_Gag, D30_PR also formed an additional 
hydrogen bond with the second oxygen atom in Q430_Gag. Moreover, WT AA G48 in PR 
hydrogen bonded with the oxygen atom of the A431V mutation. Finally, residues G49' (G148), 
I50' (I149) and P79' (P180) also hydrogen bonded with the mutated NC|p1 substrate.  
 
 
 
Figure 5.6   Amino acid interaction map showing the association between the HIV-1 isolate 
PCS069 protease and the mutated NC|p1 Gag CS. Note: the A431V Gag mutation is indicated in 
red.  
 
 
Furthermore, whilst V82A also formed a vdW interaction with the substrate, V82A' (V181A) was 
proximal to residues R429 and Q430 in Gag (Figure 5.5). Moreover, minor PRM L10F' (L109F) 
was closely located to V82A'. Interestingly, the switch from leucine to valine of residue 76 in PR 
positioned the mutant valine closer to Q430_Gag instead of K436_Gag as seen in the PCS124-
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A431V model. Additionally, several interactions were observed with A431V, namely, multiple 
alkyl bonds with WT residues V32 and I47 in PR. Finally, whilst D25 did not hydrogen bond 
with the mutated NC|p1 substrate, it formed close vdW interactions to I47 in PR which in turn 
was closely bonded to A431V in Gag.    
 
5.4 Discussion 
Generally, protein folding depends on a multiple factor process and elucidating the mechanism 
by which they fold provides a useful knowledge on their physiological role in nature (Wu et al., 
2015). While our understanding on protein folding has vastly improved over the years, the exact 
mechanism by which folding occurs in vivo is not well understood (Clark and Ugrinov, 2009). 
Though “the protein folding problem” has proved to be a challenge for half a century21 (Li et al., 
2017), the molecular structures of small proteins are well predicted by computational means (Dill 
et al., 2008). Here, we evaluated the RMSD and RMSF of the mutated Gag-PR complex over a 
100 ns MD simulation. Our analyses revealed that although the PCS124/069 models did fold and 
re-fold to alternate structures, greater conformational stability was observed over the 100 ns, 
particularly for the PCS124-A431V model which maintained relative stability from 50 ns 
onwards. However, the PCS069-A431V model stabilized for 28 ns prior to re-folding and 
restoring stability in the last 12 ns of the simulation. Goodchild et al. (2011) theorized that proteins 
can alter their folding in response to the environment whilst regulating protein functionality. 
Furthermore, a study conducted by Porter and Looger (2018) identified several proteins from the 
PDB that switch folds, thus having more than one conformation. In this context, this suggests that 
apart from drastic changes that would render the enzyme inactive, PR can alter its conformation 
to adapt to its mutated substrate as well as the drug-pressured environment. Additionally, 
Alexander et al. (2009) observed that a single AA mutation can equate to two folded states of a 
protein. Therefore, it is highly plausible that the PCS mutants, having four to five PI mutations 
can exist in several states to acclimate to the drug-pressured environment. Moreover, Agozzino 
and Dill (2018) found that least stable proteins can rapidly adapt to changing conditions. This 
suggests that the changing stability of the PCS069 mutant, having five PI mutations at functionally 
important sites maintains a less favourable structural conformation to continually adapt in favour 
of the NC|p1 CS binding as opposed to the drugs.  
 
Interestingly, the RMSF data corroborates the RMSD findings and the aforementioned protein 
folding hypotheses. As greater particle flexibility was comparable to the DRV-bound PR models, 
                                                          
21 The protein folding problem questions how an AA sequence dictates the tertiary structure of protein.  
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this suggests that the same mechanism employed to evade drug binding is used to maintain 
substrate cleavage. Specifically, as previously discussed, changing the AA torsion angles can alter 
protein conformity (Thukral et al., 2007; Ponnuraj and Saravanan, 2017; Saravanan and Selvaraj, 
2017). Additionally, the level of asymmetry in the PCS069 model indicates that each chain is 
rapidly regulated either to constrict or flex to allow movement for the highly rotatable, bulky Gag 
CS. Therefore, it is conceivable that the asymmetrical AA fluctuations in a homodimeric protein 
may evade drug binding through the rapid regulation of its subunits.  
 
While it is known that Gag cleavage occurs over several sequential steps as discussed in chapter 
one, the exact structural mechanism for this process is debatable (Mattei et al., 2018). Even though 
the PIs were designed to out-compete the natural substrate (Spearman, 2016), the HIV-1 Gag, 
consisting of approximately 500 AAs (Fun et al., 2012), is a large protein in nature. Therefore, it 
is also likely that the 10 bulky AAs recognized by PR for cleavage is also molecularly large. 
Separate studies conducted by Prabu-Jeyabalan et al. (2002) and King et al. (2004) showed that 
the PR’s substrates occupies a consensus volume within the binding cavity. Ӧzen et al. (2011) 
hypothesized that the ability of the CSs to fit within the substrate envelope is also determined by 
the substrate size and dynamics. This suggests that PR’s capability to incorporate Gag essentially 
depends on the peptide’s rotamers and ultimately its flexibility. Furthermore, the G435 and K436 
residues contributes to the fundamentally flexible nature of the NC|p1 substrate (Ӧzen et al., 
2012).  
 
Additionally, this flexibility may also contribute to the stronger binding observed in the PCS-
A431V complexes as compared to the drug-bound PR models. The increased binding affinity for 
the NC|p1 CS also reiterates that the PRMs were compatibly selected to accommodate Gag. 
Moreover, the 12 kcal/mol difference between the PCS124 and PCS069 models indicates a 
selective advantage to acquiring a 4th major PRM in favour of three (M46I+I54V+V82A). 
Therefore, it is accepted that via alternate mechanisms, patterns of mutations act synergistically 
to evade drugs (Agniswamy et al., 2016).  
 
Lastly, to explore the intricate interactions between the mutated Gag and PR, 2D interaction maps 
were constructed. Our analyses revealed that key hydrogen bonds involving several Gag residues 
(E428, Q430, N432, L434 and G435) across the substrate was observed in the PCS124-A431V 
model. While substrate dynamical flexibility allows for its incorporation (Ӧzen et al., 2011), this 
suggests that the formation of hydrogen bonds arose to stabilize the CS, keeping it relatively static 
for cleavage to occur. Furthermore, our analyses also revealed an important hydrogen bond with 
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PR’s catalytic D25 and the carbon atom of isoleucine at position 437 in the NC|p1 Gag CS. This 
bond suggests that the CS rotated into and downwards of PR’s substrate cavity to catalyze the 
reaction. Incidentally, this could be seen Figure 5.3 where the isoleucine extended down PR. Of 
note, Gag Q430, G435, K436 and I437 in Gag are also sites at which drug resistance/exposure 
associated mutations occur (Doyon et al., 1996; Gonzalez et al., 2004; Ghosn et al., 2011; Knops 
et al., 2011). As such, these regions in the substrate are variable and can therefore allow for 
alternate substrate poses to develop when PR is unable to actively accommodate the CS. 
Interestingly, the close interaction of the A431V Gag mutation with G27_PR and I47_PR indicate 
that the slightly larger valine substitution in place of alanine brings the active site and flaps closer 
together thus constricting the available space and allowing for greater binding affinity. 
Furthermore, the proximity of M46I in PR and the phenylalanine of F433 in Gag suggests that 
coordination between these two residues can regulate movement within the flaps. Of note was the 
interaction of the I50’s to each other and the substrate. Tóth and Borics (2006) showed that the 
enzyme can exist in open, semi-open and curled conformations during a single MD simulation 
and that the distance between I50’s (flap tips) indicate which conformation was favoured at the 
time. Finally, the bond between L10F_PR and A431V_Gag which was also observed in our Gag-
PR BN (chapter three), suggests that coordination between these two residues are important for 
substrate recognition and linkage.  
 
The increase of hydrogen bonds between the PCS069 PR and the NC|p1 substrate suggests that 
the L76V mutation in PR significantly contributes toward substrate recognition and favourbale 
cleavage rather than evading drug binding directly. Generally, hydrogen bonds facilitate protein-
ligand binding through the displacement of receptor water molecules (Chen et al., 2016). In 
essence, either the water molecules are displaced by the ligand or are subtly shifted (Huggins and 
Tidor, 2011). While water molecules are important mediators in protein-ligand binding (Brenk et 
al., 2006), Chen et al. (1998) showed that in an enzyme-inhibitor complex, the ligand displaced 
an active site water molecule which created favourable inhibitor orientation. Thus, in our study, 
the extensive formation of hydrogen bonds suggests that protein water displacement may have 
occurred to properly orient the ligand within the substrate cavity. Additionally, these data also 
revealed that the L76V PR mutation also closely interacted with Q430 in Gag. Incidentally, 
Q430_Gag was also involved in four out of the 12 hydrogen bonds. A study conducted by van 
Maarseveen et al. (2012) on NC|p1 CS efficiency on resistance revealed that AA position of the 
substrate significant correlated with the difference between the NC|p1 430–435 residues outside 
PR’s cavity and within the active site. Therefore, Q430 as well as A431V in Gag can alter PR’s 
active site dynamics for efficient substrate cleavage. 
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While the hydrogen bonds between the PCS069 PR and NC|p1 CS hold the substrate in place, the 
CS seemingly “sits” at the top, closer to PR’s flaps (Figure 5.3). This observation was pronounced 
by the hydrogen bond linking A431V in Gag to G48 in PR as well as the alkyl bond between 
I47_PR and A431V_Gag. Studies have shown that the positioning of PR’s flaps correlated with 
its sensitivity to the PIs (Wlodawer et al., 1989; Yedidi et al., 2014) suggesting that the same 
mechanism can be employed when bound to the mutated NC|p1 substrate. Additionally, a study 
conducted by Khan et al. (2018) suggested that switching between flap positioning during 
inhibitor binding requires additional changes in PR’s conformation which may result in 
significant energy fluctuations. In this study, conformational changes in other parts of PR were 
observed by interactions between PRMs L10F, V82A and L76V (Figure 5.5; dotted black lines). 
This suggests that when L76V is present together with A431V_Gag, the mutational dynamics 
between this PR resistance combination (L10F+M46I+I54V+V82A) changes to constrict these 
regions in PR and allow for efficient substrate processing in favour of drug binding. Contrastingly, 
the switch from hydrogen bonding to vdW interactions between D25_PR and the substrate 
indicates an indirect mechanism of cleavage which is consistent with studies evaluating L76V, as 
previously discussed (chapter four). Noteworthy, while vdW interactions are considered weak, 
these forces are often important in the interaction and shape of molecules (Atkins and de Paula, 
2006). Therefore, in this instance, cleavage is coordinated by the flaps and strong vdW 
interactions rather than direct active site dynamics. 
 
 
5.5 Conclusions                
In summary, these data indicate that the mutated PR depicted great affinity for the NC|p1 Gag 
CS. Specifically, the A431V Gag mutation coordinated several PR residues to aid in substrate 
recognition and efficient binding. In addition, the PRMs actively work together to provide a 
compatible conformation that can accommodate Gag. Particularly, PRM L76V plays an important 
role in coordinating PR resistance dynamics, suggesting that its role is closely related to CS 
recognition rather than association with the drugs. Finally, these data revealed that constricting 
and flexing specific regions in PR while allowing flexible movement of the substrate can allow 
for multiple, complex mechanisms of resistance to occur.  
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Chapter six 
 
General discussion, conclusions, future 
recommendations and study limitations 
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6.1 General discussion 
With an estimated 1.8 million new HIV infections reported in 2017 equating to approximately 
5,000 infections per day, HIV remains a serious public health risk (UNAIDS, 2018). Although 
more than a 55% reduction of AIDS-related deaths22 have been reported since 2004 due to ARV 
therapy (HIV.gov, 2019), drug resistance and thereby the virus’s ability to actively replicate 
despite the drugs remains a serious challenge (Ngo-Giang-Huong and Aghokeng, 2019). While 
the PIs show effective potency against the virus (Titanji et al., 2013), PR is able to accumulate 
resistance mutations in various regions, thus thwarting drug binding (Henderson et al., 2011). 
Furthermore, several resistance associated mutations reported at cleavage and non-CS positions 
in PR’s natural substrate Gag, have also been reported in several studies (Maguire et al., 2002; 
Verheyen et al., 2006; Kolli et al., 2009; Parry et al., 2011; Shibata et al., 2011). While these 
mutations can improve viral fitness in the presence of PRMs (Fun et al., 2012), they have also 
been shown to directly infer resistance in the absence of PRMs (Parry et al., 2011). Therefore, it 
is becoming increasingly apparent that Gag and PR share evolutionary mechanisms to 
synergistically act against PI binding.  
 
Most studies have investigated subtype B viruses even though subtype C remains the most 
prevalent subtype globally (Alcalde et al., 2012; Costa et al., 2014; Castley et al., 2017). Though 
several studies based on functional assays have provided useful information on the effect of 
resistance mutations found in Gag and PR (Brann et al., 2006; Matsunaga et al., 2015; Zhu et al., 
2015; Giandhari et al., 2016), the selection of combinations of resistance mutations and its impact 
on the structure is lacking (Zhang et al., 2010; Costa et al., 2014). It is therefore important to 
improve our understanding on the pathways to resistance and the complexities associated with 
treatment failure. 
 
Therefore, the current study investigated Gag-PR coevolution under drug selection pressure and 
the structural implications of patterns of resistance mutations in HIV-1 subtype C. To do this, we 
first identified the selection and frequency of mutations in Gag and PR using 1,972 and 130 PR 
and Gag sequences, respectively. Thereafter, we performed positive selection and coevolution 
analyses to construct Bayesian networks for elucidating probable pathways to resistance. Lastly, 
using the knowledge gained from BNL, we investigated the structural changes induced by the 
combination of resistance mutations on PI and Gag CS binding using homology modelling, 
docking and MD simulations.  
                                                          
22 Globally, in 2018, approximately 770,000 people died as a result of AIDS-related deaths, compared 
to the 1.2 and 1.7 million deaths observed in 2010 and 2004, respectively. 
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Of the 1,972 PR sequences, only 964 had major PRMs. Site-wise, the highest percentage of 
mutations occurred at positions 46 (19%), 54 (23%) and 82 (25%). Additionally, certain AAs 
were selected more frequently over others, for example M46I occurred in 16% of the dataset as 
opposed to M46L (3%), thus suggesting the role of AAs in protein functionality. The same trend 
could be seen for I54V (22%) and V82A (23%). Incidentally, the M46I+I54V+V82A 
combination, which was also the most frequent pattern observed in this study, is commonly 
associated with failure to several PIs including the 2nd-line drug, LPV (Barber et al., 2012). 
Although, L76V only occurred in 7% of the dataset, it was part of the second most recurring 
combination (M46I+I54V+L76V+V82A) in this study. Amongst the minor PRMs, L10F/I, A71V 
and T74S were highly prevalent in the dataset. While the exact impact of minor resistance 
mutations on PR is arguably unclear (Nijhuis et al., 1999; Henderson et al., 2011; Wensing et al., 
2017), it is accepted that their presence can either improve viral fitness or increase the level of 
drug resistance in the presence of other major PRMs (Scherrer et al., 2012). 
 
Of the 30 Gag resistance/exposure associated mutations (Fun et al., 2012), only A431V, L449F, 
R452K, K62R, N373P, I401V, R409K and S451T occurred at significantly (p<0.01) higher 
frequencies in the treatment associated dataset. Of these, A431V (NC|p1), L449F (p1|p6), R452K 
(p1|p6), N373P (p2|NC) and S451T (p1|p6) are Gag CS mutations. Furthermore, this study also 
identified several presumptive Gag resistance associated mutations across multiple Gag domains. 
These included T53N, S54A, Q69K, D122T, S125D and N126E in matrix, D260E, I256V, D319E 
and R335K in capsid as well as P485A and L498S in p6. While the selection of Gag CS mutations 
directly alters the CS thereby allowing for unhindered substrate processing (Fun et al., 2012), 
non-CS mutations allow for distal changes in the structure to occur (Özen et al., 2014). Since Gag 
has numerous functional roles (chapter one; section 1.10), it is conceivable that these mutations 
are selected to preserve Gag functionality rather than resistance development itself. These data 
provided useful information on the prevalence and patterns of resistance in PR and Gag. Bearing 
this in mind, we investigated the evolutionary pathways of resistance in chapter three. 
 
To evaluate the pathways leading resistance, we firstly identified the positively selected and 
coevolving sites in Gag-PR. To do this, we compiled 58 complete Gag-PR sequences from the 
PCS cohort. Accordingly, an overlapping coevolving group of 10, 46, 54, and 82 was observed 
suggesting that these positions either directly or indirectly interact with each other. Moreover, of 
these, codons 10 and 82 were also positively selected indicating that mutations at these positions 
provide a selective advantage to the enzyme. While several Gag mutations (E365, S373, A374, 
A431, R452 and Q474) were identified in the coevolution analysis. Of note was the NC|p1 Gag 
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CS mutation A431V, since it also occurred in 26% of the Gag dataset. This mutation has been 
associated with V82A, M46I and L76V in previous studies (Bally et al., 2000; Myint et al., 2004; 
Nijhuis et al., 2009). In addition to conferring resistance alone (Dam et al., 2009), it has also been 
shown to improve viral fitness in the presence of PRMs in subtype B (Mammano et al., 2000; 
Cote et al., 2001).  
 
To the best of our knowledge, the evaluation of Gag-PR resistance mutations in pathways to LPV 
resistance using BNL has not been shown before. This study proposed two probable pathways to 
LPV resistance. The first pathway connected I54V to L10F, M46I and V82A while inverse 
associations with L24 and Q58 connected L76V to M46I+I54V+V82A. The second pathway 
connected V82A with LPV via L93 in PR. We postulated that the deciding factor as to whether 
I54V or V82A is selected first in the pathway also depends on selection of L10F. Therefore, if 
L10F is selected then I54V is also selected. While conditional dependencies between 46, 54 and 
82 have been observed (Zhang et al., 2010), a recent study conducted by Vasavi et al. (2017) 
revealed that in a double PR mutant comprising L10F/N88S, the binding affinity of PR to NFV 
was lowered in the presence of these mutations. This suggest that L10F may play an important 
role in regulating resistance in the presence of major PRMs. Interestingly, in the Gag-PR network, 
the interactions between the PRMs remained unchanged whilst the Gag mutations essentially 
added to the existing network. Of note, A431V correlated with M46I+V82A via I54V. It also 
interacted with L10F. This suggests that associations between A431V and V82A depends on the 
selection of M46I and I54V which in turn depends on L10F. With numerous studies highlighting 
Gag-PR coevolution (Shibata et al., 2011; Kolli et al., 2014; Deshmukh et al., 2016; Codoñer et 
al., 2017), it is evident that the basis on which resistance occurs is dynamic and complex. 
Consequently, the structural mechanism by which these resistance mutations act on resistance is 
certainly unclear (Lin, 2016). Particularly, in the context of this study, the structural changes of 
L10F+M46I+I54V+L76V+V82A in subtype C is elusive. Therefore, chapter four evaluated the 
structural implications of this combination on LPV and DRV binding. 
 
Based on the data from chapter two and the BNL which especially highlights L76V as a 4th 
mutation, we selected two PR sequences, one with L76V (PCS069) and one without (PCS124) in 
addition to the L10F+M46I+I54V+V82A from the PCS cohort to study further. The MD 
simulations revealed that the LPV-bound PR mutants were relatively stable over the 100 ns 
simulation in comparison to the DRV-bound models. Expectedly, LPV revealed stronger binding 
to the PR mutants. Although DRV is considered extremely potent as it comfortably fits into PR’s 
substrate envelope, resistance can occur through the accumulation of several PRMs (Lockbaum 
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et al., 2018). Our data revealed that a loss of contact between DRV’s essential chemical moieties, 
bis-furyl and 4-aminobenzenesulfonamide contributes largely to DRV inefficacy which is 
consistent with findings observed elsewhere (Raugi et al., 2016). LPV resistance on the other 
hand seems to be readily affected by the direct structural changes induced by the drug resistance 
mutations as seen in this study. While it is evident that these dynamical shifts in PR can allow for 
a reduction in binding affinity of the drugs, it is unclear how these mutations would be 
advantageous during cleavage. Furthermore, the presence and link of the NC|p1 A431V Gag 
mutation to these PRMs in terms of structure is unclear. Therefore, chapter five investigated 
interactions of the mutant NC|p1 CS on the MDR PR models. 
 
The structural interactions of these specific PRMs coupled with the mutated NC|p1 Gag CS 
(A431V) has not been shown prior to the current study. These data revealed that MDR PR models 
had a stronger affinity for the CS in comparison to the PI drugs. This was particularly evident 
from the binding scores where the PCS124 and PCS069 models had a binding energy of -50.3386 
kcal/mol and -62.4605 kcal/mol, respectively. This was a 3-fold energy difference between the 
lowest binding score of drug-bound model. Furthermore, it was seen that A431V coordinated 
several residues in PR to improve substrate recognition and binding whilst the PRMs work to alter 
PR’s conformation to accommodate Gag. Additionally, it was suggested that L76V in PR provides 
a mechanistic advantage for substrate recognition and binding as opposed to directly inhibiting 
the drug as shown in other studies (Louis et al., 2011; Wong-Sam et al., 2018). Therefore, this 
study highlights that L76V utilizes an additional novel approach in PI drug resistance. Lastly, to 
our best knowledge, docking of the theoretical PR and Gag CSs to evaluate drug resistance and 
substrate binding has not been previously shown.     
 
 
6.2 Conclusions 
The current study investigated the intimate interactions between complex resistance patterns in 
Gag and PR under drug selection pressure. As observed, Gag and PR readily accumulate 
mutations in various regions to outcompete the inhibitors in favour of substrate binding. 
Importantly, the selection of mutations is not random but rather advantageous to the structural 
complexity of the enzyme-substrate complex. In particular, the mutant PR overcomes drug 
binding by switching conformations through mutations in or near the active and flap regions. 
Consequently, a balance between enzyme rigidity and flexibility through mutations and chain 
asymmetry aids the virus in restoring cleavage. Further complicating the process is the role of the 
substrate. Additionally, proper incorporation of the A431V Gag CS within PR’s cavity depended 
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on movement of the substrate. Consequently, the AA side chains can rotate to aid in substrate 
recognition. These data highlight that the functional aspects of resistance are highly correlated 
with the structural dynamics of the enzyme and substrate. 
 
6.3 Future recommendations and limitations 
Some aspects of this study were limited and are hereby recommended for future investigation: 
 
1. The Gag dataset utilized in this study was small. However, it is accepted there are 
limited viral sequences available that were genotyped from patients receiving ARV 
therapy. Increasing the sample size to evaluate a larger picture of Gag resistance 
dynamics is needed. 
2. Functional assays investigating the step-wise accumulation of the mutations reported 
in this study should be performed to present a complete picture on pathways to 
resistance. 
3. As some subtype C signature mutations were present in the BNL, a study evaluating 
these signature mutations in subtype C vs subtype B should be performed to identify 
possible subtype differences in pathways to resistance.  
4. This study only evaluated the A431V NC|p1 Gag CS mutation because of its 
importance in the Bayesian networks, however, mutations at the remaining Gag CSs 
should be further studied to elucidate their individual roles in resistance in the presence 
of the PRMs highlighted in this study. 
5. As this study did not look at the WT, the NC|p1 CS should also be evaluated without 
the A431V mutation in the presence of the PRMs to elucidate how cleavage might 
occur without this mutation.   
6. Since several non-CS mutations were identified in the Gag-PR BNL, such as Q69K 
and I256V, the structural impacts of these mutations should be studied further to 
identify its role in pathways to resistance.  
7. Accelerated molecular dynamics should be performed on a millisecond scale to 
evaluate the folding of the mutant Gag-PR proteins. 
8. Using the information obtained in this study as a foundation, a computer-based 
programme can be developed to predict viral replication capacity on a structural level.   
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Accession numbers for treatment exposed protease sequences 
KF526221 KF135163 KF135023 JN132268 KC423757 JN638200 AY529558 KF135091 
KF526227 AY529608 KF135139 JQ480293 KC423705 AY677427 KF134957 KF134930 
KF526212 KF135033 KF135029 JN638132 KC423284 FJ445708 KF134958 AY900811 
KF526218 AY677473 KF134948 JN638225 KC423763 KC423104 KF135149 KF135083 
KF526207 AY529534 KC423753 KC423404 KC423440 KC423562 KC424259 KF135084 
KF526220 KF135158 KF135015 KC951632 JN132390 JN132221 AY529578 KF135083 
KF526226 KF135159 KF134985 KC423124 JN381594 JQ480163 AY529598 KF134938 
AY677485 KF135092 KC423906 KC423703 KF135071 KC424241 AY529599 KF135165 
AY529577 KF135150 AY529533 EU308099 KF135072 JN638092 JN700932 KF135162 
JF960549 KC423127 KF135028 JQ480160 KF135031 KF134959 JN638218 AY900818 
AY529541 KF135044 KF134951 JQ480224 KF135032 KF793146 AY529592 JN638106 
AY529542 KF135045 KF134936 KC424212 AY529613 KC423799 KF793134 JN638215 
AY529543 KF135046 AY900815 JF960548 KC422880 JN638162 KC423788 JN638070 
AY529544 AY529582 AF358747 JF960554 KC423650 AY529554 KF135146 JQ480220 
AY529545 KF135030 JN638156 KC423550 AY900795 AY529555 KF135106 KC423714 
AY529573 KC423878 KC423388 KC423158 HM593308 AY901184 KF134949 JQ480222 
KF134975 KF135066 KC423813 JQ480273 AY529581 AY529561 KF134935 AY529590 
KF134994 KF134950 JN638193 KC424332 GU324863 AY529550 KF135120 KF134960 
KF134963 KC424133 KC424143 KC423006 JN638208 AY529562 KF135121 JQ480274 
MH568933 KC424348 KC422859 KC423841 KC424268 AY529563 KF135076 KF134988 
KF135003 KF134953 KC423761 AY900794 JN381618 AY529549 KF135156 JQ480297 
GU324870 KF135049 KC424273 AY589912 KC422999 AY529548 KF135157 AY677471 
KF134941 KF135151 JQ480225 KC423893 AY090850 AY529567 AY529593 KC424322 
KF134941 KF135152 AY090845 HM623531 FJ445712 AY529568 JN638207 KC423458 
KF135040 KF135078 FJ445719 JF960579 KC423358 AY529569 KF134997 KC423099 
KF135147 KF135001 AY589876 KC423437 AY900770 AY529610 AY529547 JN381572 
KF135004 KF135055 HQ843636 KC423449 KC424150 AY529587 KC423644 KC423119 
AF358760 KF134939 JQ480283 JN132295 KC424037 JN132219 JN087532 KC423957 
AF358750 EF116342 JQ480287 JF960550 JQ480157 KF134969 EU854548 AY461494 
KF241499 KF135009 KT032035 KC951639 JN638187 KC422967 EU854547 AY461495 
AY677402 EF548178 EU854490 KC423376 AY461496 AY529529 EU854562 KC423384 
KF134937 KF135068 EU854489 KT032022 FJ445727 KF135086 EU854561 KF135052 
AY900745 KF135010 EU854488 JN638145 AY900805 AY529556 EU854546 KF135127 
KF135138 AY529606 EU854487 KC951637 JN638077 AY529557 KF134929 KF135008 
KC422954 JN393305 JQ480279 JN381576 EF186986 KF766541 JN132231 KC423688 
KF135167 KC423340 KC423211 AJ577964 JN638167 DQ826648 KC422988 KC423140 
KF135128 KC424059 KC422931 AJ577965 KT351807 EF186971 HM623520 KF793177 
KF135129 KC423540 KC423359 KT032031 JN638096 JQ480275 AY090849 EU308093 
KF135131 KC424306 KC424330 AY275752 KC424044 EF186966 AY677450 KC423243 
KF135133 KC423491 KC423042 GQ401298 JN381596 JQ480210 JQ480162 JQ480227 
JN638206 KC852928 KC423070 GQ401324 KC423565 KC423652 KC423883 KC424349 
JN393296 AY677460 KC423483 JQ430823 KC424373 KC423064 KC423856 KC423153 
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JN132267 KC423610 AY901099 AY677386 JN638204 JQ480289 KC423829 JQ480226 
JN132340 KC422992 KC424067 GQ401321 KC423232 KC423228 KC423895 KC424042 
AY461501 JN132381 KF135067 GQ401303 KC422911 KF135163 AY090844 KC424319 
KC423529 JN132393 KC424028 AY313368 JN638151 KC424186 FJ445702 KC423748 
JN638083 KC423303 KC422920 AY900895 KC423380 KC422797 JN381584 KC424328 
JQ480282 KC852931 KC423193 GQ401308 KC424381 JN132364 AY090843 KC423160 
KC423693 AY589917 KF135105 GQ401299 DQ826651 EU854551 EU854536 KC424340 
KC424271 KF135016 JN381616 AY275739 KC204774 EU854550 EU854535 KC423600 
KC423150 JN638088 KT032025 AY275720 KC951636 KC422895 EU854534 JN132236 
KC423334 KC423685 KC423586 AY390191 KC424224 KC423041 JF960535 KC423853 
KJ081337 AY677436 JF960569 AY275748 KC423329 KC423180 AY900772 KC424191 
KC423915 KF134982 KC424064 GQ401307 KC423956 KC423614 KC423605 KC424167 
KC423885 KC423417 JF960555 GQ401304 JQ480214 KC016209 KC423386 KC424305 
EU854504 KC424209 KC423155 GQ401320 JN638074 KC423660 FJ445728 KC423360 
EU854502 KC852933 KC424064 GQ401316 JN132229 KC423744 JN381607 KC424354 
EU854503 KC423046 KC423467 GQ401322 JN393294 JQ361673 JN381608 HM120057 
KC423069 KC424327 KC424098 GQ401319 KF134976 KC424096 KC423653 JF960544 
JQ480280 KC423830 JQ480278 GQ401302 AF331699 KC424182 KT032051 KC424147 
JN638114 KC424285 KC422873 GQ401305 JF960574 JN638174 JN638169 KC424147 
KC424116 KC423146 KT032030 GQ401333 KC423297 DQ826627 KC423185 JN381614 
AF338992 JN638179 KC422861 KT351848 KC423828 DQ826638 JF960567 KC422852 
AY900778 KF134979 KC423210 AY275735 EF186961 DQ826653 KC951635 JQ361665 
KC422864 HM623525 JN132224 AY275730 DQ826628 HQ843518 KC423768 AY090840 
JN638203 JN132261 KC424184 AY900730 EF186975 JN638069 JN638113 KC423182 
JN132310 KT032027 AY900766 KC424377 FJ983395 KC424258 JN381587 KC422839 
JN132396 JN638117 KC423217 GQ401301 KF766542 KC423350 JN381588 KC423355 
JN132344 DQ826657 EF186968 KC016282 EF186981 FJ445721 KC424197 KC423363 
KC422906 KC423495 KF134961 DQ826629 DQ826646 KC423289 KC423545 KF134971 
KC423576 JN381567 KF134962 KJ544553 AJ577947 KC423995 KT032019 KC424356 
AY900844 JN132387 EF186965 EF186976 JQ480167 JF960545 KC423071 KC424054 
JN381615 KC423020 EF186960 DQ826665 EF186982 KC423677 JN132309 KC424130 
AY714411 JN381609 DQ826641 EF186973 KF135012 KF134995 KC423547 AY461491 
AY090856 JN381610 EF186956 DQ826654 KC424407 JX982979 KC424334 AY589932 
JF960528 KC422984 DQ826649 KC016236 KC423188 JF960561 JN638199 KC423456 
KT032024 JQ361668 DQ826662 EF186970 JN132380 KC423270 AY589898 JQ480276 
KF134993 JQ480166 EF186962 EF186958 JN132394 AY900767 JN381574 KC423815 
JN638130 JN638223 DQ826626 DQ826664 JQ480158 KT351808 EF449991 AY714457 
KC424420 KC423455 DQ826639 EF186969 JN638194 KT351809 EU854510 JN638101 
AY589925 KF134929 EF186988 DQ826645 DQ826663 JN638141 EU854509 JN638087 
KC422857 JN638082 DQ826666 JN185242 EF186957 JN132220 KC423326 KC423382 
KC423511 KC424259 DQ826630 KF134943 JN381560 KC423671 JN132299 JN638110 
KC424329 KC422869 DQ826632 DQ826660 JN381559 KC423636 JN381591 HM601455 
KC424297 KC422944 EF186984 KC423811 HM623523 KC423942 KC422940 JN638095 
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KC422991 JN132271 DQ826621 KT351811 KF135168 EU308077 JN132379 JN638115 
KC424149 JQ480294 EF186974 KT351810 DQ826667 HM623533 KC423168 JN132238 
JN638231 JN638161 EF186987 KC423525 EF186985 KC423512 JN381623 KC423707 
KC423663 AY090841 DQ826668 KJ544534 DQ826625 KC423289 JN381624 JN132341 
KC422862 KC424333 DQ826624 KJ544535 DQ826622 KC424263 JN381568 JN132227 
KC423212 KC423420 EF186955 KC016234 DQ826635 KC424132 JF960529 KC424311 
JQ480291 KC423851 DQ826633 JN381583 KC423695 KC951633 KC423962 KC423308 
KC424200 FJ445709 DQ826652 KC423875 KC424276 KC423043 KC423840 KC423946 
KF793181 AY090847 DQ826647 JN132264 KC423247 KC423402 KC422961 JF960557 
KF793157 AY090852 DQ826644 DQ826643 KC423324 AY461502 KC423379 JN638178 
KC423432 GU324882 DQ826656 DQ826659 KC423817 KC424119 KC423396 KC424344 
KC423964 EF186979 EF186926 EF186963 HM623527 KC423780 KF135054 KC423898 
AY589882 DQ826669 EF186983 DQ826637 KC423745 JN638072 JN638220 KC424257 
KC423594 EF186967 KC016240 DQ826636 KC422803 KC423687 KC422941 KC423037 
KC422943 EF186927 KC016219 DQ826658 JN638152 KC423690 KC424251 KF135006 
JF960552 EF186959 DQ826620 DQ826642 AY090860 JN638166 KC423970 JQ480223 
JN638227 AY797580 DQ826623 AY900793 FJ445701 JN638104 KC422953 KC423094 
JN132216 AY529532 JN132384 JQ480211 AY529591 KC423030 JN087540 KC423764 
JN638158 KC423936 AY677411 JN132258 AY900773 KC423987 JN087539 JN638103 
JN700929 KF135019 JN381611 AY900789 AY677447 KC424133 JN381564 KC423127 
KC423939 JN638160 JN132240 KC423286 AY900776 KC423234 KC423937 KC423913 
KC424019 KC423634 KC423892 JN638116 KC016226 KC423414 JN087541 KC424294 
JF960575 JN132342 JQ480219 EF549036 KC016211 KC423531 EU854508 KC424190 
KC423305 KC423721 KC423271 AY090854 KC424279 KT032036 EU854506 KC423012 
JN393306 GU324879 JQ480271 FJ445707 AY589931 KC423723 EU854507 JF960563 
KC423227 JN132218 JN381586 KC016237 JN087542 KC424321 KC423148 KT032038 
KC423273 KC423436 JN381585 EF186928 KC423222 KC423704 GU271172 KF134981 
JN132266 JQ480286 EU854527 EF186980 KC423114 JN132239 GU271173 KC423176 
KF793185 KC422976 EU854528 KF135060 KT032058 KC422869 KC016227 KC424080 
JN132260 KC423648 KC422853 KF135061 KC423322 JN393295 KC016197 JN638066 
JN638108 KC424033 AY677448 KF135067 KC423889 KC016213 KC016246 AY529605 
KC423380 JN132230 KC423474 AY900833 KT032033 KT032057 KJ176652 AY090853 
JN638159 JN638226 KC423767 KF135112 KC423106 KC423888 JQ361677 AY589910 
JN132228 KC422982 KC423134 KF135005 JN087536 KC423667 KC422863 AY677453 
KC423737 KC423835 KT032037 JN087535 JN087547 KT032060 KC424396 JN132385 
KC423603 AY589913 AY589936 KC422997 EU854553 AY589899 KC423137 JN132305 
AY589907 JQ480228 JN638071 KC423161 KC423577 KT032055 KC423008 JN132235 
KT351819 FJ445709 KC951661 AY677479 KC016243 KC423765 KT032056 EU854500 
KT351818 KC424094 JQ480292 AY900786 JN087537 KC423603 AY589908 EU854499 
AY275733 KC424156 JQ480215 AJ577870 KT032053 EU854498 KF134952 KF793156 
KC423454 KC424376 KC422877 JF960542 JN087531 JN087545 AY900762 JQ480288 
JN132255 KC423054 JN638097 AY677426 KT032050 EU854496 AY714443 JQ480296 
KC422971 KC424087 KC423943 AY900769 KC423718 EU854497 EF525661 KC423933 
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JN132363 KC423963 DQ826631 JN638163 KT032034 KC424348 KC423100 JQ480216 
JN638175 JN638142 JN638143 AY589937 JN087533 AY589904 KC423192 JN638191 
JN132237 JN638073 KC423063 AY677417 KT032012 EU854483 KC423977 KC423983 
JN638094 KC424181 KC422916 FJ445724 KC423147 EU854482 KC424335 GQ401316 
KC423126 JN638222 KC422855 AY589894 KC016212 JN087546 KC423684 KF135160 
EU308079 AY677400 JN638186 AY900768 KT032061 EU854481 KC423858 EU308081 
KC951650 JF960526 JN638098 EF186929 KT032043 HM623509 KC423735 KT032062 
AY529531 KC423588 JN638105 EF186978 KC424424 KT032040 JN638229 KC424352 
FM251950 KC423852 KC423191 KC423062 JN638224 JN638230 KC423276 EU854559 
AY677381 KC422850 GU324885 KC423802 EU854525 JN638181 KC423774 JN638109 
JN638177 KC423055 KC423878 KC423948 EU854524 KC424345 JN381590 KC423839 
AY589920 KC423429 GU324884 KC423503 KC423669 KC423559 JN638136 KC422948 
KC422908 EU854480 KC424092 JN638079 KC422867 JN393304 JN393303 JN638148 
KF527077 KC424418 JN638067 JQ480229 KC424144 JN132256 JN638091 JN381606 
KF527173 JQ480218 KC424152 JN638164 KC423649 KC422806 KF134934 JN638144 
KF527176 KC424275 KC422807 JN700927 KC424196 KC424177 JN132294 JN638090 
KF527067 JN638168 JN638075 AY589870 JN638147 KC424244 KT032014 JN638137 
KF527180 JN381619 KC423257 JN132226 KC424303 JN638198 JN638099 JN638131 
KF527192 JN132270 JN638085 JN381579 KC423945 KC423639 JN638213 KC423075 
KF527185 JN132343 AY589889 JN132392 KC423416 JN381605 KC423424 EU854541 
KF527189 KC423891 JN638081 JN638146 JN638112 JQ480232 JN638202 EU854542 
KF527181 KC424246 KC423755 JN638212 KC423854 KC423451 KT032029 KC423315 
KF527061 KC423139 KC424136 KC423787 JN638124 JN638197 KC951811 KT032046 
KF527187 KC424035 KC422935 KC423034 JF960537 JN638171 JN638221 KC423490 
KF527191 KC423221 KC423971 KC422983 JN638084 KC423149 AY901102 KC422979 
JN638150 KC424078 KC423101 AY901107 JN381571 JN638189 KC423828 KC423855 
KF134990 JN087538 JN393301 JN638139 KF793182 KC424062 JF960558 JN638182 
KC424004 JN087534 KC422898 KC423860 JN638219 KC422965 JF960566 JN638176 
KC423378 KC423722 JQ480165 KC423563 KC423818 KC423694 KC424221 KC423725 
KT032054 KC423225 KC423795 KF793138 KC424406 KC423504 JN132269 KC424108 
KC424114 KC423291 KC424323 JN638126 KC423758 KC852930 JN638102 KC423089 
KC423004 KC422825 KC423373 JN700931 KC423762 HM623503 KT032002 KC423216 
KC423568 KC423385 EU854532 KC423750 JF960572 KC423061 KC422836 KC423198 
EU854523 KC422843 EU854530 JN638209 JN381557 EU854519 KC423253 KC423927 
EU854522 KC423876 EU854533 JN638185 KC423341 EU854520 KJ081322 JQ480212 
KC424079 JQ480209 KC423864 EU308066 EU854494 JN638118 JN381612 JN087543 
JF960547 KC422917 KC424397 KT032032 EU854495 KC423258 JN132292 JN087544 
KC423387 KC423868 KC423256 KC423201 JN381603 JQ480208 KC423832 JN638120 
KC423444 JN381578 KC423174 KC423398 KC423904 KC422831 JN638180 KC424312 
JF960549 JN381577 KC424101 KC424291 JN638210 JN132389 KF793139 JN638119 
KC424138 KT032052 KC424166 KT032042 JN638216 AY900781 EU854557 KC423053 
KC424172 KC423651 JF960546 EU854526 KC423683 JF960530 EU854558 KC424179 
JF960577 KC423558 JN700933 AY529559 JF960536 KF793171 EU854539 KC951646 
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KC423190 JN638125 JN638183 KC423553 KF793121 JN381581 EU854538 KC423300 
JN638192 JN638076 KC852932 KC424362 KF793136 KC424009 EU854543 KC422984 
JN638190 KC424400 JN393292 KC423471 JN132257 KC424126 EU854545 JQ480290 
KC424280 KC423260 JN132225 KC424178 EF549368 AY090858 JQ361682 JN638214 
KC423949 KC423036 KF793174 KC422977 EU854515 JN132388 KC423896 JN638086 
JN638165 KC423708 AY677456 KF135107 EU854514 JN638133 KC423173 KF135070 
KC424359 KC423082 KT032041 JF960534 EU854513 KC423018 JQ480168 AY529595 
KC423279 KC423920 AF425391 KC423357 EU854512 AY589897 KC424111 KF135140 
KC424416 JN132293 KC423117 KC423804 KC424255 JQ480284 JQ480272 KF135119 
KF135110 HM119721 JQ480185 KC951640 KC423292 KC423831 KC423235 KF135153 
KC423554 KT032047 JN132215 AY677441 JN638170 KC951634 KC422921 KF135154 
KC424238 JN638172 KC423142 JQ480217 KC423797 HM119983 KC423175 KF135075 
KC424109 KC423361 KC424338 AY900765 KC424093 JN381562 KC423661 KF134956 
KC423112 JQ480164 HM623529 DQ826640 KC423686 JN638127 KC424000 KF134999 
JN132391 JN132262 JN638129 JN381566 JQ480298 KT351817 KT351815 AY529594 
KC423167 KC423497 KC424384 JN381565 KC423116 KF135053 JQ480159 AY529619 
JN381604 KC423781 KC423290 JN638111 KC424090 JN132382 KT032028 KF135114 
JN638153 KC423098 JQ480295 KC423323 KT032048 KC423812 KC423816 KF135144 
AY900763 JN132263 JN381598 JN381600 EF548284 JN132217 KF135133 AY529602 
JN381561 KC423519 JN381599 JN381601 JQ480231 KC424112 AF339009 AY529570 
JF960565 JN132259 AY589906 KC423502 KC423249 KC424135 KC424081 AY529571 
KC424117 KC423026 KC423903 JN381570 AY140821 AY900807 AY714447 JN132333 
KC424405 KC213589 JN132265 KC423729 AY140823 AY900761 KC951668 KF134970 
KC422875 KC423742 JN393297 AY900849 AY900833 AY900800 JN638128 AY529583 
KC424401 EU854484 KC423181 JQ480281 AY900803 FJ445710 KC423215 KF135118 
JF960576 EU854485 KC424236 KC423372 AY900757 JF960559 JQ480207 AY529609 
KC424176 JN132298 KC424107 KC424093 JN638196 JQ480285 JN638068 KP411835 
KC424317 FJ445729 KC423239 KC423686 KT032039 KC422800 KC424222 AY900816 
EU854518 KC423973 JQ361684 AY090851 JQ480230 AY677425 KF134990 AY529588 
EU854516 KF135123 KC424387 AY900779 AY900845 KF135022 KF135014 AY529572 
EU854517 KC422796 KC423873 KC423906 JQ480221 KC424422 JN638080 AY529596 
JQ480213 DQ826650 JN132307 KC423044 KC423655 KC423633 JN638107 KF135064 
JN638121 EF186964 KF135013 KC424371 KC852929 EU854537 AY714404 KF135065 
KF135002 KF134973 KF135097 KF135085 AY529566 AY529617 KC423832 KF135089 
AY529537 GQ401326 KF135098 KC423340 AY900813 AY529616 KF135018 AY529530 
AY529538 GQ401327 KF135099 KC424373 KC424217 AY529621 KF135103 KF135033 
AY529607 AY677445 KF135117 KF135165 KF135047 KF135173 KF135104 AY900885 
KF134934 KF135141 AY529579 KF135082 KF135048 KF135174 KF134989 KF135094 
KF135055 KF135142 AY529564 KF135155 KF135024 KF135175 AY529612 KF135095 
KF135077 AY529600 AY529575 KF135110 KF135025 KF135080 AY529620 KF135096 
KF135172 AY529601 AY529574 KF135111 AY529576 AY529618 KF135164 AY010422 
KC424004 KF134954 AY529565 KF135116 KF134987 AY529622 KF135143 AY010425 
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Accession numbers for naïve protease sequences 
AB081151 AB285773 AB285817 AB640496 AM071421 AY007739 AY136977 AY165216 
AB081152 AB285774 AB285818 AF527205 AM071422 AY007740 AY136978 AY165219 
AB081154 AB285775 AB285819 AF527207 AM071423 AY007741 AY136979 AY165220 
AB081155 AB285776 AB285820 AF527211 AM071424 AY007742 AY136980 AY165223 
AB081156 AB285777 AB285821 AF527213 AM071425 AY007743 AY136981 AY165224 
AB081157 AB285778 AB285822 AF527217 AM071426 AY007744 AY136982 AY165225 
AB081158 AB285779 AB285823 AF527222 AM071427 AY007746 AY136983 AY165226 
AB081159 AB285780 AB285824 AF527230 AM071428 AY036312 AY136984 AY165230 
AB081161 AB285781 AB285825 AF527240 AM071429 AY036325 AY136985 AY165235 
AB081162 AB285782 AB285826 AF527242 AM071430 AY036329 AY136986 AY165252 
AB081163 AB285783 AB285827 AF527246 AM071431 AY036377 AY136987 AY165253 
AB081164 AB285784 AB285828 AF527248 AM071432 AY036391 AY136988 AY165255 
AB081165 AB285786 AB285829 AF527250 AM071433 AY036394 AY136989 AY165257 
AB081166 AB285787 AB285831 AF527256 AM071434 AY036395 AY136990 AY165260 
AB081167 AB285788 AB285832 AF527264 AM071435 AY036397 AY136991 AY165263 
AB081168 AB285789 AB285833 AF527266 AM071436 AY036399 AY136992 AY165266 
AB081169 AB285790 AB285834 AF527272 AM071437 AY036401 AY136993 AY165272 
AB081170 AB285791 AB285835 AF527277 AM071438 AY036404 AY136994 AY165281 
AB081171 AB285792 AB285836 AF527284 AM071439 AY036405 AY136995 AY196498 
AB081172 AB285793 AB285837 AF527286 AM071440 AY036406 AY136996 AY196499 
AB081173 AB285794 AB285838 AF527292 AM071441 AY036408 AY136997 AY196500 
AB081175 AB285795 AB285839 AF527294 AM071442 AY136954 AY136998 AY196501 
AB285752 AB285796 AB285840 AF527305 AM071443 AY136955 AY136999 AY196502 
AB285753 AB285797 AB285841 AF527340 AM071444 AY136956 AY137000 AY196503 
AB285754 AB285798 AB285842 AJ287005 AM071445 AY136957 AY137001 AY196504 
AB285755 AB285799 AB285843 AM040985 AM071446 AY136958 AY137002 AY196505 
AB285756 AB285800 AB356162 AM040991 AM071447 AY136959 AY137003 AY196506 
AB285757 AB285801 AB356179 AM041002 AM071448 AY136960 AY137004 AY196507 
AB285758 AB285802 AB356180 AM041004 AM071449 AY136961 AY137005 AY196508 
AB285759 AB285803 AB356214 AM041011 AM071450 AY136962 AY137006 AY196509 
AB285760 AB285804 AB356260 AM041013 AM071451 AY136963 AY137007 AY196510 
AB285761 AB285805 AB356269 AM041017 AM071452 AY136964 AY137008 AY196511 
AB285762 AB285806 AB356345 AM041034 AM071453 AY136965 AY165186 AY196512 
AB285763 AB285807 AB356375 AM041050 AM071454 AY136966 AY165187 AY196513 
AB285764 AB285808 AB442231 AM071412 AY007730 AY136967 AY165196 AY196514 
AB285765 AB285809 AB442233 AM071413 AY007731 AY136968 AY165205 AY196515 
AB285766 AB285810 AB442259 AM071414 AY007732 AY136969 AY165207 AY196516 
AB285767 AB285811 AB640061 AM071415 AY007733 AY136970 AY165208 AY196517 
AB285768 AB285812 AB640066 AM071416 AY007734 AY136971 AY165209 AY213437 
AB285769 AB285813 AB640073 AM071417 AY007735 AY136972 AY165211 AY213521 
AB285770 AB285814 AB640195 AM071418 AY007736 AY136973 AY165213 AY213522 
AB285771 AB285815 AB640318 AM071419 AY007737 AY136975 AY165214 AY213525 
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AB285772 AB285816 AB640380 AM071420 AY007738 AY136976 AY165215 AY213542 
AY213550 AY463228 AY515763 AY515809 AY585266 AY746362 AY829282 AY829326 
AY228556 AY463229 AY515764 AY515810 AY585267 AY746365 AY829283 AY829327 
AY228557 AY463230 AY515765 AY515811 AY585268 AY746368 AY829284 AY829328 
AY267321 AY463231 AY515766 AY515812 AY589839 AY746371 AY829285 AY829329 
AY331723 AY463232 AY515767 AY515813 AY589840 AY746374 AY829286 AY829330 
AY359695 AY463233 AY515768 AY515814 AY589841 AY746376 AY829287 AY829331 
AY359696 AY463234 AY515769 AY515815 AY589842 AY746379 AY829288 AY829332 
AY359697 AY463236 AY515771 AY515816 AY589843 AY746382 AY829290 AY829333 
AY390076 AY463237 AY515772 AY515817 AY589844 AY746385 AY829291 AY829334 
AY390079 AY515728 AY515773 AY515818 AY589845 AY746386 AY829292 AY829335 
AY390080 AY515729 AY515774 AY515819 AY589846 AY746389 AY829293 AY829336 
AY390081 AY515730 AY515775 AY515820 AY589847 AY749171 AY829294 AY829337 
AY390188 AY515731 AY515776 AY515821 AY589848 AY749174 AY829295 AY829338 
AY390190 AY515732 AY515777 AY515822 AY589849 AY749177 AY829296 AY878054 
AY390193 AY515733 AY515778 AY515823 AY589850 AY772690 AY829297 AY878055 
AY390194 AY515734 AY515779 AY515824 AY589851 AY772691 AY829298 AY878056 
AY390196 AY515735 AY515780 AY515825 AY589852 AY772692 AY829299 AY878057 
AY390198 AY515736 AY515781 AY515826 AY589853 AY772693 AY829300 AY878058 
AY435389 AY515737 AY515782 AY515827 AY589854 AY772694 AY829301 AY878059 
AY444208 AY515738 AY515783 AY515828 AY589855 AY772695 AY829302 AY878060 
AY444209 AY515739 AY515784 AY515829 AY589856 AY772696 AY829303 AY878061 
AY444210 AY515740 AY515785 AY515830 AY589857 AY772698 AY829304 AY878062 
AY444211 AY515741 AY515786 AY515831 AY589858 AY772699 AY829305 AY878063 
AY444212 AY515742 AY515787 AY515832 AY589859 AY772700 AY829306 AY878064 
AY444213 AY515744 AY515789 AY515833 AY589860 AY787492 AY829307 AY878065 
AY444214 AY515745 AY515791 AY515834 AY589861 AY787522 AY829308 AY878068 
AY444215 AY515746 AY515792 AY515835 AY589862 AY787532 AY829309 AY878070 
AY444216 AY515747 AY515793 AY515836 AY589863 AY787535 AY829310 AY878071 
AY444217 AY515748 AY515794 AY515837 AY589864 AY787536 AY829311 AY878072 
AY444218 AY515749 AY515795 AY515838 AY589865 AY829268 AY829312 AY900740 
AY444219 AY515750 AY515796 AY515839 AY589866 AY829269 AY829313 AY900752 
AY444220 AY515751 AY515797 AY515840 AY589867 AY829270 AY829314 AY900759 
AY463217 AY515752 AY515798 AY515841 AY589868 AY829271 AY829315 AY900760 
AY463218 AY515753 AY515799 AY515842 AY589869 AY829272 AY829316 AY900774 
AY463219 AY515754 AY515800 AY515843 AY611649 AY829273 AY829317 AY900775 
AY463220 AY515755 AY515801 AY515844 AY611650 AY829274 AY829318 AY900777 
AY463221 AY515756 AY515802 AY515845 AY611651 AY829275 AY829319 AY900780 
AY463222 AY515757 AY515803 AY515846 AY703908 AY829276 AY829320 AY900782 
AY463223 AY515758 AY515804 AY515847 AY703909 AY829277 AY829321 AY900785 
AY463224 AY515759 AY515805 AY515848 AY703910 AY829278 AY829322 AY900787 
AY463225 AY515760 AY515806 AY515849 AY703911 AY829279 AY829323 AY900797 
AY463226 AY515761 AY515807 AY585264 AY739911 AY829280 AY829324 AY900806 
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AY463227 AY515762 AY515808 AY585265 AY739913 AY829281 AY829325 AY900832 
AY900834 DQ011172 DQ093589 DQ222250 DQ275652 DQ369988 DQ445633 DQ660009 
AY900835 DQ011173 DQ093590 DQ222251 DQ275653 DQ369989 DQ445634 DQ660013 
AY900836 DQ011174 DQ093591 DQ222252 DQ275654 DQ369990 DQ445635 DQ660014 
AY900837 DQ011175 DQ093592 DQ222253 DQ275655 DQ369991 DQ445637 DQ660015 
AY900839 DQ011176 DQ093593 DQ222254 DQ275656 DQ369992 DQ659965 DQ660016 
AY900843 DQ011177 DQ093594 DQ222255 DQ275657 DQ369993 DQ659966 DQ660017 
AY900850 DQ011178 DQ093595 DQ222256 DQ275658 DQ369994 DQ659967 DQ660019 
AY900853 DQ011179 DQ093596 DQ222257 DQ275659 DQ369995 DQ659968 DQ660020 
AY900855 DQ011180 DQ093597 DQ222258 DQ275660 DQ369996 DQ659969 DQ660021 
AY900858 DQ013271 DQ093598 DQ222259 DQ275661 DQ369997 DQ659970 DQ660022 
AY900914 DQ013277 DQ093599 DQ222260 DQ275664 DQ396364 DQ659972 DQ660023 
AY900917 DQ056302 DQ093600 DQ222261 DQ351216 DQ396365 DQ659973 DQ660024 
AY900920 DQ056404 DQ093601 DQ222262 DQ351217 DQ396367 DQ659974 DQ660025 
AY900936 DQ056405 DQ093602 DQ222263 DQ351218 DQ396368 DQ659975 DQ660026 
AY900953 DQ056406 DQ093604 DQ222264 DQ351219 DQ396369 DQ659976 DQ660027 
AY900954 DQ056408 DQ093605 DQ222265 DQ351220 DQ396370 DQ659977 DQ660028 
AY900955 DQ056409 DQ093607 DQ222266 DQ351221 DQ396371 DQ659978 DQ660029 
AY900956 DQ056410 DQ164104 DQ222267 DQ351222 DQ396372 DQ659979 DQ660031 
AY900957 DQ056411 DQ164106 DQ222268 DQ351223 DQ396373 DQ659980 DQ660032 
AY901965 DQ056412 DQ164107 DQ222269 DQ351224 DQ396374 DQ659982 DQ660033 
AY901966 DQ056413 DQ164108 DQ222270 DQ351225 DQ396375 DQ659983 DQ660035 
AY901967 DQ056414 DQ164109 DQ222271 DQ351226 DQ396376 DQ659984 DQ660036 
AY901968 DQ056415 DQ164110 DQ222272 DQ351227 DQ396377 DQ659985 DQ660037 
AY901969 DQ056416 DQ164111 DQ222273 DQ351228 DQ396378 DQ659986 DQ660038 
AY901970 DQ056417 DQ164113 DQ222274 DQ351229 DQ396379 DQ659987 DQ660039 
AY901971 DQ056418 DQ164114 DQ222275 DQ351230 DQ396380 DQ659988 DQ660041 
AY901972 DQ060209 DQ164115 DQ222276 DQ351231 DQ396381 DQ659989 DQ660042 
AY901973 DQ060212 DQ164117 DQ222277 DQ351232 DQ396382 DQ659990 DQ660043 
AY901974 DQ060213 DQ164118 DQ222278 DQ351234 DQ396383 DQ659991 DQ660045 
AY901975 DQ060215 DQ164119 DQ222279 DQ351235 DQ396384 DQ659992 DQ660046 
AY901976 DQ060216 DQ164121 DQ222280 DQ351237 DQ396385 DQ659993 DQ660047 
AY901977 DQ060218 DQ164122 DQ222281 DQ369976 DQ396386 DQ659994 DQ660048 
AY901978 DQ060219 DQ164126 DQ222282 DQ369977 DQ396387 DQ659995 DQ660050 
AY901979 DQ060220 DQ164127 DQ275642 DQ369978 DQ396388 DQ659996 DQ660051 
AY901980 DQ060221 DQ164129 DQ275643 DQ369979 DQ396389 DQ659998 DQ660052 
AY901981 DQ060226 DQ205288 DQ275644 DQ369980 DQ396390 DQ659999 DQ660053 
AY945738 DQ060227 DQ222243 DQ275645 DQ369981 DQ396391 DQ660000 DQ660054 
DQ011165 DQ060228 DQ222244 DQ275646 DQ369982 DQ396392 DQ660001 DQ660055 
DQ011166 DQ070553 DQ222245 DQ275647 DQ369983 DQ396393 DQ660003 DQ660056 
DQ011167 DQ093585 DQ222246 DQ275648 DQ369984 DQ396394 DQ660004 DQ660057 
DQ011169 DQ093586 DQ222247 DQ275649 DQ369985 DQ396395 DQ660005 DQ660058 
DQ011170 DQ093587 DQ222248 DQ275650 DQ369986 DQ396399 DQ660007 DQ660059 
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DQ011171 DQ093588 DQ222249 DQ275651 DQ369987 DQ445632 DQ660008 DQ660060 
DQ660061 EF120336 EF379168 EF407723 EF491938 EF602206 EF602250 EF602297 
DQ660062 EF120337 EF379171 EF407724 EF491939 EF602207 EF602251 EF602298 
DQ660063 EF122539 EF379174 EF407725 EF491940 EF602208 EF602252 EF602299 
DQ660064 EF143496 EF379176 EF407726 EF491941 EF602209 EF602253 EF602301 
DQ660065 EF143499 EF379177 EF407727 EF491942 EF602210 EF602254 EF602582 
DQ660066 EF143501 EF379178 EF407728 EF491943 EF602211 EF602255 EF602583 
DQ660067 EF143502 EF379181 EF407729 EF491944 EF602212 EF602256 EF602584 
DQ660068 EF143518 EF379191 EF407730 EF491945 EF602213 EF602257 EF602585 
DQ660069 EF143521 EF379193 EF407731 EF491946 EF602214 EF602258 EF602586 
DQ660070 EF143527 EF379195 EF407732 EF491947 EF602215 EF602259 EF602587 
DQ660071 EF143529 EF379198 EF407733 EF491948 EF602216 EF602260 EF602588 
DQ660073 EF143532 EF379199 EF407734 EF491950 EF602217 EF602261 EF602589 
DQ660074 EF143533 EF379203 EF407735 EF602172 EF602218 EF602263 EF602590 
DQ660075 EF157888 EF379204 EF407736 EF602173 EF602219 EF602264 EF602591 
DQ666390 EF186933 EF379206 EF407737 EF602174 EF602220 EF602265 EF602592 
DQ826595 EF186934 EF379207 EF407738 EF602175 EF602221 EF602266 EF602593 
DQ826596 EF186935 EF379208 EF407739 EF602176 EF602222 EF602267 EF602594 
DQ826597 EF186936 EF379209 EF407740 EF602177 EF602223 EF602268 EF602595 
DQ826598 EF186938 EF379211 EF407741 EF602180 EF602224 EF602269 EF602596 
DQ826599 EF186939 EF379212 EF407742 EF602181 EF602225 EF602270 EF602597 
DQ826600 EF186940 EF379213 EF407743 EF602182 EF602226 EF602271 EF602598 
DQ826601 EF186942 EF407701 EF407744 EF602183 EF602227 EF602272 EF602599 
DQ826602 EF186952 EF407702 EF407745 EF602184 EF602228 EF602273 EF602600 
DQ826603 EF186953 EF407703 EF407746 EF602185 EF602229 EF602274 EF602601 
DQ826604 EF186954 EF407704 EF407747 EF602186 EF602230 EF602275 EF602602 
DQ826605 EF195277 EF407705 EF407748 EF602187 EF602231 EF602277 EF602603 
DQ826606 EF368549 EF407706 EF407749 EF602188 EF602232 EF602278 EF602604 
DQ826607 EF368642 EF407707 EF407750 EF602189 EF602233 EF602279 EF602605 
DQ826608 EF368697 EF407708 EF407751 EF602190 EF602235 EF602280 EF602606 
DQ826609 EF368731 EF407709 EF469243 EF602191 EF602236 EF602282 EF602607 
DQ826610 EF368743 EF407710 EF491925 EF602192 EF602237 EF602283 EF602608 
DQ826611 EF368805 EF407711 EF491926 EF602193 EF602238 EF602284 EF602609 
DQ826612 EF368807 EF407712 EF491927 EF602195 EF602239 EF602285 EF602610 
DQ826613 EF368846 EF407713 EF491928 EF602196 EF602240 EF602286 EF602611 
DQ826614 EF368925 EF407714 EF491929 EF602197 EF602241 EF602288 EF602612 
DQ826615 EF369040 EF407715 EF491930 EF602198 EF602242 EF602289 EF602613 
DQ826616 EF369043 EF407716 EF491931 EF602199 EF602243 EF602290 EF602614 
DQ826617 EF369057 EF407717 EF491932 EF602200 EF602244 EF602291 EF602615 
DQ826618 EF369085 EF407718 EF491933 EF602201 EF602245 EF602292 EF602616 
DQ826619 EF369163 EF407719 EF491934 EF602202 EF602246 EF602293 EF602617 
EF064480 EF369173 EF407720 EF491935 EF602203 EF602247 EF602294 EF602618 
EF120244 EF379154 EF407721 EF491936 EF602204 EF602248 EF602295 EF602619 
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EF120254 EF379159 EF407722 EF491937 EF602205 EF602249 EF602296 EF602620 
EF602621 EU110070 EU244654 EU248348 EU449520 EU683754 EU683800 FJ199618 
EF602622 EU110071 EU244655 EU248356 EU449521 EU683755 EU683801 FJ199621 
EF602623 EU110072 EU244656 EU248376 EU449522 EU683756 EU693681 FJ199628 
EF602624 EU110073 EU244657 EU248393 EU449523 EU683757 EU693717 FJ199639 
EF602625 EU110074 EU244658 EU248397 EU449524 EU683758 EU693892 FJ199641 
EF602626 EU110075 EU244659 EU248441 EU449525 EU683759 EU744912 FJ199646 
EF602627 EU110078 EU244660 EU248453 EU449526 EU683761 EU744913 FJ199662 
EF602628 EU110079 EU244661 EU248485 EU449527 EU683762 EU744914 FJ199668 
EU030410 EU110080 EU244662 EU248490 EU449528 EU683763 EU786673 FJ199671 
EU030412 EU110083 EU244663 EU248493 EU449529 EU683764 EU786681 FJ199673 
EU030413 EU158865 EU244664 EU248516 EU449530 EU683765 EU822552 FJ199676 
EU030414 EU158866 EU244665 EU248523 EU449531 EU683766 EU822566 FJ199680 
EU030415 EU158867 EU244666 EU248524 EU449532 EU683767 EU822638 FJ199683 
EU030416 EU158868 EU244667 EU248543 EU449533 EU683768 EU822697 FJ199689 
EU030417 EU158869 EU244668 EU248545 EU449534 EU683769 EU822704 FJ199691 
EU030418 EU158870 EU244669 EU248558 EU449535 EU683770 EU822714 FJ199692 
EU106117 EU158871 EU244670 EU248561 EU449536 EU683771 EU856363 FJ199700 
EU106118 EU158872 EU244671 EU248569 EU449537 EU683772 EU884500 FJ199703 
EU106119 EU158873 EU244672 EU248584 EU449538 EU683773 FJ030660 FJ199707 
EU106120 EU158874 EU244673 EU248586 EU449539 EU683775 FJ030696 FJ199710 
EU106121 EU158875 EU244674 EU255374 EU449540 EU683776 FJ199532 FJ199712 
EU106122 EU158876 EU244675 EU255465 EU449542 EU683777 FJ199533 FJ199714 
EU106123 EU158877 EU244676 EU255509 EU449543 EU683778 FJ199537 FJ199719 
EU106124 EU158878 EU244677 EU255513 EU449544 EU683780 FJ199546 FJ199722 
EU106125 EU158879 EU244678 EU293445 EU449545 EU683781 FJ199552 FJ199726 
EU106126 EU158880 EU244679 EU293446 EU449546 EU683782 FJ199553 FJ199732 
EU110053 EU158881 EU244680 EU293447 EU449547 EU683783 FJ199560 FJ199734 
EU110054 EU158882 EU244681 EU293448 EU449548 EU683784 FJ199561 FJ199735 
EU110055 EU158885 EU244682 EU293449 EU449550 EU683785 FJ199563 FJ199736 
EU110056 EU158886 EU244683 EU293450 EU449551 EU683786 FJ199565 FJ199738 
EU110057 EU158887 EU244684 EU306757 EU449552 EU683787 FJ199569 FJ199741 
EU110058 EU158888 EU244685 EU312784 EU449553 EU683788 FJ199570 FJ199742 
EU110059 EU158889 EU244686 EU345720 EU449554 EU683789 FJ199571 FJ199744 
EU110060 EU158890 EU244687 EU345911 EU484322 EU683790 FJ199572 FJ199745 
EU110061 EU158891 EU244688 EU345933 EU484323 EU683791 FJ199573 FJ199749 
EU110062 EU158892 EU244689 EU345935 EU484324 EU683792 FJ199575 FJ199750 
EU110063 EU244647 EU244690 EU345945 EU673374 EU683793 FJ199576 FJ199759 
EU110064 EU244648 EU244691 EU429990 EU673391 EU683794 FJ199578 FJ199760 
EU110065 EU244649 EU244692 EU447776 EU673400 EU683795 FJ199580 FJ199764 
EU110066 EU244650 EU244693 EU447778 EU673406 EU683796 FJ199586 FJ199765 
EU110067 EU244651 EU248293 EU447779 EU673407 EU683797 FJ199589 FJ199766 
EU110068 EU244652 EU248298 EU447780 EU683752 EU683798 FJ199594 FJ199768 
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EU110069 EU244653 EU248333 EU447781 EU683753 EU683799 FJ199610 FJ199773 
FJ199775 FJ199845 FJ498263 FJ498306 FJ498349 FJ498393 FJ498437 FJ498483 
FJ199776 FJ199863 FJ498264 FJ498307 FJ498350 FJ498394 FJ498438 FJ498484 
FJ199779 FJ199864 FJ498265 FJ498308 FJ498351 FJ498395 FJ498439 FJ498486 
FJ199780 FJ199868 FJ498266 FJ498309 FJ498352 FJ498396 FJ498440 FJ498487 
FJ199781 FJ199878 FJ498267 FJ498310 FJ498353 FJ498397 FJ498441 FJ498488 
FJ199782 FJ199907 FJ498268 FJ498311 FJ498354 FJ498398 FJ498442 FJ498489 
FJ199786 FJ199915 FJ498269 FJ498312 FJ498355 FJ498399 FJ498443 FJ498490 
FJ199787 FJ199943 FJ498270 FJ498313 FJ498356 FJ498400 FJ498444 FJ498491 
FJ199790 FJ199966 FJ498271 FJ498314 FJ498357 FJ498401 FJ498445 FJ498492 
FJ199792 FJ199970 FJ498272 FJ498315 FJ498358 FJ498402 FJ498446 FJ498493 
FJ199794 FJ199973 FJ498273 FJ498316 FJ498359 FJ498403 FJ498447 FJ498494 
FJ199795 FJ199978 FJ498274 FJ498317 FJ498360 FJ498404 FJ498448 FJ498495 
FJ199797 FJ199983 FJ498275 FJ498318 FJ498361 FJ498405 FJ498449 FJ498496 
FJ199798 FJ199985 FJ498276 FJ498319 FJ498362 FJ498406 FJ498450 FJ498498 
FJ199799 FJ199986 FJ498277 FJ498320 FJ498363 FJ498408 FJ498451 FJ498499 
FJ199800 FJ360877 FJ498278 FJ498321 FJ498364 FJ498409 FJ498452 FJ498500 
FJ199803 FJ360878 FJ498279 FJ498322 FJ498365 FJ498410 FJ498453 FJ498501 
FJ199804 FJ360879 FJ498280 FJ498323 FJ498366 FJ498411 FJ498455 FJ498503 
FJ199807 FJ360880 FJ498281 FJ498324 FJ498367 FJ498412 FJ498456 FJ498504 
FJ199808 FJ360881 FJ498282 FJ498325 FJ498368 FJ498413 FJ498457 FJ498505 
FJ199809 FJ360882 FJ498283 FJ498326 FJ498369 FJ498414 FJ498458 FJ498506 
FJ199812 FJ360883 FJ498284 FJ498327 FJ498371 FJ498415 FJ498459 FJ498507 
FJ199815 FJ481652 FJ498285 FJ498328 FJ498372 FJ498416 FJ498460 FJ498508 
FJ199816 FJ481654 FJ498286 FJ498329 FJ498373 FJ498417 FJ498461 FJ498509 
FJ199817 FJ481655 FJ498287 FJ498330 FJ498374 FJ498418 FJ498462 FJ498510 
FJ199818 FJ498244 FJ498288 FJ498331 FJ498375 FJ498419 FJ498463 FJ498511 
FJ199820 FJ498245 FJ498289 FJ498332 FJ498376 FJ498420 FJ498464 FJ498512 
FJ199821 FJ498246 FJ498290 FJ498333 FJ498377 FJ498421 FJ498465 FJ498513 
FJ199824 FJ498247 FJ498291 FJ498334 FJ498378 FJ498422 FJ498466 FJ498514 
FJ199825 FJ498248 FJ498292 FJ498335 FJ498379 FJ498423 FJ498467 FJ498515 
FJ199826 FJ498249 FJ498293 FJ498336 FJ498380 FJ498424 FJ498468 FJ498516 
FJ199827 FJ498250 FJ498294 FJ498337 FJ498381 FJ498425 FJ498469 FJ498517 
FJ199828 FJ498251 FJ498295 FJ498338 FJ498382 FJ498426 FJ498470 FJ498518 
FJ199830 FJ498253 FJ498296 FJ498339 FJ498383 FJ498427 FJ498471 FJ498519 
FJ199831 FJ498254 FJ498297 FJ498340 FJ498384 FJ498428 FJ498472 FJ498520 
FJ199835 FJ498255 FJ498298 FJ498341 FJ498385 FJ498429 FJ498473 FJ498521 
FJ199837 FJ498256 FJ498299 FJ498342 FJ498386 FJ498430 FJ498474 FJ498522 
FJ199838 FJ498257 FJ498300 FJ498343 FJ498387 FJ498431 FJ498475 FJ498524 
FJ199839 FJ498258 FJ498301 FJ498344 FJ498388 FJ498432 FJ498476 FJ498525 
FJ199841 FJ498259 FJ498302 FJ498345 FJ498389 FJ498433 FJ498478 FJ498526 
FJ199842 FJ498260 FJ498303 FJ498346 FJ498390 FJ498434 FJ498480 FJ498527 
FJ199843 FJ498261 FJ498304 FJ498347 FJ498391 FJ498435 FJ498481 FJ498529 
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FJ199844 FJ498262 FJ498305 FJ498348 FJ498392 FJ498436 FJ498482 FJ498530 
FJ498531 FJ595394 FJ595442 FJ878959 GQ294621 GQ399875 GQ400595 GQ427134 
FJ498532 FJ595395 FJ595443 FJ878960 GQ372203 GQ399890 GQ400599 GQ427135 
FJ498533 FJ595396 FJ595444 FJ878961 GQ398837 GQ399932 GQ400608 GQ427136 
FJ498534 FJ595397 FJ595445 FJ878962 GQ398838 GQ399970 GQ400615 GQ427137 
FJ498535 FJ595398 FJ595446 FJ878963 GQ398881 GQ399972 GQ400619 GQ427138 
FJ498536 FJ595399 FJ595447 FJ878964 GQ398909 GQ399981 GQ400644 GQ427139 
FJ498537 FJ595400 FJ595448 FJ878965 GQ398966 GQ399985 GQ400646 GQ427140 
FJ498538 FJ595401 FJ595450 FJ878966 GQ399028 GQ400018 GQ400651 GQ433802 
FJ498539 FJ595402 FJ595451 FJ878967 GQ399033 GQ400025 GQ400661 GQ433803 
FJ498540 FJ595403 FJ595452 FJ878968 GQ399069 GQ400044 GQ400682 GQ433804 
FJ498541 FJ595404 FJ595453 FJ878969 GQ399082 GQ400064 GQ400699 GQ433805 
FJ498542 FJ595405 FJ595454 FJ878970 GQ399122 GQ400077 GQ400816 GQ433806 
FJ498543 FJ595406 FJ595455 FM251949 GQ399127 GQ400095 GQ400909 GQ433807 
FJ548791 FJ595407 FJ595456 FN557337 GQ399144 GQ400143 GQ400924 GQ433808 
FJ594149 FJ595408 FJ595457 FN557338 GQ399200 GQ400145 GQ400942 GQ433809 
FJ595365 FJ595409 FJ595458 FN599687 GQ399228 GQ400149 GQ400949 GQ433810 
FJ595367 FJ595410 FJ595459 FN599688 GQ399252 GQ400151 GQ400950 GQ433811 
FJ595368 FJ595411 FJ595460 FN599712 GQ399298 GQ400158 GQ400980 GQ433812 
FJ595369 FJ595412 FJ595461 FN599718 GQ399345 GQ400161 GQ400993 GQ433813 
FJ595370 FJ595414 FJ595462 FN599720 GQ399346 GQ400193 GQ401022 GQ433814 
FJ595371 FJ595415 FJ670521 FN599737 GQ399364 GQ400211 GQ427111 GQ433815 
FJ595372 FJ595416 FJ878937 FN599773 GQ399391 GQ400237 GQ427112 GQ433816 
FJ595373 FJ595417 FJ878938 FN599776 GQ399394 GQ400273 GQ427113 GQ433817 
FJ595374 FJ595418 FJ878939 FR666608 GQ399408 GQ400288 GQ427114 GQ433818 
FJ595375 FJ595420 FJ878940 FR666613 GQ399414 GQ400298 GQ427115 GQ433819 
FJ595376 FJ595421 FJ878941 FR666617 GQ399464 GQ400339 GQ427116 GQ433820 
FJ595377 FJ595422 FJ878942 FR666620 GQ399501 GQ400369 GQ427117 GQ433821 
FJ595378 FJ595423 FJ878943 FR666621 GQ399507 GQ400374 GQ427118 GQ433822 
FJ595379 FJ595425 FJ878944 FR666622 GQ399517 GQ400394 GQ427119 GQ433823 
FJ595380 FJ595426 FJ878945 FR666625 GQ399518 GQ400400 GQ427120 GQ433824 
FJ595381 FJ595427 FJ878946 FR666631 GQ399556 GQ400428 GQ427121 GQ433825 
FJ595382 FJ595428 FJ878947 FR666642 GQ399593 GQ400431 GQ427122 GQ433826 
FJ595383 FJ595430 FJ878948 FR666649 GQ399616 GQ400463 GQ427123 GQ433827 
FJ595384 FJ595431 FJ878949 FR666650 GQ399666 GQ400496 GQ427124 GQ433828 
FJ595385 FJ595432 FJ878950 FR666658 GQ399679 GQ400501 GQ427125 GQ433829 
FJ595386 FJ595434 FJ878951 FR666669 GQ399697 GQ400504 GQ427126 GQ433830 
FJ595387 FJ595435 FJ878952 GQ240958 GQ399711 GQ400508 GQ427127 GQ433831 
FJ595388 FJ595436 FJ878953 GQ241015 GQ399715 GQ400526 GQ427128 GQ433832 
FJ595389 FJ595437 FJ878954 GQ241016 GQ399733 GQ400527 GQ427129 GQ433833 
FJ595390 FJ595438 FJ878955 GQ241017 GQ399752 GQ400542 GQ427130 GQ433834 
FJ595391 FJ595439 FJ878956 GQ241019 GQ399768 GQ400570 GQ427131 GQ433835 
FJ595392 FJ595440 FJ878957 GQ290728 GQ399796 GQ400585 GQ427132 GQ433836 
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FJ595393 FJ595441 FJ878958 GQ294616 GQ399801 GQ400592 GQ427133 GQ433837 
GQ433838 GQ433882 GU188837 GU199556 GU201815 GU253426 HM191529 HM593130 
GQ433839 GQ433883 GU188838 GU199557 GU201816 GU253428 HM191539 HM593131 
GQ433840 GQ433884 GU188839 GU199558 GU201817 GU324862 HM191541 HM593132 
GQ433841 GQ433885 GU188840 GU199559 GU201818 GU326106 HM191542 HM593133 
GQ433842 GQ433886 GU188841 GU199560 GU201819 GU326122 HM191545 HM593136 
GQ433843 GQ433887 GU188842 GU199561 GU201820 GU326127 HM191551 HM593149 
GQ433844 GQ433888 GU188843 GU199562 GU201821 GU326128 HM191553 HM593157 
GQ433845 GQ433889 GU188844 GU199563 GU201822 GU326172 HM191554 HM593158 
GQ433846 GQ433890 GU188845 GU199564 GU201823 GU326187 HM191556 HM593162 
GQ433847 GQ433891 GU188846 GU199565 GU201824 GU906868 HM468977 HM593166 
GQ433848 GQ433892 GU188847 GU199566 GU201825 GU906870 HM572396 HM593173 
GQ433849 GQ433893 GU188848 GU199567 GU201826 HG421606 HM572397 HM593177 
GQ433850 GQ862311 GU188849 GU199568 GU214076 HG421607 HM572398 HM593186 
GQ433851 GQ999989 GU199525 GU199569 GU214085 HG421655 HM572399 HM593187 
GQ433852 GU188807 GU199526 GU199570 GU214086 HG421662 HM572400 HM593193 
GQ433853 GU188808 GU199527 GU199571 GU253395 HG421665 HM572401 HM593194 
GQ433854 GU188809 GU199528 GU199572 GU253396 HM037812 HM572402 HM593195 
GQ433855 GU188810 GU199529 GU199573 GU253397 HM119611 HM572403 HM593201 
GQ433856 GU188811 GU199530 GU199574 GU253399 HM119629 HM572404 HM593202 
GQ433857 GU188812 GU199531 GU199575 GU253400 HM119650 HM572405 HM593204 
GQ433858 GU188813 GU199532 GU199576 GU253401 HM119655 HM572406 HM593205 
GQ433859 GU188814 GU199533 GU199577 GU253402 HM119656 HM572407 HM593206 
GQ433860 GU188815 GU199534 GU199578 GU253403 HM119659 HM572408 HM593207 
GQ433861 GU188816 GU199535 GU199579 GU253404 HM119667 HM572409 HM593211 
GQ433862 GU188818 GU199536 GU199580 GU253405 HM119714 HM572410 HM593213 
GQ433863 GU188819 GU199537 GU199582 GU253406 HM119754 HM572411 HM593215 
GQ433864 GU188820 GU199538 GU201798 GU253407 HM119768 HM572413 HM593217 
GQ433865 GU188821 GU199539 GU201799 GU253408 HM119815 HM572414 HM593218 
GQ433866 GU188822 GU199540 GU201800 GU253410 HM119836 HM572415 HM593224 
GQ433867 GU188823 GU199541 GU201801 GU253411 HM119841 HM572416 HM593226 
GQ433868 GU188824 GU199542 GU201802 GU253412 HM119868 HM572417 HM593227 
GQ433869 GU188825 GU199543 GU201803 GU253413 HM119876 HM593106 HM593228 
GQ433870 GU188826 GU199544 GU201804 GU253414 HM119902 HM593107 HM593229 
GQ433871 GU188827 GU199545 GU201805 GU253415 HM119932 HM593108 HM593230 
GQ433872 GU188828 GU199546 GU201806 GU253416 HM119938 HM593109 HM593235 
GQ433873 GU188829 GU199548 GU201807 GU253417 HM119953 HM593112 HM593237 
GQ433874 GU188830 GU199549 GU201808 GU253418 HM119975 HM593113 HM593238 
GQ433875 GU188831 GU199550 GU201809 GU253419 HM120023 HM593115 HM593243 
GQ433876 GU188832 GU199551 GU201810 GU253420 HM120046 HM593121 HM593244 
GQ433877 GU188833 GU199552 GU201811 GU253422 HM120061 HM593122 HM593246 
GQ433878 GU188834 GU199553 GU201812 GU253423 HM120062 HM593126 HM593247 
GQ433879 GU188835 GU199554 GU201813 GU253424 HM120091 HM593128 HM593253 
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GQ433880 GU188836 GU199555 GU201814 GU253425 HM120150 HM593129 HM593254 
HM593255 HM593300 HM593346 HM593391 HM593438 HM593498 HQ166857 HQ453370 
HM593256 HM593301 HM593347 HM593392 HM593440 HM593499 HQ166858 HQ453371 
HM593257 HM593302 HM593348 HM593393 HM593441 HM593500 HQ166859 HQ453372 
HM593258 HM593303 HM593349 HM593394 HM593442 HM593501 HQ166860 HQ453373 
HM593259 HM593304 HM593350 HM593396 HM593443 HM593502 HQ166861 HQ453374 
HM593260 HM593305 HM593351 HM593397 HM593444 HM593503 HQ166862 HQ453375 
HM593261 HM593306 HM593352 HM593398 HM593445 HM593505 HQ166863 HQ453376 
HM593262 HM593307 HM593353 HM593399 HM593446 HM593507 HQ166864 HQ453377 
HM593263 HM593308 HM593354 HM593400 HM593447 HM593510 HQ166865 HQ453378 
HM593265 HM593309 HM593355 HM593401 HM593448 HM627515 HQ166866 HQ453379 
HM593266 HM593310 HM593356 HM593402 HM593449 HM752148 HQ166867 HQ453380 
HM593267 HM593311 HM593357 HM593403 HM593450 HM752151 HQ166868 HQ453381 
HM593268 HM593312 HM593358 HM593404 HM593451 HM752152 HQ166869 HQ453382 
HM593269 HM593313 HM593359 HM593405 HM593452 HM752158 HQ166870 HQ453384 
HM593270 HM593315 HM593360 HM593407 HM593453 HM752160 HQ166871 HQ453385 
HM593271 HM593316 HM593361 HM593408 HM593454 HM752163 HQ166872 HQ453386 
HM593272 HM593317 HM593362 HM593409 HM593455 HM752164 HQ166873 HQ453387 
HM593273 HM593318 HM593363 HM593410 HM593456 HM752165 HQ166874 HQ453388 
HM593274 HM593319 HM593364 HM593411 HM593457 HM752175 HQ166875 HQ453389 
HM593275 HM593320 HM593366 HM593412 HM593458 HM752176 HQ166876 HQ453390 
HM593276 HM593321 HM593367 HM593413 HM593459 HM752177 HQ166877 HQ453392 
HM593277 HM593322 HM593368 HM593414 HM593460 HM752180 HQ166878 HQ453393 
HM593278 HM593323 HM593369 HM593415 HM593461 HM752186 HQ166879 HQ453394 
HM593279 HM593324 HM593370 HM593416 HM593462 HM752191 HQ166880 HQ539009 
HM593280 HM593325 HM593371 HM593418 HM593463 HM854124 HQ166881 HQ539035 
HM593281 HM593326 HM593372 HM593419 HM593464 HQ108352 HQ166882 HQ539197 
HM593282 HM593327 HM593373 HM593420 HM593465 HQ108366 HQ166883 HQ588277 
HM593283 HM593328 HM593374 HM593421 HM593466 HQ166841 HQ166884 HQ638705 
HM593284 HM593329 HM593375 HM593422 HM593468 HQ166842 HQ166885 HQ638709 
HM593285 HM593330 HM593377 HM593423 HM593470 HQ166843 HQ166886 HQ638713 
HM593286 HM593331 HM593378 HM593424 HM593471 HQ166844 HQ166887 HQ638727 
HM593287 HM593332 HM593379 HM593425 HM593473 HQ166845 HQ234749 HQ638739 
HM593288 HM593333 HM593380 HM593426 HM593475 HQ166846 HQ234750 HQ696823 
HM593289 HM593335 HM593381 HM593427 HM593478 HQ166847 HQ234751 HQ696824 
HM593290 HM593336 HM593382 HM593429 HM593479 HQ166848 HQ234752 HQ696825 
HM593291 HM593337 HM593383 HM593430 HM593483 HQ166849 HQ234753 HQ696826 
HM593293 HM593338 HM593384 HM593431 HM593484 HQ166850 HQ234754 HQ696827 
HM593294 HM593339 HM593385 HM593432 HM593485 HQ166851 HQ453364 HQ696828 
HM593295 HM593340 HM593386 HM593433 HM593486 HQ166852 HQ453365 HQ702662 
HM593296 HM593341 HM593387 HM593434 HM593489 HQ166853 HQ453366 HQ844570 
HM593297 HM593342 HM593388 HM593435 HM593491 HQ166854 HQ453367 HQ844571 
HM593298 HM593343 HM593389 HM593436 HM593493 HQ166855 HQ453368 HQ844572 
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HM593299 HM593344 HM593390 HM593437 HM593494 HQ166856 HQ453369 HQ844573 
HQ844574 HQ916283 HQ993962 HQ994204 HQ994249 HQ994294 HQ994338 HQ994383 
HQ844575 HQ916284 HQ993963 HQ994205 HQ994250 HQ994295 HQ994339 HQ994384 
HQ844576 HQ916286 HQ993969 HQ994206 HQ994251 HQ994296 HQ994340 HQ994385 
HQ844577 HQ916287 HQ994129 HQ994207 HQ994252 HQ994297 HQ994341 HQ994386 
HQ844578 HQ916288 HQ994148 HQ994208 HQ994253 HQ994298 HQ994342 HQ994387 
HQ844579 HQ916289 HQ994162 HQ994209 HQ994254 HQ994299 HQ994343 HQ994388 
HQ844580 HQ916290 HQ994163 HQ994210 HQ994255 HQ994300 HQ994344 HQ994389 
HQ844581 HQ916291 HQ994164 HQ994211 HQ994256 HQ994301 HQ994345 HQ994390 
HQ844582 HQ993580 HQ994165 HQ994212 HQ994257 HQ994302 HQ994346 HQ994391 
HQ844583 HQ993597 HQ994166 HQ994213 HQ994258 HQ994303 HQ994347 HQ994392 
HQ844584 HQ993611 HQ994167 HQ994214 HQ994259 HQ994304 HQ994348 HQ994393 
HQ844585 HQ993615 HQ994168 HQ994215 HQ994260 HQ994305 HQ994349 HQ994394 
HQ844586 HQ993623 HQ994169 HQ994216 HQ994261 HQ994306 HQ994350 HQ994395 
HQ844587 HQ993632 HQ994170 HQ994217 HQ994262 HQ994307 HQ994351 HQ994396 
HQ844588 HQ993653 HQ994172 HQ994218 HQ994263 HQ994308 HQ994352 HQ994397 
HQ844589 HQ993678 HQ994173 HQ994219 HQ994264 HQ994309 HQ994354 HQ994398 
HQ844590 HQ993684 HQ994174 HQ994220 HQ994265 HQ994310 HQ994355 HQ994399 
HQ844591 HQ993690 HQ994175 HQ994221 HQ994266 HQ994311 HQ994356 HQ994400 
HQ844592 HQ993692 HQ994176 HQ994222 HQ994267 HQ994312 HQ994357 HQ994401 
HQ844593 HQ993699 HQ994177 HQ994223 HQ994269 HQ994313 HQ994358 HQ994402 
HQ844594 HQ993702 HQ994178 HQ994224 HQ994270 HQ994314 HQ994359 HQ994403 
HQ844595 HQ993729 HQ994179 HQ994225 HQ994271 HQ994315 HQ994360 HQ994405 
HQ844596 HQ993734 HQ994180 HQ994228 HQ994272 HQ994316 HQ994361 HQ994406 
HQ844597 HQ993750 HQ994181 HQ994229 HQ994273 HQ994317 HQ994362 HQ994407 
HQ844598 HQ993789 HQ994182 HQ994230 HQ994274 HQ994318 HQ994363 HQ994408 
HQ844599 HQ993806 HQ994183 HQ994231 HQ994275 HQ994319 HQ994364 HQ994409 
HQ844600 HQ993813 HQ994184 HQ994232 HQ994276 HQ994320 HQ994366 HQ994410 
HQ844601 HQ993819 HQ994185 HQ994233 HQ994277 HQ994321 HQ994367 HQ994411 
HQ844602 HQ993831 HQ994186 HQ994234 HQ994278 HQ994322 HQ994368 HQ994412 
HQ844603 HQ993833 HQ994187 HQ994235 HQ994279 HQ994323 HQ994369 HQ994413 
HQ844604 HQ993837 HQ994188 HQ994236 HQ994280 HQ994324 HQ994370 HQ994414 
HQ844605 HQ993849 HQ994191 HQ994237 HQ994281 HQ994325 HQ994371 HQ994415 
HQ844606 HQ993858 HQ994192 HQ994238 HQ994282 HQ994326 HQ994372 HQ994416 
HQ844607 HQ993886 HQ994193 HQ994239 HQ994283 HQ994327 HQ994373 HQ994417 
HQ844608 HQ993891 HQ994194 HQ994240 HQ994284 HQ994329 HQ994374 HQ994420 
HQ844609 HQ993909 HQ994195 HQ994241 HQ994285 HQ994330 HQ994375 HQ994421 
HQ844610 HQ993926 HQ994197 HQ994242 HQ994286 HQ994331 HQ994376 HQ994422 
HQ844611 HQ993927 HQ994198 HQ994243 HQ994287 HQ994332 HQ994377 HQ994423 
HQ844612 HQ993937 HQ994199 HQ994244 HQ994289 HQ994333 HQ994378 HQ994424 
HQ844613 HQ993938 HQ994200 HQ994245 HQ994290 HQ994334 HQ994379 HQ994425 
HQ844614 HQ993943 HQ994201 HQ994246 HQ994291 HQ994335 HQ994380 HQ994426 
HQ844615 HQ993949 HQ994202 HQ994247 HQ994292 HQ994336 HQ994381 HQ994427 
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HQ844616 HQ993952 HQ994203 HQ994248 HQ994293 HQ994337 HQ994382 HQ994428 
HQ994429 HQ994476 HQ994522 HQ994572 HQ994621 HQ994671 HQ994721 HQ994767 
HQ994430 HQ994477 HQ994523 HQ994573 HQ994622 HQ994672 HQ994722 HQ994768 
HQ994431 HQ994478 HQ994524 HQ994574 HQ994623 HQ994673 HQ994723 HQ994769 
HQ994432 HQ994479 HQ994525 HQ994575 HQ994624 HQ994674 HQ994724 HQ994770 
HQ994433 HQ994480 HQ994526 HQ994576 HQ994625 HQ994675 HQ994725 HQ994771 
HQ994434 HQ994481 HQ994527 HQ994577 HQ994626 HQ994676 HQ994726 HQ994772 
HQ994435 HQ994482 HQ994528 HQ994578 HQ994627 HQ994677 HQ994727 HQ994773 
HQ994436 HQ994483 HQ994529 HQ994579 HQ994628 HQ994678 HQ994728 HQ994774 
HQ994437 HQ994484 HQ994530 HQ994580 HQ994629 HQ994679 HQ994729 HQ994775 
HQ994438 HQ994485 HQ994532 HQ994581 HQ994630 HQ994681 HQ994730 HQ994776 
HQ994439 HQ994486 HQ994534 HQ994582 HQ994631 HQ994682 HQ994731 HQ994777 
HQ994441 HQ994487 HQ994535 HQ994583 HQ994632 HQ994683 HQ994732 HQ994778 
HQ994442 HQ994488 HQ994536 HQ994584 HQ994633 HQ994684 HQ994733 HQ994779 
HQ994444 HQ994489 HQ994537 HQ994585 HQ994634 HQ994685 HQ994734 HQ994780 
HQ994445 HQ994490 HQ994538 HQ994586 HQ994635 HQ994686 HQ994735 HQ994781 
HQ994446 HQ994491 HQ994539 HQ994587 HQ994636 HQ994689 HQ994736 HQ994782 
HQ994447 HQ994492 HQ994540 HQ994588 HQ994637 HQ994690 HQ994737 HQ994783 
HQ994448 HQ994493 HQ994542 HQ994590 HQ994638 HQ994691 HQ994738 HQ994784 
HQ994449 HQ994494 HQ994543 HQ994591 HQ994639 HQ994692 HQ994739 HQ994785 
HQ994450 HQ994495 HQ994545 HQ994592 HQ994641 HQ994693 HQ994740 HQ994786 
HQ994451 HQ994496 HQ994546 HQ994593 HQ994643 HQ994695 HQ994741 HQ994787 
HQ994452 HQ994497 HQ994547 HQ994594 HQ994644 HQ994697 HQ994742 HQ994788 
HQ994453 HQ994498 HQ994548 HQ994596 HQ994645 HQ994698 HQ994743 HQ994789 
HQ994454 HQ994499 HQ994549 HQ994597 HQ994646 HQ994699 HQ994744 HQ994790 
HQ994455 HQ994500 HQ994550 HQ994598 HQ994647 HQ994700 HQ994746 HQ994791 
HQ994456 HQ994501 HQ994551 HQ994599 HQ994648 HQ994701 HQ994747 HQ994792 
HQ994457 HQ994502 HQ994552 HQ994600 HQ994649 HQ994702 HQ994748 HQ994794 
HQ994458 HQ994503 HQ994553 HQ994601 HQ994651 HQ994703 HQ994749 HQ994795 
HQ994459 HQ994504 HQ994554 HQ994602 HQ994653 HQ994704 HQ994750 HQ994796 
HQ994460 HQ994505 HQ994555 HQ994603 HQ994654 HQ994705 HQ994751 HQ994797 
HQ994461 HQ994506 HQ994556 HQ994604 HQ994655 HQ994706 HQ994752 HQ994798 
HQ994462 HQ994507 HQ994557 HQ994605 HQ994656 HQ994707 HQ994753 HQ994799 
HQ994463 HQ994508 HQ994560 HQ994606 HQ994657 HQ994709 HQ994754 HQ994800 
HQ994465 HQ994510 HQ994561 HQ994607 HQ994658 HQ994710 HQ994755 HQ994801 
HQ994466 HQ994511 HQ994562 HQ994608 HQ994659 HQ994711 HQ994757 HQ994802 
HQ994467 HQ994512 HQ994563 HQ994609 HQ994660 HQ994712 HQ994758 HQ994803 
HQ994469 HQ994513 HQ994564 HQ994612 HQ994662 HQ994713 HQ994759 HQ994804 
HQ994470 HQ994514 HQ994565 HQ994614 HQ994663 HQ994714 HQ994760 HQ994805 
HQ994471 HQ994515 HQ994566 HQ994615 HQ994664 HQ994715 HQ994761 HQ994806 
HQ994472 HQ994516 HQ994567 HQ994617 HQ994665 HQ994716 HQ994762 HQ994807 
HQ994473 HQ994517 HQ994568 HQ994618 HQ994666 HQ994718 HQ994764 HQ994808 
HQ994474 HQ994518 HQ994569 HQ994619 HQ994669 HQ994719 HQ994765 HQ994809 
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HQ994475 HQ994519 HQ994570 HQ994620 HQ994670 HQ994720 HQ994766 HQ994811 
HQ994812 HQ994856 HQ994899 JF414421 JF414465 JF505601 JN010590 JN222644 
HQ994813 HQ994857 HQ994900 JF414422 JF414466 JF773983 JN010592 JN628493 
HQ994814 HQ994858 HQ994901 JF414423 JF414467 JF774000 JN010599 JN628500 
HQ994815 HQ994859 HQ994902 JF414424 JF414468 JF774001 JN010601 JN628507 
HQ994816 HQ994860 HQ994903 JF414425 JF487831 JF774014 JN010603 JN628518 
HQ994817 HQ994861 HQ994904 JF414426 JF487832 JF774028 JN010606 JN639188 
HQ994818 HQ994862 HQ994905 JF414427 JF487833 JF774043 JN010618 JN639189 
HQ994819 HQ994863 HQ994906 JF414428 JF487834 JF774050 JN010620 JN639190 
HQ994820 HQ994864 HQ994907 JF414429 JF487835 JF774051 JN010622 JN639191 
HQ994821 HQ994865 HQ994908 JF414430 JF487836 JF774053 JN010624 JN639192 
HQ994822 HQ994866 HQ994909 JF414432 JF487837 JF774055 JN010625 JN639193 
HQ994823 HQ994867 HQ994910 JF414433 JF487838 JF906616 JN010629 JN639194 
HQ994824 HQ994868 HQ994911 JF414434 JF487841 JF906695 JN010637 JN639195 
HQ994825 HQ994869 HQ994912 JF414435 JF487843 JF906698 JN010640 JN639196 
HQ994826 HQ994870 HQ994913 JF414436 JF487844 JN000018 JN010642 JN639197 
HQ994827 HQ994871 HQ994914 JF414437 JF487851 JN010442 JN010644 JN639199 
HQ994828 HQ994872 HQ994915 JF414438 JF487852 JN010446 JN010673 JN639200 
HQ994829 HQ994873 HQ994916 JF414439 JF487853 JN010448 JN010697 JN639201 
HQ994830 HQ994874 HQ994917 JF414440 JF487855 JN010449 JN010702 JN639202 
HQ994831 HQ994875 HQ994932 JF414441 JF487856 JN010462 JN010704 JN639203 
HQ994832 HQ994876 HQ994940 JF414442 JF487864 JN010463 JN010707 JN639205 
HQ994833 HQ994877 HQ994996 JF414443 JF487867 JN010467 JN010710 JN639206 
HQ994834 HQ994878 HQ995027 JF414444 JF487868 JN010470 JN010713 JN639207 
HQ994835 HQ994879 HQ995037 JF414445 JF487875 JN010474 JN010715 JN639208 
HQ994836 HQ994880 HQ995038 JF414446 JF487878 JN010476 JN010718 JN639209 
HQ994837 HQ994881 HQ995112 JF414447 JF487881 JN010492 JN010720 JN639210 
HQ994838 HQ994882 HQ995246 JF414448 JF487883 JN010494 JN010727 JN639211 
HQ994839 HQ994883 HQ995288 JF414449 JF487885 JN010496 JN010729 JN639212 
HQ994840 HQ994884 HQ995401 JF414450 JF487886 JN010500 JN010734 JN639213 
HQ994842 HQ994885 HQ995414 JF414451 JF487887 JN010502 JN010739 JN639214 
HQ994843 HQ994886 HQ995477 JF414452 JF487889 JN010508 JN010741 JN664970 
HQ994844 HQ994887 HQ995493 JF414453 JF487891 JN010512 JN010743 JN664971 
HQ994845 HQ994888 HQ995494 JF414454 JF487894 JN010517 JN010753 JN664972 
HQ994846 HQ994889 HQ995495 JF414455 JF487905 JN010519 JN010758 JN664973 
HQ994847 HQ994890 HQ995496 JF414456 JF487906 JN010521 JN010761 JN664974 
HQ994848 HQ994891 HQ995497 JF414457 JF487907 JN010524 JN010764 JN664975 
HQ994849 HQ994892 JF342273 JF414458 JF487908 JN010540 JN114121 JN664976 
HQ994850 HQ994893 JF342277 JF414459 JF487909 JN010550 JN114216 JN664977 
HQ994851 HQ994894 JF342290 JF414460 JF487910 JN010553 JN214931 JN664978 
HQ994852 HQ994895 JF342301 JF414461 JF487911 JN010555 JN214962 JN664979 
HQ994853 HQ994896 JF342317 JF414462 JF487912 JN010557 JN215115 JN664980 
HQ994854 HQ994897 JF414419 JF414463 JF487913 JN010568 JN215125 JN664981 
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HQ994855 HQ994898 JF414420 JF414464 JF487914 JN010584 JN222612 JN664982 
JN664983 JN665027 JQ658521 JQ658627 JQ658772 JX256211 JX300330 JX507823 
JN664984 JN665028 JQ658522 JQ658629 JQ698679 JX256212 JX300339 JX507824 
JN664985 JN665029 JQ658527 JQ658630 JQ698681 JX256213 JX300343 JX507825 
JN664986 JN665030 JQ658529 JQ658632 JQ698683 JX256214 JX300363 JX507826 
JN664987 JN665031 JQ658530 JQ658639 JQ698684 JX256215 JX300376 JX507827 
JN664988 JN665032 JQ658531 JQ658642 JQ698687 JX256216 JX300427 JX507828 
JN664989 JN665033 JQ658536 JQ658644 JQ698692 JX256218 JX300428 JX507829 
JN664990 JN665034 JQ658538 JQ658651 JQ698695 JX299585 JX300450 JX507830 
JN664991 JN665035 JQ658543 JQ658652 JQ698715 JX299590 JX300458 JX507831 
JN664992 JN665036 JQ658544 JQ658653 JQ698722 JX299607 JX300526 JX507832 
JN664993 JN665037 JQ658548 JQ658654 JQ698723 JX299624 JX300602 JX507833 
JN664994 JN665038 JQ658551 JQ658658 JQ698725 JX299674 JX300649 JX507834 
JN664995 JN665039 JQ658554 JQ658663 JQ698726 JX299706 JX300661 JX507835 
JN664996 JN665040 JQ658557 JQ658670 JQ698731 JX299739 JX300755 JX507836 
JN664997 JN665041 JQ658558 JQ658674 JQ698747 JX299741 JX300776 JX507837 
JN664998 JQ071460 JQ658559 JQ658675 JQ698760 JX299743 JX300789 JX507838 
JN664999 JQ071464 JQ658560 JQ658699 JQ698778 JX299827 JX300813 JX507839 
JN665000 JQ071465 JQ658566 JQ658705 JQ698783 JX299847 JX300863 JX507840 
JN665001 JQ071468 JQ658570 JQ658710 JQ698790 JX299877 JX300865 JX507841 
JN665002 JQ071471 JQ658571 JQ658712 JQ698791 JX299904 JX300897 JX507842 
JN665003 JQ071474 JQ658574 JQ658714 JQ698796 JX299916 JX300969 JX507843 
JN665004 JQ071475 JQ658576 JQ658715 JQ698802 JX299940 JX300989 JX507844 
JN665005 JQ071478 JQ658577 JQ658716 JQ698822 JX299990 JX300993 JX507845 
JN665006 JQ071483 JQ658578 JQ658718 JQ698827 JX300049 JX301014 JX507846 
JN665007 JQ071486 JQ658580 JQ658724 JQ698828 JX300071 JX301068 JX507847 
JN665008 JQ071488 JQ658581 JQ658726 JQ698843 JX300090 JX301078 JX507848 
JN665009 JQ071491 JQ658585 JQ658731 JQ750698 JX300105 JX301105 JX507849 
JN665010 JQ266060 JQ658586 JQ658732 JX256193 JX300115 JX301120 JX507850 
JN665011 JQ658476 JQ658589 JQ658734 JX256194 JX300118 JX499012 JX507851 
JN665012 JQ658480 JQ658591 JQ658735 JX256196 JX300121 JX507809 JX507852 
JN665014 JQ658488 JQ658592 JQ658736 JX256197 JX300129 JX507810 JX507853 
JN665015 JQ658497 JQ658594 JQ658740 JX256198 JX300164 JX507811 JX507854 
JN665016 JQ658498 JQ658599 JQ658744 JX256199 JX300176 JX507812 JX507855 
JN665017 JQ658503 JQ658600 JQ658745 JX256200 JX300198 JX507813 JX507856 
JN665018 JQ658504 JQ658604 JQ658751 JX256201 JX300222 JX507814 JX507857 
JN665019 JQ658505 JQ658608 JQ658753 JX256202 JX300223 JX507815 JX507858 
JN665020 JQ658507 JQ658615 JQ658754 JX256204 JX300233 JX507816 JX507859 
JN665021 JQ658511 JQ658616 JQ658755 JX256205 JX300254 JX507817 JX507860 
JN665022 JQ658512 JQ658617 JQ658756 JX256206 JX300261 JX507818 JX507861 
JN665023 JQ658513 JQ658620 JQ658757 JX256207 JX300271 JX507819 JX507862 
JN665024 JQ658514 JQ658621 JQ658766 JX256208 JX300322 JX507820 JX507863 
JN665025 JQ658519 JQ658624 JQ658767 JX256209 JX300325 JX507821 JX507864 
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JN665026 JQ658520 JQ658626 JQ658769 JX256210 JX300326 JX507822 JX507865 
JX507866 JX507909 KC537232 KC764457 KF026065 KF026111 KF026157 KF026202 
JX507867 JX507910 KC537233 KC764458 KF026067 KF026112 KF026158 KF026204 
JX507868 JX507911 KC537234 KC810411 KF026068 KF026113 KF026159 KF026207 
JX507869 JX507912 KC537235 KC810488 KF026069 KF026114 KF026160 KF026209 
JX507870 JX507913 KC537236 KC810511 KF026070 KF026116 KF026161 KF059615 
JX507871 JX507914 KC537242 KC841660 KF026071 KF026117 KF026162 KF059617 
JX507872 JX507915 KC537243 KC841663 KF026072 KF026118 KF026163 KF059702 
JX507873 JX507916 KC740523 KC841674 KF026073 KF026119 KF026164 KF530909 
JX507874 JX507917 KC764421 KC841688 KF026074 KF026120 KF026165 KF530955 
JX507875 JX507918 KC764422 KC841702 KF026075 KF026121 KF026166 KF530988 
JX507876 JX507919 KC764423 KC841719 KF026076 KF026122 KF026167 KF531001 
JX507877 JX507920 KC764424 KC841733 KF026077 KF026123 KF026168 KF531053 
JX507878 JX847172 KC764425 KC841738 KF026078 KF026126 KF026169 KF531072 
JX507879 JX847173 KC764426 KC841744 KF026079 KF026127 KF026170 KF531144 
JX507880 JX847174 KC764427 KC841756 KF026080 KF026128 KF026171 KF531156 
JX507881 JX966498 KC764428 KC841757 KF026081 KF026129 KF026172 KF531186 
JX507882 JX966501 KC764429 KC841762 KF026082 KF026130 KF026173 KF531197 
JX507883 JX966511 KC764430 KC841768 KF026083 KF026131 KF026174 KF531283 
JX507884 JX966535 KC764431 KC879721 KF026084 KF026132 KF026175 KF531287 
JX507885 KC133219 KC764432 KC879722 KF026085 KF026133 KF026176 KF531293 
JX507886 KC181291 KC764433 KC879723 KF026086 KF026134 KF026177 KF531337 
JX507887 KC286155 KC764434 KC879725 KF026087 KF026135 KF026178 KF531507 
JX507888 KC340200 KC764435 KC879726 KF026089 KF026136 KF026179 KF671784 
JX507889 KC340392 KC764436 KC879727 KF026090 KF026137 KF026180 KF671785 
JX507890 KC340393 KC764437 KC879728 KF026092 KF026138 KF026181 KF671790 
JX507891 KC340422 KC764438 KC879729 KF026093 KF026139 KF026182 KF700961 
JX507892 KC340491 KC764439 KC879730 KF026094 KF026140 KF026183 KF727691 
JX507893 KC340492 KC764440 KC879731 KF026095 KF026141 KF026184 KF727692 
JX507894 KC340804 KC764441 KC879732 KF026096 KF026142 KF026186 KF727693 
JX507895 KC340887 KC764442 KC921843 KF026097 KF026143 KF026187 KF727694 
JX507896 KC516875 KC764444 KC970885 KF026098 KF026144 KF026188 KF727695 
JX507897 KC516889 KC764445 KC988060 KF026099 KF026145 KF026189 KF727696 
JX507898 KC516939 KC764446 KC994221 KF026100 KF026146 KF026190 KF727697 
JX507899 KC516954 KC764447 KC994246 KF026101 KF026147 KF026191 KF727698 
JX507900 KC516970 KC764448 KC994280 KF026102 KF026148 KF026192 KF727699 
JX507901 KC516987 KC764449 KC994361 KF026103 KF026149 KF026193 KF727700 
JX507902 KC517017 KC764450 KC994370 KF026104 KF026150 KF026194 KF727701 
JX507903 KC517029 KC764451 KC994382 KF026105 KF026151 KF026195 KF727702 
JX507904 KC517037 KC764452 KF026059 KF026106 KF026152 KF026196 KF727703 
JX507905 KC517038 KC764453 KF026060 KF026107 KF026153 KF026197 KF727704 
JX507906 KC517042 KC764454 KF026061 KF026108 KF026154 KF026198 KF727705 
JX507907 KC517043 KC764455 KF026063 KF026109 KF026155 KF026199 KF727706 
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JX507908 KC517051 KC764456 KF026064 KF026110 KF026156 KF026200 KF727707 
KF727708 KF780982 KF781056 KF793166 KF806979 KF890232 KF927203 KF927364 
KF727709 KF780984 KF781057 KF793168 KF806980 KF890233 KF927204 KF927365 
KF727710 KF780985 KF781058 KF793170 KF806981 KF890234 KF927205 KF927366 
KF727711 KF780987 KF781059 KF793173 KF806982 KF890235 KF927206 KF927367 
KF727712 KF780988 KF781060 KF793178 KF806983 KF890236 KF927207 KF927368 
KF727713 KF780989 KF781061 KF793179 KF853754 KF890237 KF927209 KF927370 
KF727715 KF780992 KF781062 KF793180 KF853759 KF890238 KF927210 KF927371 
KF727716 KF780995 KF781063 KF806938 KF853761 KF890239 KF927211 KF927372 
KF727717 KF780996 KF781064 KF806939 KF853771 KF890240 KF927212 KF927373 
KF727718 KF780998 KF781065 KF806940 KF853777 KF890241 KF927213 KF927374 
KF727719 KF781001 KF781066 KF806941 KF853782 KF890243 KF927214 KF927376 
KF727720 KF781003 KF781067 KF806943 KF853793 KF927170 KF927215 KF927379 
KF727721 KF781006 KF781068 KF806944 KF853797 KF927171 KF927217 KF927380 
KF727722 KF781007 KF781069 KF806945 KF853810 KF927172 KF927218 KF927381 
KF727723 KF781009 KF781070 KF806946 KF853816 KF927173 KF927219 KF927383 
KF727724 KF781010 KF782764 KF806947 KF853818 KF927174 KF927221 KF927384 
KF727725 KF781011 KF782771 KF806948 KF853822 KF927175 KF927222 KF927385 
KF727726 KF781013 KF782772 KF806949 KF853837 KF927176 KF927223 KF927387 
KF727727 KF781018 KF793123 KF806950 KF853857 KF927177 KF927224 KF927388 
KF727728 KF781020 KF793125 KF806951 KF853861 KF927178 KF927225 KF927390 
KF727729 KF781021 KF793126 KF806952 KF853864 KF927179 KF927226 KF927393 
KF727730 KF781023 KF793127 KF806954 KF853869 KF927180 KF927227 KF927394 
KF727731 KF781024 KF793128 KF806955 KF853871 KF927181 KF927228 KF927396 
KF727732 KF781025 KF793129 KF806956 KF853873 KF927182 KF927229 KF927397 
KF766537 KF781026 KF793130 KF806958 KF853874 KF927183 KF927230 KF927398 
KF766540 KF781027 KF793131 KF806959 KF853876 KF927184 KF927231 KF927399 
KF768007 KF781028 KF793132 KF806960 KF853877 KF927185 KF927232 KF927402 
KF780965 KF781031 KF793133 KF806961 KF853878 KF927186 KF927233 KF927403 
KF780966 KF781032 KF793135 KF806962 KF853881 KF927188 KF927234 KF927404 
KF780967 KF781033 KF793137 KF806963 KF853882 KF927189 KF927235 KF927405 
KF780968 KF781034 KF793141 KF806965 KF890214 KF927190 KF927237 KF927406 
KF780969 KF781035 KF793143 KF806966 KF890217 KF927191 KF927238 KF927407 
KF780970 KF781036 KF793144 KF806968 KF890218 KF927192 KF927239 KF927408 
KF780971 KF781037 KF793148 KF806969 KF890220 KF927193 KF927240 KF927409 
KF780972 KF781039 KF793150 KF806970 KF890221 KF927194 KF927241 KF927410 
KF780973 KF781040 KF793151 KF806971 KF890222 KF927195 KF927242 KF927411 
KF780974 KF781041 KF793152 KF806972 KF890223 KF927196 KF927243 KF927412 
KF780975 KF781043 KF793153 KF806973 KF890224 KF927197 KF927244 KF927413 
KF780976 KF781046 KF793154 KF806974 KF890225 KF927198 KF927245 KF927414 
KF780977 KF781049 KF793158 KF806975 KF890228 KF927199 KF927358 KF927415 
KF780978 KF781050 KF793160 KF806976 KF890229 KF927200 KF927359 KF927416 
KF780980 KF781052 KF793164 KF806977 KF890230 KF927201 KF927362 KF927417 
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KF780981 KF781055 KF793165 KF806978 KF890231 KF927202 KF927363 KF927418 
KF927419 KJ770722 KJ807674 KJ807717 KM049920 KM050009 KM050084 KM050152 
KF927420 KJ770805 KJ807675 KJ807718 KM049921 KM050010 KM050085 KM050154 
KF927421 KJ770815 KJ807676 KJ807719 KM049922 KM050011 KM050086 KM050155 
KF927422 KJ771012 KJ807677 KJ807720 KM049923 KM050012 KM050087 KM050160 
KF927423 KJ771138 KJ807678 KJ807721 KM049924 KM050019 KM050088 KM050161 
KF927424 KJ771184 KJ807679 KJ807722 KM049925 KM050020 KM050089 KM050176 
KF927426 KJ771234 KJ807680 KJ807723 KM049926 KM050021 KM050090 KM050178 
KF927427 KJ771303 KJ807681 KJ807724 KM049927 KM050022 KM050091 KM050179 
KF927428 KJ771313 KJ807682 KJ807725 KM049928 KM050023 KM050092 KM050180 
KF927429 KJ771420 KJ807683 KJ807726 KM049935 KM050024 KM050093 KM050181 
KF927431 KJ771422 KJ807684 KJ807727 KM049936 KM050025 KM050094 KM050182 
KF927432 KJ771486 KJ807685 KJ807728 KM049943 KM050026 KM050096 KM050183 
KF927433 KJ771588 KJ807686 KJ807729 KM049944 KM050027 KM050097 KM050184 
KJ194683 KJ771644 KJ807687 KJ807730 KM049946 KM050028 KM050105 KM050191 
KJ194694 KJ771675 KJ807688 KJ807731 KM049947 KM050030 KM050106 KM050192 
KJ364641 KJ771680 KJ807689 KJ906630 KM049948 KM050031 KM050107 KM050199 
KJ467927 KJ771785 KJ807690 KJ906709 KM049949 KM050032 KM050112 KM050200 
KJ467929 KJ771788 KJ807691 KJ906739 KM049950 KM050033 KM050113 KM050201 
KJ467991 KJ807649 KJ807692 KJ906772 KM049951 KM050040 KM050114 KM050202 
KJ467999 KJ807650 KJ807693 KJ906793 KM049957 KM050041 KM050115 KM050209 
KJ561122 KJ807651 KJ807694 KJ906795 KM049958 KM050048 KM050116 KM050210 
KJ561123 KJ807652 KJ807695 KJ906879 KM049963 KM050055 KM050117 KM050216 
KJ561124 KJ807653 KJ807696 KJ906977 KM049964 KM050056 KM050118 KM050217 
KJ561125 KJ807654 KJ807697 KJ906991 KM049965 KM050057 KM050119 KM050218 
KJ561126 KJ807655 KJ807698 KJ907007 KM049966 KM050059 KM050120 KM050225 
KJ561127 KJ807656 KJ807699 KJ907019 KM049973 KM050060 KM050121 KM050226 
KJ561128 KJ807657 KJ807700 KJ907025 KM049980 KM050067 KM050122 KM050227 
KJ561129 KJ807658 KJ807701 KJ907053 KM049981 KM050068 KM050123 KM050228 
KJ561130 KJ807659 KJ807702 KJ907054 KM049982 KM050069 KM050124 KM050229 
KJ561131 KJ807660 KJ807703 KJ907110 KM049983 KM050070 KM050125 KM050230 
KJ561132 KJ807661 KJ807704 KJ907157 KM049990 KM050071 KM050126 KM050231 
KJ561133 KJ807662 KJ807705 KJ907166 KM049991 KM050072 KM050127 KM050232 
KJ561134 KJ807663 KJ807706 KJ907169 KM049992 KM050073 KM050130 KM050233 
KJ561135 KJ807664 KJ807707 KJ907174 KM049999 KM050074 KM050131 KM050238 
KJ561136 KJ807665 KJ807708 KM049900 KM050000 KM050075 KM050132 KM050240 
KJ722081 KJ807666 KJ807709 KM049901 KM050001 KM050076 KM050133 KM050243 
KJ723062 KJ807667 KJ807710 KM049902 KM050002 KM050077 KM050135 KM050248 
KJ723387 KJ807668 KJ807711 KM049903 KM050003 KM050078 KM050136 KM050249 
KJ724222 KJ807669 KJ807712 KM049904 KM050004 KM050079 KM050137 KM050254 
KJ769722 KJ807670 KJ807713 KM049905 KM050005 KM050080 KM050144 KM050255 
KJ770036 KJ807671 KJ807714 KM049911 KM050006 KM050081 KM050145 KM050256 
KJ770134 KJ807672 KJ807715 KM049912 KM050007 KM050082 KM050150 KM050257 
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KJ770421 KJ807673 KJ807716 KM049919 KM050008 KM050083 KM050151 KM050264 
KM050265 KM050371 KM050463 KM050570 KM050650 KM050709 KM050763 KP224495 
KM050266 KM050372 KM050468 KM050571 KM050651 KM050710 KM050764 KP224496 
KM050267 KM050373 KM050469 KM050572 KM050652 KM050711 KM050765 KP224500 
KM050272 KM050374 KM050474 KM050573 KM050653 KM050712 KM050766 KP224501 
KM050279 KM050375 KM050475 KM050575 KM050654 KM050717 KM050767 KP227524 
KM050280 KM050380 KM050494 KM050576 KM050661 KM050718 KM057331 KP227525 
KM050285 KM050381 KM050495 KM050577 KM050662 KM050719 KM057334 KP227526 
KM050286 KM050382 KM050500 KM050578 KM050663 KM050720 KM057337 KP227527 
KM050291 KM050383 KM050501 KM050579 KM050664 KM050721 KM057346 KP227528 
KM050292 KM050388 KM050502 KM050580 KM050665 KM050722 KM057348 KP227529 
KM050297 KM050389 KM050503 KM050581 KM050666 KM050723 KM057354 KP227530 
KM050298 KM050394 KM050508 KM050588 KM050667 KM050724 KM057355 KP227531 
KM050299 KM050395 KM050509 KM050589 KM050668 KM050725 KM057359 KP227532 
KM050300 KM050400 KM050510 KM050596 KM050669 KM050726 KM218448 KP227533 
KM050304 KM050406 KM050511 KM050597 KM050670 KM050727 KM218449 KP227534 
KM050305 KM050407 KM050512 KM050601 KM050671 KM050728 KM218450 KP227535 
KM050311 KM050408 KM050513 KM050602 KM050672 KM050729 KM218451 KP227536 
KM050316 KM050409 KM050514 KM050609 KM050673 KM050736 KM218452 KP227537 
KM050317 KM050410 KM050515 KM050610 KM050674 KM050737 KM218453 KP227538 
KM050320 KM050411 KM050520 KM050617 KM050677 KM050739 KM218454 KP227539 
KM050321 KM050416 KM050521 KM050618 KM050678 KM050740 KM218455 KP227540 
KM050326 KM050417 KM050526 KM050623 KM050679 KM050741 KM218456 KP227541 
KM050327 KM050422 KM050527 KM050624 KM050680 KM050742 KM218457 KP227542 
KM050328 KM050423 KM050532 KM050625 KM050681 KM050743 KM218458 KP227543 
KM050329 KM050428 KM050538 KM050631 KM050682 KM050744 KM218459 KP227544 
KM050334 KM050429 KM050539 KM050632 KM050683 KM050745 KM218460 KP227545 
KM050335 KM050430 KM050540 KM050633 KM050684 KM050746 KM283950 KP227546 
KM050340 KM050431 KM050541 KM050634 KM050685 KM050747 KM284236 KP227547 
KM050341 KM050437 KM050547 KM050635 KM050686 KM050748 KM284256 KP227548 
KM050347 KM050438 KM050548 KM050636 KM050687 KM050749 KM284345 KP227549 
KM050350 KM050439 KM050553 KM050637 KM050688 KM050750 KM284424 KP227550 
KM050351 KM050440 KM050554 KM050638 KM050689 KM050751 KM284520 KP227552 
KM050352 KM050441 KM050556 KM050639 KM050690 KM050752 KM820312 KP227553 
KM050353 KM050442 KM050557 KM050640 KM050691 KM050753 KP224476 KP227554 
KM050358 KM050447 KM050558 KM050641 KM050692 KM050754 KP224479 KP227555 
KM050359 KM050448 KM050559 KM050642 KM050699 KM050755 KP224483 KP227556 
KM050360 KM050449 KM050560 KM050643 KM050700 KM050756 KP224484 KP227557 
KM050361 KM050450 KM050564 KM050644 KM050701 KM050757 KP224485 KP227558 
KM050362 KM050455 KM050565 KM050645 KM050702 KM050758 KP224487 KP227559 
KM050363 KM050456 KM050566 KM050646 KM050703 KM050759 KP224489 KP227560 
KM050364 KM050460 KM050567 KM050647 KM050704 KM050760 KP224491 KP227561 
KM050365 KM050461 KM050568 KM050648 KM050705 KM050761 KP224492 KP227563 
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KM050370 KM050462 KM050569 KM050649 KM050706 KM050762 KP224493 KP227564 
KP227565 KP227609 KP411832 KT318906 KP227600 KP227644 KT318898 KT318928 
KP227566 KP227610 KP411833 KT318907 KP227601 KP227646 KT318899 KT318929 
KP227567 KP227611 KP411834 KT318908 KP227602 KP227647 KT318900 KT318930 
KP227568 KP227612 KP411836 KT318909 KP227604 KP227648 KT318901 KT318931 
KP227569 KP227613 KP411837 KT318910 KP227605 KP227649 KT318902 KT318932 
KP227570 KP227614 KP411838 KT318911 KP227606 KP227650 KT318903 KT318933 
KP227571 KP227615 KP411839 KT318912 KP227607 KP411830 KT318904 KT318934 
KP227572 KP227616 KP688090 KT318913 KP227608 KP411831 KT318905 KT343876 
KP227573 KP227617 KP688093 KT318914 KP227586 KP227630 KT318883 KT343882 
KP227574 KP227618 KP688112 KT318915 KP227587 KP227631 KT318884 KT343890 
KP227575 KP227619 KP688119 KT318916 KP227588 KP227632 KT318885 KT343896 
KP227576 KP227620 KP688142 KT318917 KP227589 KP227633 KT318886 KT343898 
KP227577 KP227621 KP688143 KT318918 KP227590 KP227634 KT318887 KT343901 
KP227578 KP227622 KP968789 KT318919 KP227591 KP227635 KT318888 KP227599 
KP227579 KP227623 KP968802 KT318920 KP227592 KP227636 KT318890 KP227643 
KP227580 KP227624 KP968803 KT318922 KP227593 KP227637 KT318891 KT318897 
KP227581 KP227625 KP968826 KT318923 KP227594 KP227638 KT318892 KT318896 
KP227582 KP227626 KT022362 KT318924 KP227595 KP227639 KT318893 KP227642 
KP227583 KP227627 KT022366 KT318925 KP227596 KP227640 KT318894 KP227598 
KP227584 KP227628 KT022371 KT318926 KP227597 KP227641 KT318895 KT318927 
KP227585 KP227629 KT191993 U52953     
 
 
Accession numbers for treated Gag sequences. 
DQ351220 KF527065 KF527076 KF526225 
KF766542 KF527071 KF527173 KF526209 
KF766541 KF527072 KF526222 KF526214 
KF527061 KF527074 KF526208 KF526217 
KF527062 KF527075 KF526212 KF526218 
KF526207 KF526220 HQ846903  
 
 
Accession numbers for the naïve Gag sequences. 
AY228556 EU786673 FJ606409 HM593308 JF704309 JF704596 KM048445 KM048730 
AY228557 EU786681 FJ606410 HM593309 JF704310 JF704597 KM048446 KM048731 
AY463217 EU884500 FJ606411 HM593310 JF704311 JF704598 KM048447 KM048732 
AY463218 FJ155203 FJ606412 HM593311 JF704312 JF704599 KM048448 KM048733 
AY463219 FJ606114 FJ606413 HM593312 JF704313 JF704600 KM048449 KM048734 
AY463220 FJ606116 FJ606414 HM593313 JF704314 JF704601 KM048450 KM048735 
AY463221 FJ606117 FJ606415 HM593314 JF704315 JF704602 KM048451 KM048736 
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AY463222 FJ606118 FJ606416 HM593315 JF704316 JF704603 KM048452 KM048737 
AY463223 FJ606119 FJ606417 HM593316 JF704317 JF704604 KM048453 KM048738 
AY463224 FJ606120 FJ606418 HM593317 JF704318 JF704605 KM048454 KM048739 
AY463225 FJ606121 FJ606419 HM593318 JF704319 JF704606 KM048455 KM048740 
AY463226 FJ606122 FJ606420 HM593319 JF704320 JF704607 KM048456 KM048741 
AY463227 FJ606123 FJ606421 HM593320 JF704321 JF704608 KM048457 KM048742 
AY463228 FJ606124 FJ606422 HM593321 JF704322 JF704609 KM048458 KM048743 
AY463229 FJ606125 FJ606423 HM593322 JF704323 JF704610 KM048459 KM048744 
AY463230 FJ606126 FJ606424 HM593323 JF704324 JF704611 KM048460 KM048745 
AY463231 FJ606127 FJ606425 HM593324 JF704325 JF704612 KM048461 KM048746 
AY463232 FJ606128 FJ606426 HM593325 JF704326 JF704613 KM048462 KM048747 
AY463233 FJ606129 FJ606427 HM593326 JF704327 JF704614 KM048463 KM048748 
AY463234 FJ606130 FJ606428 HM593327 JF704328 JF704615 KM048464 KM048749 
AY463236 FJ606131 FJ606429 HM593328 JF704329 JF704616 KM048465 KM048750 
AY463237 FJ606132 FJ606430 HM593329 JF704330 JF704617 KM048466 KM048751 
AY484419 FJ606133 FJ606431 HM593330 JF704331 JF704618 KM048467 KM048752 
AY484420 FJ606134 FJ606432 HM593331 JF704332 JF704619 KM048468 KM048753 
AY484421 FJ606135 FJ606433 HM593332 JF704333 JF704620 KM048469 KM048754 
AY484422 FJ606136 FJ606434 HM593333 JF704334 JF704621 KM048470 KM048755 
AY484423 FJ606137 FJ606435 HM593334 JF704335 JF704622 KM048472 KM048756 
AY484424 FJ606138 FJ606436 HM593335 JF704336 JF704623 KM048473 KM048757 
AY585264 FJ606141 FJ606437 HM593336 JF704337 JF704624 KM048474 KM048758 
AY585265 FJ606142 FJ606438 HM593337 JF704338 JF704625 KM048475 KM048759 
AY585266 FJ606143 FJ606439 HM593338 JF704339 JF704626 KM048476 KM048760 
AY585267 FJ606144 FJ606440 HM593339 JF704340 JF704627 KM048477 KM048761 
AY585268 FJ606145 FJ606441 HM593340 JF704341 JF704628 KM048478 KM048762 
AY703908 FJ606146 FJ606442 HM593341 JF704342 JF704629 KM048479 KM048763 
AY703909 FJ606147 FJ606443 HM593342 JF704343 JF704630 KM048480 KM048764 
AY703910 FJ606148 FJ606444 HM593343 JF704344 JF704631 KM048481 KM048765 
AY703911 FJ606149 FJ606445 HM593344 JF704345 JF704632 KM048482 KM048766 
AY772690 FJ606150 FJ606446 HM593345 JF704346 JF704633 KM048483 KM048767 
AY772691 FJ606151 FJ670521 HM593346 JF704347 JF704634 KM048484 KM048768 
AY772692 FJ606152 FJ853501 HM593347 JF704348 JF704635 KM048485 KM048769 
AY772693 FJ606153 FJ853502 HM593348 JF704349 JF704636 KM048486 KM048770 
AY772694 FJ606154 FJ853503 HM593349 JF704350 JF704637 KM048487 KM048771 
AY772695 FJ606155 FJ853504 HM593350 JF704351 JF704638 KM048488 KM048772 
AY772696 FJ606156 FJ853507 HM593351 JF704352 JF704639 KM048489 KM048773 
AY772698 FJ606157 FJ853512 HM593352 JF704353 JF704640 KM048490 KM048774 
AY772699 FJ606158 FJ853514 HM593353 JF704354 JF704641 KM048491 KM048775 
AY772700 FJ606160 FJ853515 HM593354 JF704355 JF704642 KM048492 KM048776 
AY838565 FJ606162 FJ853519 HM593355 JF704356 JF704643 KM048493 KM048777 
AY838566 FJ606163 FJ853520 HM593356 JF704357 JF704644 KM048494 KM048778 
AY838567 FJ606164 FJ853522 HM593357 JF704358 JF704645 KM048495 KM048779 
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AY838568 FJ606165 FJ853523 HM593358 JF704359 JF704646 KM048496 KM048780 
AY878054 FJ606166 FJ853524 HM593359 JF704360 JF704647 KM048497 KM048781 
AY878055 FJ606167 FJ853525 HM593360 JF704361 JF704648 KM048498 KM048782 
AY878056 FJ606168 FJ853528 HM593361 JF704362 JF704649 KM048499 KM048783 
AY878057 FJ606169 FJ853529 HM593362 JF704363 JF704650 KM048500 KM048784 
AY878058 FJ606170 FJ853532 HM593363 JF704364 JF704651 KM048501 KM048785 
AY878059 FJ606171 FJ853539 HM593364 JF704365 JF704652 KM048502 KM048786 
AY878060 FJ606172 FJ853542 HM593365 JF704366 JF704653 KM048503 KM048787 
AY878061 FJ606173 FJ853549 HM593366 JF704367 JF704654 KM048504 KM048788 
AY878062 FJ606174 FJ853551 HM593367 JF704368 JF704655 KM048505 KM048789 
AY878063 FJ606175 FJ853553 HM593368 JF704369 JF704656 KM048506 KM048790 
AY878064 FJ606176 FJ853554 HM593369 JF704370 JF704657 KM048507 KM048791 
AY878065 FJ606177 FJ853555 HM593370 JF704371 JF704658 KM048508 KM048792 
AY878068 FJ606178 FJ853557 HM593371 JF704372 JF704659 KM048509 KM048793 
AY878070 FJ606179 FJ853559 HM593372 JF704373 JF704660 KM048510 KM048794 
AY878071 FJ606180 FJ853560 HM593373 JF704374 JF704661 KM048511 KM048795 
AY878072 FJ606181 FJ853561 HM593374 JF704375 JF704662 KM048512 KM048796 
AY901965 FJ606182 FJ853562 HM593375 JF704376 JF704663 KM048513 KM048797 
AY901966 FJ606183 FJ853563 HM593376 JF704377 JF704664 KM048514 KM048798 
AY901967 FJ606184 FJ853564 HM593377 JF704378 JF704665 KM048515 KM048799 
AY901968 FJ606185 FJ853566 HM593378 JF704379 JF704666 KM048516 KM048800 
AY901969 FJ606186 FJ853567 HM593379 JF704380 JF704667 KM048517 KM048801 
AY901970 FJ606187 FJ853569 HM593380 JF704381 JF704668 KM048518 KM048802 
AY901971 FJ606189 FJ853573 HM593381 JF704382 JF704669 KM048519 KM048803 
AY901972 FJ606190 FJ853574 HM593382 JF704383 JF704670 KM048520 KM048804 
AY901973 FJ606191 FJ853575 HM593383 JF704384 JF704671 KM048521 KM048805 
AY901974 FJ606192 FJ853578 HM593384 JF704385 JF704672 KM048522 KM048806 
AY901975 FJ606193 FJ853579 HM593385 JF704386 JF704673 KM048523 KM048807 
AY901976 FJ606194 FJ853580 HM593386 JF704387 JF704674 KM048524 KM048808 
AY901977 FJ606195 FJ853581 HM593387 JF704388 JF704675 KM048525 KM048809 
AY901978 FJ606196 FJ853586 HM593388 JF704389 JF704676 KM048526 KM048810 
AY901979 FJ606197 FJ853590 HM593389 JF704390 JF704677 KM048527 KM048811 
AY901980 FJ606198 GQ999989 HM593390 JF704391 JF704678 KM048528 KM048812 
AY901981 FJ606199 HM593106 HM593391 JF704392 JF704679 KM048529 KM048813 
DQ011165 FJ606200 HM593107 HM593392 JF704393 JF704680 KM048530 KM048814 
DQ011166 FJ606201 HM593108 HM593393 JF704394 JF704681 KM048531 KM048815 
DQ011167 FJ606202 HM593109 HM593394 JF704395 JF704682 KM048532 KM048816 
DQ011169 FJ606203 HM593110 HM593395 JF704396 JF704683 KM048533 KM048821 
DQ011170 FJ606204 HM593111 HM593396 JF704397 JF704684 KM048534 KM048822 
DQ011171 FJ606205 HM593112 HM593397 JF704398 JF704685 KM048535 KM048823 
DQ011172 FJ606206 HM593113 HM593398 JF704399 JF704686 KM048536 KM048824 
DQ011173 FJ606207 HM593114 HM593399 JF704400 JF704687 KM048537 KM048825 
DQ011174 FJ606208 HM593115 HM593400 JF704401 JF704688 KM048538 KM048826 
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DQ011175 FJ606209 HM593116 HM593401 JF704402 JF704689 KM048539 KM048827 
DQ011176 FJ606210 HM593117 HM593402 JF704403 JF704690 KM048540 KM048828 
DQ011177 FJ606211 HM593118 HM593403 JF704404 JF704691 KM048541 KM048829 
DQ011178 FJ606212 HM593119 HM593404 JF704405 JF704692 KM048542 KM048830 
DQ011179 FJ606213 HM593120 HM593405 JF704406 JF704693 KM048543 KM048831 
DQ011180 FJ606214 HM593121 HM593406 JF704407 JF704694 KM048544 KM048832 
DQ056404 FJ606215 HM593122 HM593407 JF704408 JF704695 KM048545 KM048833 
DQ056405 FJ606216 HM593123 HM593408 JF704409 JF704696 KM048546 KM048834 
DQ056406 FJ606217 HM593124 HM593409 JF704410 JF704697 KM048547 KM048835 
DQ056408 FJ606218 HM593125 HM593410 JF704411 JF704698 KM048548 KM048836 
DQ056409 FJ606219 HM593126 HM593411 JF704412 JF704699 KM048549 KM048837 
DQ056410 FJ606220 HM593127 HM593412 JF704413 JF704700 KM048550 KM048838 
DQ056411 FJ606221 HM593128 HM593413 JF704414 JF704701 KM048551 KM048839 
DQ056412 FJ606222 HM593129 HM593414 JF704415 JF704702 KM048552 KM048840 
DQ056413 FJ606223 HM593130 HM593415 JF704416 JF704703 KM048553 KM048841 
DQ056414 FJ606224 HM593131 HM593416 JF704417 JF704704 KM048554 KM048842 
DQ056415 FJ606225 HM593132 HM593417 JF704418 JF704705 KM048555 KM048843 
DQ056416 FJ606226 HM593133 HM593418 JF704419 JF704706 KM048557 KM048844 
DQ056417 FJ606227 HM593134 HM593419 JF704420 JF704707 KM048558 KM048845 
DQ056418 FJ606228 HM593135 HM593420 JF704421 JF704708 KM048559 KM048846 
DQ093585 FJ606229 HM593136 HM593421 JF704422 JF704709 KM048560 KM048847 
DQ093586 FJ606230 HM593137 HM593422 JF704423 JF704710 KM048561 KM048848 
DQ093587 FJ606231 HM593138 HM593423 JF704424 JF704711 KM048562 KM048849 
DQ093588 FJ606232 HM593139 HM593424 JF704425 JQ219842 KM048563 KM048850 
DQ093589 FJ606233 HM593140 HM593425 JF704426 JX140662 KM048564 KM048851 
DQ093590 FJ606234 HM593141 HM593426 JF704427 KC149035 KM048565 KM048852 
DQ093591 FJ606235 HM593142 HM593427 JF704428 KC149036 KM048566 KM048853 
DQ093592 FJ606236 HM593143 HM593428 JF704429 KC149037 KM048567 KM048854 
DQ093593 FJ606237 HM593144 HM593429 JF704430 KC149038 KM048568 KM048855 
DQ093594 FJ606238 HM593145 HM593430 JF704431 KC149039 KM048569 KM048856 
DQ093595 FJ606239 HM593146 HM593431 JF704432 KC149040 KM048570 KM048857 
DQ093596 FJ606240 HM593147 HM593432 JF704433 KC149041 KM048571 KM048858 
DQ093597 FJ606241 HM593148 HM593433 JF704434 KC149042 KM048572 KM048859 
DQ093598 FJ606242 HM593149 HM593434 JF704435 KC149043 KM048573 KM048860 
DQ093599 FJ606243 HM593150 HM593435 JF704436 KC149044 KM048574 KM048861 
DQ093600 FJ606244 HM593152 HM593436 JF704437 KC149045 KM048575 KM048862 
DQ093601 FJ606245 HM593153 HM593437 JF704438 KC149046 KM048576 KM048863 
DQ093602 FJ606246 HM593154 HM593438 JF704439 KC149047 KM048577 KM048864 
DQ093604 FJ606247 HM593155 HM593439 JF704440 KC149048 KM048578 KM048865 
DQ093605 FJ606248 HM593156 HM593440 JF704441 KC149049 KM048579 KM048866 
DQ093607 FJ606249 HM593157 HM593441 JF704442 KC149050 KM048580 KM048867 
DQ164104 FJ606250 HM593158 HM593442 JF704443 KC149051 KM048581 KM048868 
DQ164105 FJ606251 HM593159 HM593443 JF704444 KC149052 KM048582 KM048869 
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DQ164106 FJ606252 HM593160 HM593444 JF704445 KC149054 KM048583 KM048870 
DQ164107 FJ606253 HM593161 HM593445 JF704446 KC149055 KM048584 KM048871 
DQ164108 FJ606254 HM593162 HM593446 JF704447 KC149056 KM048585 KM048872 
DQ164109 FJ606255 HM593163 HM593447 JF704448 KC149057 KM048586 KM048873 
DQ164110 FJ606256 HM593164 HM593448 JF704449 KC149058 KM048587 KM048874 
DQ164111 FJ606257 HM593165 HM593449 JF704450 KC149059 KM048588 KM048875 
DQ164112 FJ606258 HM593166 HM593450 JF704451 KC149060 KM048589 KM048876 
DQ164113 FJ606259 HM593167 HM593451 JF704452 KC149061 KM048590 KM048885 
DQ164114 FJ606260 HM593168 HM593452 JF704453 KC149062 KM048591 KM048886 
DQ164115 FJ606261 HM593169 HM593453 JF704454 KC149063 KM048592 KM048887 
DQ164116 FJ606262 HM593170 HM593454 JF704455 KC149064 KM048593 KM048888 
DQ164117 FJ606263 HM593171 HM593455 JF704456 KC149065 KM048594 KM048889 
DQ164118 FJ606264 HM593172 HM593456 JF704457 KC149066 KM048595 KM048890 
DQ164119 FJ606265 HM593173 HM593457 JF704458 KC149067 KM048596 KM048891 
DQ164121 FJ606266 HM593174 HM593458 JF704459 KC149068 KM048597 KM048892 
DQ164122 FJ606267 HM593175 HM593459 JF704460 KC149069 KM048598 KM048893 
DQ164126 FJ606268 HM593176 HM593460 JF704461 KC149070 KM048599 KM048894 
DQ164127 FJ606269 HM593177 HM593461 JF704462 KC149071 KM048600 KM048895 
DQ164129 FJ606270 HM593178 HM593462 JF704464 KC149072 KM048601 KM048896 
DQ275642 FJ606271 HM593179 HM593463 JF704465 KC149073 KM048602 KM048897 
DQ275643 FJ606272 HM593180 HM593464 JF704466 KC149074 KM048603 KM048898 
DQ275644 FJ606273 HM593181 HM593465 JF704467 KC149075 KM048604 KM048899 
DQ275645 FJ606274 HM593182 HM593466 JF704468 KC149076 KM048605 KM048900 
DQ275646 FJ606275 HM593183 HM593467 JF704469 KC149077 KM048606 KM048901 
DQ275647 FJ606276 HM593184 HM593468 JF704470 KC149078 KM048607 KM048902 
DQ275648 FJ606277 HM593185 HM593469 JF704471 KC149079 KM048608 KM048903 
DQ275649 FJ606278 HM593186 HM593470 JF704472 KC149080 KM048609 KM048904 
DQ275650 FJ606279 HM593187 HM593471 JF704473 KC149081 KM048610 KM048905 
DQ275651 FJ606280 HM593188 HM593472 JF704474 KC149082 KM048611 KM048906 
DQ275652 FJ606281 HM593189 HM593473 JF704475 KC149083 KM048612 KM048907 
DQ275653 FJ606282 HM593190 HM593474 JF704476 KC149084 KM048613 KM048908 
DQ275654 FJ606283 HM593191 HM593475 JF704477 KC149085 KM048614 KM048909 
DQ275655 FJ606284 HM593192 HM593476 JF704478 KC149086 KM048615 KM048910 
DQ275656 FJ606285 HM593193 HM593477 JF704479 KC149087 KM048616 KM048911 
DQ275657 FJ606286 HM593194 HM593478 JF704480 KC149088 KM048617 KM048912 
DQ275658 FJ606287 HM593195 HM593479 JF704481 KC149089 KM048618 KM048913 
DQ275659 FJ606288 HM593196 HM593480 JF704482 KC149090 KM048619 KM048914 
DQ275660 FJ606289 HM593197 HM593481 JF704483 KC149091 KM048620 KM048915 
DQ275661 FJ606290 HM593199 HM593482 JF704484 KC149092 KM048621 KM048916 
DQ275664 FJ606292 HM593200 HM593483 JF704485 KC149093 KM048622 KM048917 
DQ351216 FJ606293 HM593201 HM593484 JF704486 KC149094 KM048623 KM048918 
DQ351217 FJ606294 HM593202 HM593485 JF704487 KC149095 KM048624 KM048919 
DQ351218 FJ606295 HM593203 HM593486 JF704488 KC149096 KM048625 KM048920 
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DQ351219 FJ606296 HM593204 HM593487 JF704489 KC149097 KM048626 KM048921 
DQ351220 FJ606298 HM593205 HM593488 JF704490 KC149098 KM048627 KM048922 
DQ351221 FJ606299 HM593206 HM593489 JF704492 KC149099 KM048628 KM048923 
DQ351222 FJ606300 HM593207 HM593490 JF704494 KC149100 KM048629 KM048924 
DQ351223 FJ606301 HM593208 HM593491 JF704496 KC149101 KM048630 KM048925 
DQ351224 FJ606302 HM593209 HM593492 JF704497 KC149102 KM048631 KM048926 
DQ351225 FJ606303 HM593210 HM593493 JF704498 KC149103 KM048632 KM048927 
DQ351226 FJ606304 HM593211 HM593494 JF704499 KC149104 KM048633 KM048928 
DQ351227 FJ606305 HM593212 HM593495 JF704500 KC149105 KM048634 KM048929 
DQ351228 FJ606306 HM593213 HM593496 JF704501 KC149106 KM048635 KM048930 
DQ351229 FJ606307 HM593214 HM593497 JF704502 KC149107 KM048636 KM048931 
DQ351230 FJ606308 HM593215 HM593498 JF704503 KC149108 KM048637 KM048932 
DQ351231 FJ606309 HM593216 HM593499 JF704504 KC149109 KM048638 KM048933 
DQ351232 FJ606310 HM593217 HM593500 JF704505 KC149110 KM048639 KM048934 
DQ351233 FJ606311 HM593218 HM593501 JF704506 KC149111 KM048640 KM048935 
DQ351234 FJ606312 HM593219 HM593502 JF704507 KC149112 KM048641 KM048936 
DQ351235 FJ606313 HM593220 HM593503 JF704508 KC149113 KM048642 KM048937 
DQ351237 FJ606314 HM593221 HM593504 JF704509 KC149114 KM048643 KM048938 
DQ369976 FJ606315 HM593222 HM593505 JF704510 KC149115 KM048644 KM048939 
DQ369977 FJ606316 HM593223 HM593506 JF704511 KC149116 KM048645 KM048940 
DQ369978 FJ606317 HM593224 HM593507 JF704512 KC149117 KM048646 KM048941 
DQ369979 FJ606320 HM593225 HM593508 JF704513 KC149118 KM048647 KM048942 
DQ369980 FJ606321 HM593226 HM593509 JF704514 KC149119 KM048648 KM048943 
DQ369981 FJ606322 HM593227 HM593510 JF704515 KC149120 KM048649 KM048944 
DQ369982 FJ606323 HM593228 HQ696823 JF704516 KC149121 KM048650 KM048945 
DQ369983 FJ606324 HM593229 HQ696824 JF704517 KC149122 KM048651 KM048946 
DQ369984 FJ606325 HM593230 HQ696825 JF704518 KC149123 KM048652 KM048947 
DQ369985 FJ606326 HM593231 HQ696826 JF704519 KC149124 KM048653 KM048948 
DQ369986 FJ606327 HM593232 HQ696827 JF704520 KC149125 KM048654 KM048949 
DQ369987 FJ606328 HM593233 HQ696828 JF704521 KC149126 KM048655 KM048950 
DQ369988 FJ606329 HM593234 JF704235 JF704522 KC149127 KM048656 KM048951 
DQ369989 FJ606330 HM593235 JF704236 JF704523 KC149128 KM048657 KM048952 
DQ369990 FJ606331 HM593236 JF704237 JF704524 KC149129 KM048658 KM048953 
DQ369991 FJ606332 HM593237 JF704238 JF704525 KC149130 KM048659 KM048954 
DQ369992 FJ606333 HM593238 JF704239 JF704526 KC149131 KM048660 KM048955 
DQ369993 FJ606334 HM593239 JF704240 JF704527 KC149132 KM048661 KM048956 
DQ369994 FJ606335 HM593240 JF704241 JF704528 KC149133 KM048662 KM048957 
DQ369995 FJ606336 HM593241 JF704242 JF704529 KC149134 KM048663 KM048958 
DQ369996 FJ606337 HM593242 JF704243 JF704530 KC149135 KM048664 KM048959 
DQ369997 FJ606338 HM593243 JF704244 JF704531 KC149136 KM048665 KM048960 
DQ396364 FJ606339 HM593244 JF704245 JF704532 KC149137 KM048666 KM048961 
DQ396365 FJ606340 HM593245 JF704246 JF704533 KF578465 KM048667 KM048962 
DQ396366 FJ606341 HM593246 JF704247 JF704534 KF578466 KM048668 KM048963 
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DQ396367 FJ606342 HM593247 JF704248 JF704535 KF578467 KM048669 KM048964 
DQ396368 FJ606343 HM593248 JF704249 JF704536 KF766537 KM048670 KM048965 
DQ396369 FJ606344 HM593249 JF704250 JF704537 KF766538 KM048671 KM048966 
DQ396370 FJ606345 HM593250 JF704251 JF704538 KF766539 KM048672 KM048967 
DQ396371 FJ606346 HM593251 JF704252 JF704539 KF766540 KM048673 KM048968 
DQ396372 FJ606347 HM593252 JF704253 JF704540 KM048382 KM048674 KM048969 
DQ396373 FJ606348 HM593253 JF704254 JF704541 KM048383 KM048675 KM048970 
DQ396374 FJ606349 HM593254 JF704255 JF704542 KM048384 KM048676 KM048971 
DQ396375 FJ606350 HM593255 JF704256 JF704543 KM048392 KM048677 KM048972 
DQ396376 FJ606351 HM593256 JF704257 JF704544 KM048393 KM048678 KM048973 
DQ396377 FJ606352 HM593257 JF704258 JF704545 KM048394 KM048679 KM048974 
DQ396378 FJ606353 HM593258 JF704259 JF704546 KM048395 KM048680 KM048975 
DQ396379 FJ606354 HM593259 JF704260 JF704547 KM048396 KM048681 KM048976 
DQ396380 FJ606355 HM593260 JF704261 JF704548 KM048397 KM048682 KM048977 
DQ396381 FJ606356 HM593261 JF704262 JF704549 KM048398 KM048683 KM048978 
DQ396382 FJ606357 HM593262 JF704263 JF704550 KM048399 KM048684 KM048979 
DQ396383 FJ606358 HM593263 JF704264 JF704551 KM048400 KM048685 KM048980 
DQ396384 FJ606359 HM593264 JF704265 JF704552 KM048401 KM048686 KM048981 
DQ396385 FJ606360 HM593265 JF704266 JF704553 KM048402 KM048687 KM048982 
DQ396386 FJ606361 HM593266 JF704267 JF704554 KM048403 KM048688 KM048983 
DQ396387 FJ606362 HM593267 JF704268 JF704555 KM048404 KM048689 KM048984 
DQ396388 FJ606363 HM593268 JF704269 JF704556 KM048405 KM048690 KM048985 
DQ396389 FJ606364 HM593269 JF704270 JF704557 KM048406 KM048691 KM048986 
DQ396390 FJ606365 HM593270 JF704271 JF704558 KM048407 KM048692 KM048987 
DQ396391 FJ606366 HM593271 JF704272 JF704559 KM048408 KM048693 KM048988 
DQ396392 FJ606369 HM593272 JF704273 JF704560 KM048409 KM048694 KM048989 
DQ396393 FJ606370 HM593273 JF704274 JF704561 KM048410 KM048695 KM048990 
DQ396394 FJ606371 HM593274 JF704275 JF704562 KM048411 KM048696 KM048991 
DQ396395 FJ606372 HM593275 JF704276 JF704563 KM048412 KM048697 KM048992 
DQ396396 FJ606373 HM593276 JF704277 JF704564 KM048413 KM048698 KM048993 
DQ396397 FJ606374 HM593277 JF704278 JF704565 KM048414 KM048699 KM048994 
DQ396399 FJ606375 HM593278 JF704279 JF704566 KM048415 KM048700 KM048995 
DQ445631 FJ606376 HM593279 JF704280 JF704567 KM048416 KM048701 KM048996 
DQ445632 FJ606378 HM593280 JF704281 JF704568 KM048417 KM048702 KM048997 
DQ445633 FJ606379 HM593281 JF704282 JF704569 KM048418 KM048703 KM048998 
DQ445634 FJ606380 HM593282 JF704283 JF704570 KM048419 KM048704 KM048999 
DQ445635 FJ606381 HM593283 JF704284 JF704571 KM048420 KM048705 KM049000 
DQ445637 FJ606382 HM593284 JF704285 JF704572 KM048421 KM048706 KM049001 
EF122539 FJ606383 HM593285 JF704286 JF704573 KM048422 KM048707 KM049002 
EF469243 FJ606384 HM593286 JF704287 JF704574 KM048423 KM048708 KM049004 
EU242016 FJ606385 HM593287 JF704288 JF704575 KM048424 KM048709 KM049005 
EU242294 FJ606386 HM593288 JF704289 JF704576 KM048425 KM048710 KM049006 
EU242369 FJ606387 HM593289 JF704290 JF704577 KM048426 KM048711 KM192379 
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EU242409 FJ606388 HM593290 JF704291 JF704578 KM048427 KM048712 KM192380 
EU242415 FJ606389 HM593291 JF704292 JF704579 KM048428 KM048713 KM192381 
EU242470 FJ606390 HM593292 JF704293 JF704580 KM048429 KM048714 KM192382 
EU242490 FJ606391 HM593293 JF704294 JF704581 KM048430 KM048715 KM192383 
EU293445 FJ606392 HM593294 JF704295 JF704582 KM048431 KM048716 KM192384 
EU293446 FJ606393 HM593295 JF704296 JF704583 KM048432 KM048717 KM192385 
EU293447 FJ606394 HM593296 JF704297 JF704584 KM048433 KM048718 KM192386 
EU293448 FJ606395 HM593297 JF704298 JF704585 KM048434 KM048719 KM192387 
EU293449 FJ606396 HM593298 JF704299 JF704586 KM048435 KM048720 KM192388 
EU293450 FJ606397 HM593299 JF704300 JF704587 KM048436 KM048721 KM192389 
EU347706 FJ606398 HM593300 JF704301 JF704588 KM048437 KM048722 KM192390 
EU347707 FJ606399 HM593301 JF704302 JF704589 KM048438 KM048723 KM192391 
EU347708 FJ606401 HM593302 JF704303 JF704590 KM048439 KM048724 KM192392 
EU673411 FJ606402 HM593303 JF704304 JF704591 KM048440 KM048725 KM192393 
EU673428 FJ606403 HM593304 JF704305 JF704592 KM048441 KM048726 KM192425 
EU673437 FJ606404 HM593305 JF704306 JF704593 KM048442 KM048727 KM192426 
EU673443 FJ606406 HM593306 JF704307 JF704594 KM048443 KM048728 KM192427 
EU673444 FJ606407 HM593307 JF704308 JF704595 KM048444 KM048729 KM192428 
KM192429        
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Appendix C: Molecular Dynamic Scripts 
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Minimization of waters 
 &cntrl 
   imin=1, 
   maxcyc=5000, ncyc=3000, 
   ntb=1, cut=10.0, ntpr=5, 
   ntr=1, restraintmask=':1-
198', 
   restraint_wt=2.0 
 &end 
   / 
                                
  
Minimization of the whole 
system 
 &cntrl 
   imin=1, 
   maxcyc=10000, ncyc=7000, 
   ntb=1, ntr=0, cut=10.0, 
ntpr=5 
 &end 
   / 
 
Heating of proteins from 0K to 
300K 
 &cntrl 
   imin=0, irest=0, ntx=1, 
ig=-1, 
   nstlim=25000, dt=0.002, 
   ntc=2, ntf=2, 
   cut=8.0, ntb=1, 
   ntpr=500, ntwx=500, 
   ntt=3, gamma_ln=2.0, 
   tempi=0.0, temp0=300.0, 
   ntr=1, restraintmask=':1-
198', 
   restraint_wt=2.0, 
   nmropt=1, ioutfm=1 
 / 
 &wt TYPE='TEMP0', istep1=0, 
istep2=25000, 
  value1=0.1, value2=300.0, / 
 &wt TYPE='END' / 
 
Equilibrate the density 
 &cntrl 
   imin=0, 
   irest=1, 
   ntx=5, 
   nstlim=25000, dt=0.002, 
   ntc=2, ntf=2, 
   cut=8.0, ntb=2, 
   ntp=1, taup=1.0, 
   ntpr=500, ntwx=500, 
   ntt=3, gamma_ln=2.0, 
   temp0=300.0, 
   ntr=1, restraintmask=':1-
198', 
   restraint_wt=2.0, 
   ig=-1, 
   ioutfm=1 
 &end 
   / 
Equilibrate 
 &cntrl 
   imin=0, irest=1, ntx=5, 
   nstlim=1000000, dt=0.002, 
   ntc=2, ntf=2, 
   cut=10.0, ntb=2, 
   ntp=1, taup=2.0, 
   ntpr=1000, ntwx=1000, 
   ntt=3, gamma_ln=2.0, 
   temp0=300.0, 
   ig=-1, ioutfm=1 
 &end 
   / 
 
 
*The same scripts were used to optimize the protein structure and for the final 100 ns enzyme-
substrate MD simulations. Only the “restraintmask” flag (bold) was altered for the addition of 
the inhibitor. 
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Figure 1   Screenshot of the Stanford HIV Drug Resistance Database protease inhibitor (PI) 
resistance notes. The top row indicates the consensus amino acid and position. The following 
rows indicate each of the eight PIs and the major protease resistance mutations that occurs at a 
specific position.  
 
 
 
 
 
Figure 2   Screenshot of output from the HIVdb algorithm showing the effects of M46I, I54V 
and V82A on Atazanavir/Ritonavir (ATV/r), Darunavir/Ritonavir (DRV/r) and 
Lopinavir/Ritonavir treatment (LPV/r).  
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Figure 3   Screenshot of the output from the HIVdb algorithm showing the effects of M46I, I54V, 
L76V and V82A on Atazanavir/Ritonavir (ATV/r), Darunavir/Ritonavir (DRV/r) and 
Lopinavir/Ritonavir (LPV/r) treatment.  
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Figure 4   Illustration of the 20 common amino acids showing their structure, single and three letter code.  
 
  
 
165 
 
 
 
 
 
 
 
 
Appendix E: Ethics Certificate 
 
 
 
 
 
 
 
 
 
166 
 
 
  
 
 
 
 
167 
 
 
 
 
 
 
 
 
 
 
 
